All Episodes

• Oct 17, 2026 Strattera (Atomoxetine) vs Wellbutrin (Bupropion): Non-Stimulant Uses | PMHNP Boards

  💎 Strattera is the FDA-approved non-stimulant to reach for when stimulants are off the table; Wellbutrin's home turf is depression — its executive-function help is the side benefit, not the main event.

  📇 Key Takeaways — the index card

  • Stimulants (the methylphenidate and amphetamine families) remain first line and work within about an hour; atomoxetine takes weeks and dose optimization before it kicks in, but once optimized it gives non-habit-forming, around-the-clock coverage instead of wearing off mid-afternoon.
  • The mechanisms sit in the same neighborhood but do different jobs: atomoxetine is a selective norepinephrine reuptake inhibitor that secondarily raises prefrontal dopamine, while bupropion is an NDRI — Strattera is FDA-approved for ADHD, Wellbutrin for depression and smoking cessation, not ADHD.
  • Atomoxetine's fine dose steps (10 mg, 18 mg, and up toward a 100 mg max, with response often at 40 mg and above) matter because CYP2D6 poor metabolizers can carry roughly 10 times the expected drug level — puzzling side effects or non-response are exactly where the FDA label raises considering genetic testing.
  • The ideal Wellbutrin patient is depressed, sleeping too much, gaining weight, and anhedonic, with maybe a whiff of executive dysfunction underneath the depression that improves as a two-for-one; many patients feel more jittery and anxious on it, though some report less rumination as their executive control tightens.
  • Hard stops shape the choice: a seizure disorder, or a current or prior diagnosis of anorexia or bulimia, contraindicates Wellbutrin, while Strattera calls for watching liver impairment and its mild heart rate and blood pressure elevation.
• Oct 13, 2026 Saphris (Asenapine): Bipolar Mania & Schizophrenia Prescribing | PMHNP Boards

  💎 Saphris is the only truly sublingual antipsychotic — absorbed through the oral mucosa, not swallowed like an ODT — and NP Z reaches for it in mania when he wants sleep and less weight gain than olanzapine, without much anticholinergic fog.

  📇 Key Takeaways — the index card

  • Sublingual is not ODT: Saphris (asenapine) is absorbed transmucosally under the tongue, which is fundamentally different from a Zyprexa ODT that dissolves and is basically swallowed — the route is the opening for a manic patient who will not or cannot swallow pills, or has a pill phobia.
  • Built for mania, weak for acute bipolar depression: FDA-approved for schizophrenia in adults, bipolar I acute mania and mixed episodes in adults, pediatric bipolar I mania/mixed ages 10 to 17, and bipolar I maintenance — it can treat the current manic fire and may lengthen time to the next episode, but for acute bipolar depression NP Z looks instead to lurasidone, lumateperone, or quetiapine.
  • Receptor story in one pass: D2 blockade for psychosis and mania, potent 5-HT2A blockade that softens dopamine blockade and helps keep motor side effects down, 5-HT2C blockade behind appetite — think C for craving carbs — and H1 blockade that helps a manic patient sleep.
  • Almost no muscarinic activity is the quiet advantage: compared with olanzapine and clozapine, Saphris carries relatively little classic anticholinergic burden — less constipation, dry mouth, urinary retention, and cognitive dulling to add on top of negative symptoms, which matters for patients whose jobs demand sharp focus the next day, though H1 sedation can still leave them groggy.
  • Metabolic middle ground, not a free pass: patients can and do gain weight on Saphris, sometimes substantially, but NP Z places it as comparatively friendlier than olanzapine, which can drive rapid, heavy gain — and if sleep is the goal in mania, he would reach for Saphris before aripiprazole, which he often finds does not make patients drowsy.
  • The adherence price is real: Saphris is dosed twice daily, it has no long-acting injectable to steady levels the way aripiprazole, olanzapine, risperidone, and paliperidone do, missed or once-daily dosing lets levels drop, and many patients dislike the taste and the numb mouth and throat it leaves behind.
• Oct 11, 2026 Wellbutrin (Bupropion) vs Trintellix (Vortioxetine) After SSRI Failure | PMHNP Boards

  💎 Flat on an SSRI is often blunting, not residual depression — SSRIs quiet the salience network's response to rewarding cues as well as aversive ones

  📇 Key Takeaways — the index card

  • Blunting lives in the salience network: amygdala, insula, anterior cingulate, ventral striatum — ask about joy, motivation, and emotional range, not just sadness scores
  • Don't scrap a winning SSRI: inventory what it fixed first, because dose-lowering to ease blunting can undercut the antidepressant response
  • Wellbutrin is the dopamine pivot: an NDRI that leaves serotonin alone, counters the serotonergic brake on dopamine, and pairs with an SSRI like wine and cheese
  • Wellbutrin's hard stops are dose-related seizure risk plus seizure disorder and current or prior anorexia or bulimia; its sweet spot is the sluggish, low-energy patient
  • Trintellix fine-tunes serotonin: SERT blockade plus 5-HT1A agonism, 5-HT1B partial agonism, and 5-HT3 antagonism that releases dopamine, norepinephrine, acetylcholine, histamine, and glutamate downstream
  • The call: augment with Wellbutrin when the SSRI carries real wins and drive is missing; switch to Trintellix when the patient still needs serotonin, fine-tuned for cognition, blunting, and sexual tolerability

  📋 Flash-Card Summary — the article version

• Oct 6, 2026 Vraylar (Cariprazine) vs Abilify (Aripiprazole): D2, D3 Differences | PMHNP Boards

  💎 Vraylar has about 10 times Abilify's affinity at D3, the reward-and-motivation receptor tied to the negative symptoms that predict disability.

  📇 Key Takeaways — the index card

  • Both are D2 partial agonists - a dimmer switch that turns dopamine down in psychosis and props it up where it runs low, with 5-HT1A partial agonism and 5-HT2A blockade on both
  • Only Vraylar is FDA-approved for bipolar I depression; Abilify is approved for bipolar I mania and mixed presentations and as an MDD add-on, but augmenting depression does not make it an antidepressant for acute bipolar depression
  • Half-life gap: Abilify runs about 75 hours, while Vraylar's active metabolite persists for weeks - forgiving missed doses, but slow to clear and slow for late-emerging side effects to resolve
  • Akathisia on either drug usually sounds like 'I'm so anxious I can't sit still and want to jump out of my skin' - do not mistake it for worsening psychosis and raise the dose
  • Abilify carries an FDA impulse-control warning for compulsive gambling, shopping, and binge eating - ask directly, because patients rarely volunteer it
  • The call: despite Vraylar's D3 and bipolar-depression edge, NP Z's island pick is Abilify - generic and available as a long-acting injectable, while Vraylar has no LAI form and could cost around $1,600 a month
• Sep 29, 2026 Panic Disorder vs PTSD: Differential Diagnosis Case Study | PMHNP Boards

  💎 Ask what he's running from — the feeling of the next attack, or the memory of the crash — and the panic disorder vs PTSD differential settles.

  📇 Key Takeaways — the index card

  • Criterion A can be real and still mislead: Freddie witnessed a serious multi-vehicle collision and saw a driver bleeding out, but a vivid trauma story is a bias delivery system, not a diagnosis
  • His attacks are unexpected: abrupt surges peaking in 2–3 minutes, with seven of the 13 panic symptoms and no clear trigger, followed by a month-plus of dread, pulse-checking, and a life reorganized around not having the next one
  • His intrusions replay his own attacks — gripping the wheel, unable to breathe, losing control — not the crash; PTSD intrusions replay the event itself
  • Panic avoidance is placeless, clustering anywhere escape is hard — highways, an airplane, a line at Denny's, public transit; PTSD avoidance is tethered to concrete, sensory cues tied to the event
  • Panic attacks inside PTSD are provoked by trauma reminders, and PTSD hypervigilance runs as a baseline state while Freddie dysregulates with the attacks themselves — the presence of attacks settles nothing, the trigger settles everything, and the two diagnoses can still be comorbid
  • The call: panic disorder, not PTSD on today's evidence — but keep re-asking about the crash, because PTSD can emerge with delayed expression six months or more after the event, and a substantial minority of cases present that way

  📋 Flash-Card Summary — the article version

• Sep 22, 2026 Schizoid vs Schizotypal Personality Disorder: Clinical Clues | PMHNP Boards

  💎 Both withdraw socially, but for opposite reasons — the schizoid patient doesn't want closeness, while the schizotypal patient's magical, referential thinking gets in the way of the closeness in front of them.

  📇 Key Takeaways — the index card

  • Start with trait vs state: personality disorders are long-standing organization, not a days-long mood state — ask 'is this how you've always been?' before calling withdrawal a schizophrenia prodrome, depression, or social anxiety.
  • Schizoid detachment is indifference, not fear: no desire for close relationships (family included), little interest in sex, praise, or criticism, and a preference for solitary activities — and it is usually ego-syntonic, so these patients rarely present asking for help with it.
  • Don't medicate the temperament: a content loner does not need Wellbutrin or a stimulant to get him out of the bedroom — the lever, if the pattern ever becomes ego-dystonic, is psychotherapy exploring how he perceives relationships.
  • Schizotypal clues are perceptual: ideas of reference (the way the grill was closed meant he wasn't wanted), magical thinking and superstition, odd metaphorical speech ('yesterday was a bunch of saucy meatballs'), and paranoia-tinged social anxiety — odd, but not psychotic: no hallucinations or fixed delusions.
  • Separate the look-alikes: autism-spectrum patients often want social connection but miss cues, and avoidant patients want in but feel inadequate. Probe psychosis more thoroughly in either Cluster A presentation — schizotypal in particular shares genetic overlap with schizophrenia.
• Sep 15, 2026 Latuda (Lurasidone): When It Shines & When It Falls Short | PMHNP Boards

  💎 Latuda without food is a fraction of the dose — write 'with at least 350 calories' on every script.

  📇 Key Takeaways — the index card

  • Latuda is FDA-approved for schizophrenia and bipolar I depression — acute depressive episodes. Its usefulness in mania is not established on the label, it does not prevent mania, and there are case reports of it triggering hypomania or mania even at low bipolar-depression doses.
  • Ask two questions of every bipolar patient: what fire do I put out today, and how do I fireproof the other pole? Latuda extinguishes today's depression but leaves mania unprotected, so pair it with a plan — lithium is its natural dance partner — rather than stacking a second antipsychotic.
  • Its serotonergic signature explains the niche: 5-HT7 antagonism (mood, cognition, and sleep-wake reset), strong 5-HT2A blockade (fewer motor effects), and 5-HT1A partial agonism (a built-in, buspirone-like anxiolytic) — plus a weight profile that patients who refuse Zyprexa or Seroquel weight gain will actually accept.
  • The 350-calorie rule is pharmacokinetics, not trivia: without food you cut its efficacy roughly in half, which makes Latuda (like Geodon) a poor choice for food-insecure patients who cannot count on a meal with every dose.
  • Watch dose-dependent akathisia, nausea and vomiting, and rigidity or dystonia despite the 5-HT2A protection — and there is no Latuda LAI. NP Z's verdict: a scalpel, not a Swiss Army knife — one job, bipolar depression, done extremely well.
• Sep 8, 2026 Effexor (Venlafaxine) vs Cymbalta (Duloxetine): SNRI Differences | PMHNP Boards

  💎 Pain picks Cymbalta and panic picks Effexor — until protein binding, liver disease, blood pressure, or unreliable adherence overrules both.

  📇 Key Takeaways — the index card

  • Cymbalta is FDA-approved for diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain — one drug for mood, pain, and pain-wrecked sleep, framed as a psych med that softens the pain response, not a pain med.
  • Effexor is FDA-approved for generalized anxiety, panic disorder, and social anxiety disorder; Cymbalta's anxiety approval is generalized anxiety only, so panic and social anxiety use is off-label and needs an informed-consent conversation.
  • Duloxetine looks far stronger for norepinephrine in vitro by Ki, but in vivo the gap narrows — protein binding, metabolism, and reachable dose rewrite the lab result.
  • Duloxetine is highly protein bound: warfarin can displace it and be displaced in return, raising unpredictability and bleeding risk; liver disease cuts albumin, raises free drug, and the label cautions against use with substantial alcohol use or chronic liver disease.
  • Robust norepinephrine reuptake tends to sit near 120 mg duloxetine and 225 mg venlafaxine, but side effects gate the climb and a slow metabolizer may get the effect at 60 to 90 mg of duloxetine.
  • The call: let the most functionally impairing symptom lead — pain to Cymbalta if the med list and liver allow, panic to Effexor if blood pressure and reliable adherence allow, with a baseline BP and a venlafaxine taper plan counselled before the first dose.

  📋 Flash-Card Summary — the article version

• Sep 4, 2026 Psychiatric Interview Skills: 4 Techniques for New PMHNPs | PMHNP Boards

  💎 Let the intake do the robot work before the visit, so the session itself can be a human conversation instead of a DSM checklist read aloud.

  📇 Key Takeaways — the index card

  • Build a real intake: DSM-tethered questions plus scales like the PHQ-9 and GAD-7, and a 'what is the most important thing you want to talk about?' prompt — then spend about 10 minutes rapidly confirming it ('You're on Lexapro 10, no other meds or allergies — correct?') and pin anything unexpected for deeper oxygen later.
  • The intake raises or lowers your index of suspicion; it does not diagnose. A patient can flag every PTSD item with no Criterion A trauma underneath, or leave sections blank while pressured speech and 2 a.m. business launches give bipolar away in the room.
  • Use the 'life raft' move: mirror the patient's own words back — 'weighed down by a heavy blanket,' not 'depression' — because feeling accurately heard is what turns a flailing patient into a therapeutic alliance. Jumping into Lexapro-and-Prozac solution mode too early breaks that.
  • Squeeze the oranges: never breeze past a dropped detail — 'fired three times in two years,' a brother with schizophrenia, anemia, or 'I don't know how much longer I can do this' (your organic opening for the suicide risk assessment) each deserves follow-up now, or pocketing for later in the interview.
  • Have a system and stick to it 99 times out of 100 — rapid rule-outs first, then give the patient the floor on what brought them in — deviating mainly for panic, active psychosis, or severe trauma.
• Sep 1, 2026 Long-Acting Injectables (LAIs) in Psychiatry: Benefits Explained | PMHNP Boards

  💎 An LAI's absorption is the rate-limiting step — flip-flop kinetics turn a daily roller coaster of peaks and troughs into a slow, steady drip you can plan around.

  📇 Key Takeaways — the index card

  • Intramuscular delivery bypasses the gut wall and first-pass hepatic metabolism, so plasma levels are more predictable, with less interpatient variability from CYP polymorphisms and fewer food and drug interaction swings than the same drug by mouth.
  • Stay in the D2 window: oral dosing oscillates daily between too much drug (sedation, akathisia, EPS as occupancy pushes past roughly 80%) and too little (breakthrough psychosis, insomnia, irritability below the roughly 65–80% sweet spot). LAI curves are flatter, so less time is spent at either bad end — steadier levels and no daily pill burden, not a blanket promise of fewer side effects.
  • Adherence becomes visible: an estimated 40–50% of patients with schizophrenia take less than 70% of their prescribed oral doses, and many get mislabeled treatment-resistant. With a monthly injection, a missed appointment is an early-warning system — and the slow muscle absorption buys you weeks to call and reschedule instead of five half-lives to zero.
  • The injection visit doubles as a healthcare touchpoint every 2–8 weeks — vitals, weight, glucose, depression and suicide screening — and NP Z cites evidence tying LAIs to 28–44% fewer suicide attempts and roughly 20–30% lower all-cause mortality. His LAI patients in community practice were his easiest, best-monitored patients.
  • Offer LAIs proactively, not as a reaction after relapse: guidance supports considering them across the illness course, even in first-episode psychosis — but road-test the oral form first, because a dystonic or akathisia reaction is far messier to undo once a month of drug is already in the muscle.
• Aug 25, 2026 False Positive Drug Screens: What Psychiatric Providers Must Know | PMHNP Boards

  💎 Jimmy lost his take-homes, his job, and unsupervised visits with his daughter over screens his own prescribed meds caused — an immunoassay is presumptive, and only confirmatory GC-MS testing makes it a verdict.

  📇 Key Takeaways — the index card

  • Know the cross-reactors cold: sertraline is FDA-labeled to cause false-positive benzodiazepine screens, quetiapine can produce a false-positive methadone result (making a stable patient look like he is taking extra methadone on the side), and trazodone — via its mCPP metabolite — can also trip the amphetamine assay.
  • Amphetamine immunoassays are the worst offender — roughly 4–10% of positives are false in published reviews — and one methadone immunoassay showed a false-positive rate around 30%, with quetiapine a frequent cross-reactant among those false positives.
  • Jimmy's setup: 34, on methadone 90 mg daily for 14 months with 12 consecutive months of negative screens and earned take-home privileges, when a separate psychiatrist — who never communicated with the opioid treatment program — added sertraline 100 mg daily, trazodone 100 mg at bedtime, and quetiapine 100 mg at bedtime.
  • The cascade: two 'positive' screens brought revoked take-homes, daily observed dosing, a documented contract violation, and a report to family court; the required 6 a.m. clinic arrivals got him fired, his unsupervised weekend visits with his daughter were suspended, and he dropped out of treatment and relapsed on fentanyl.
  • The system failure is common: in a retrospective review of 160 urine drug tests across five clinics, 45% had no documented provider interpretation at all and 28% were interpreted wrong. Your move: document the interfering meds, teach the patient which of their meds can pop which panel so they can advocate for themselves anywhere, loop in the whole care team, and insist on confirmatory GC-MS before any consequence lands.
• Aug 11, 2026 ADHD vs Bipolar Disorder: Key Questions for Differential Diagnosis | PMHNP Boards

  💎 For Debbie, 32 and asking for Adderall, the discriminator is not the symptom list — it is pattern over time: ADHD is a steady daily drip, bipolar is discrete episodes.

  📇 Key Takeaways — the index card

  • Get collateral and ask the pattern question directly: is the spending and impulsivity a constant day-to-day foot on the gas (a trait — ADHD), or days-to-weeks bursts that are out of character, often followed by a depressive crash (a state — bipolar)? Debbie's $12,000 of credit card debt in the last year means very different things depending on that answer.
  • Sleep is the highest-yield split. ADHD patients want to sleep but cannot wind down, and wake tired and frustrated; in hypomania or mania patients feel they do not need sleep, wake rested and wired, and fill the night with goal-directed activity — ask what she is actually doing at 3 a.m., because cleaning the entire house is a classic tell.
  • Squeeze the job-loss orange: 'What do you think led to you losing your job?' Bipolar firings often run through episodic irritability and arguments ('I just wake up mad at the world'); ADHD irritability usually has context — frustration on detail-heavy tasks that tax attention, like assembling furniture from a manual.
  • Interrogate new ventures for grandiosity and connectedness: three side businesses in four months with a thought-out, contextual plan is one thing; a disconnected scheme she now looks back on as 'that was not me' points to an episode. ADHD projects are usually dropped from boredom and sometimes picked back up.
  • Timing and stakes: ADHD onset is before age 12, median bipolar onset around 25, and the two co-occur often — about 1 in 13 adults with ADHD also has bipolar disorder. In the cited Swedish registry study, starting methylphenidate alone — without a mood stabilizer — in bipolar disorder was associated with a roughly 6.7-fold hazard of manic episodes within 3 months, so stabilize mood first and only then treat ADHD cautiously under that cover.
• Aug 10, 2026 Insomnia in Psychiatric Patients: Depression, Anxiety, ADHD & Trauma | PMHNP Boards

  💎 Before reaching for a sedative, ask what is actually keeping them awake — depression ruminates about the past, anxiety forecasts the future, ADHD spins on unfinished tasks, and each answers to different treatment.

  📇 Key Takeaways — the index card

  • The question that does the work: 'What gets in the way of your sleep — what thoughts are churning as you try to fall asleep?' Past-focused guilt and replay points to depression; future-oriented worry to anxiety; productivity dread (the unsent email, tomorrow's reports) to ADHD; hypervigilance and nightmares to PTSD.
  • Treating the underlying disorder often treats sleep indirectly: SSRIs and SNRIs are not sedating, but less rumination and a less sensitive amygdala smoke-detector mean less hyperarousal at bedtime — and prazosin cools the same fight-or-flight system in PTSD.
  • Match the agent to the picture instead of sedating by default: mirtazapine for the anxious, depressed patient who is not eating and needs sleep tonight (alpha-2 blockade bringing appetite and sedation in one), and duloxetine when pain is the driver keeping them awake.
  • For primary chronic insomnia, CBT-I is the guideline-backed first-line treatment and works better long-term than pills (digital options like Insomnia Coach count) — even when access, cost, and patient time make it frustratingly hard to deliver in real practice.
  • If a drug is still needed, NP Z reaches for ramelteon 8 mg (non-addictive, helps sleep onset) or low-dose doxepin 3–6 mg (FDA-approved for staying asleep). Trazodone is cheap and widely used off-label but its insomnia evidence is limited, Z-drugs are a short-term fix for a chronic problem, and activating agents need care — go low and slow with fluoxetine, and expect bupropion to worsen anxiety-driven insomnia.
  • Screen the medical drivers too: hyperthyroidism, restless legs, caffeine, other medications, and sleep apnea — snoring, gasping, morning headaches, and brain fog deserve a sleep study, not a sleeping pill.
• Aug 8, 2026 Effexor (Venlafaxine): When & Why to Choose This SNRI | PMHNP Boards

  💎 Effexor is NP Z's first SNRI after two SSRIs fail — unless pain leads, then it is Cymbalta — and above 150 mg it stops behaving like an SSRI as the noradrenergic action comes in.

  📇 Key Takeaways — the index card

  • Broad label, strong panic performance: FDA approvals span major depression, generalized anxiety, social anxiety disorder, and panic disorder, and NP Z finds his patients panic notably less on it than on the SSRI that failed first.
  • Dose changes the drug: mostly serotonergic at lower doses, with meaningful norepinephrine reuptake inhibition as you push above roughly 150 mg — built-in help for residual fatigue, poor concentration, and low energy without adding a second agent.
  • The withdrawal is the deal: a very short half-life means even one missed dose can bring brain zaps, flu-like symptoms, diarrhea, and irritability. That ironically drives adherence in reliable patients — and makes Effexor a setup-to-fail choice for anyone with a shaky adherence history.
  • Bonus indications with a real evidence base: menopausal vasomotor symptoms (hot flashes, via serotonin and norepinephrine effects on thermoregulation) and migraine prophylaxis — a menopausal patient with GAD or panic is a textbook fit.
  • Polypharmacy-friendly, with one trap: venlafaxine is only a weak CYP inhibitor itself, but it is metabolized by CYP2D6 — a potent 2D6 inhibitor still on board (paroxetine, or fluoxetine that has not washed out) can push venlafaxine levels up as you start it.
• Aug 4, 2026 Metformin for Antipsychotic Weight Gain: An Easy Win | PMHNP Boards

  💎 Weight gain is the number one patient-reported reason patients stop antipsychotics — and metformin, a $4-a-month generic, can help prevent or reverse the weight gain driving it.

  📇 Key Takeaways — the index card

  • How it works, in NP Z's order: metformin reduces how much sugar the gut absorbs, improves insulin sensitivity, and — the single biggest driver — blocks the liver from overproducing sugar. It does not trigger insulin release or beta-cell stimulation, so hypoglycemia is not the expected concern.
  • The metabolic cascade starts early, not eventually: quetiapine blocks H1 receptors at just 50 mg, hunger can surge within days, and olanzapine can drive rapid, substantial weight gain that keeps accumulating over months — then visceral fat, insulin resistance, rising cholesterol, hypertension and prediabetes. Patients with serious mental illness die 15 to 20 years earlier, and cardiovascular disease is their leading killer.
  • It is drastically underused: NP Z cites a JAMA study of about 30,000 youth in which only 2.3% were co-prescribed metformin alongside a second-generation antipsychotic.
  • Dose and tolerability: the antipsychotic-induced weight-gain trials used 1,000 to 2,000 mg a day, with doses above 1,500 mg typically linked to greater weight loss in the general population. Start at 500 mg with food, titrate slowly, and use the extended-release form to ease the dose-related, usually transient nausea and diarrhea and to help adherence.
  • Do not defer this to primary care: you prescribed the antipsychotic, so ordering the labs and metabolically insulating the patient is your job — many patients have no PCP, or will not see one for 90 days or more, and a lot of metabolic damage can happen in those 90 days.
  • The call — his mother of all pearls: consider metformin every time you start a second-generation antipsychotic, even a low dose for major depressive disorder augmentation, and start it proactively at initiation instead of after the damage is done. Flip the question from should I add it? to why wouldn't I add it right now?
• Aug 3, 2026 Prozac (Fluoxetine) vs Zoloft (Sertraline): Real SSRI Differences | PMHNP Boards

  💎 Prozac's active metabolite lingers one to two weeks - it largely tapers itself, but its CYP2D6 blockade and side effects linger just as long.

  📇 Key Takeaways — the index card

  • Half-life chasm: Zoloft's parent half-life is about a day (its metabolite lasts longer); Prozac's norfluoxetine lasts 1-2 weeks, forgiving missed doses but needing about a 5-week washout before an MAOI, versus roughly 2 weeks for Zoloft
  • Prozac potently blocks CYP2D6 for weeks, raising levels of aripiprazole and risperidone and blocking tamoxifen from activating; Zoloft inhibits mildly and clears through several CYP pathways
  • Zoloft is the calmer pick on a long med list and in cardiology settings (SADHART post-heart-attack safety data), and it carries the best breastfeeding evidence
  • Prozac tends to activate - early jitteriness, insomnia, appetite suppression; Zoloft's signature is GI - nausea and loose stool; both commonly cause sexual side effects, so ask
  • Approval map: Zoloft adds PTSD and social anxiety disorder; PMDD is not a Zoloft-only add — Prozac (fluoxetine, formerly marketed for PMDD as Sarafem) is also FDA-approved for PMDD; Prozac is the only SSRI approved for bulimia nervosa at 60 mg, and with olanzapine (Symbyax) it treats bipolar I depression
  • The call: start panic patients at half the usual dose - Prozac 10 mg instead of 20 mg, Zoloft 25 mg instead of 50 mg - and check your own prescribing bias against the trial evidence
• Jul 31, 2026 PTSD vs Depression vs Adjustment Disorder: Differential Diagnosis | PMHNP Boards

  💎 Barry meets Criterion A and still does not have PTSD — a qualifying trauma is the entry ticket, not the diagnosis.

  📇 Key Takeaways — the index card

  • The case: Barry, 34, learned three weeks ago that his godfather and lifelong mentor died accidentally, choking on a steak at dinner. His PHQ-9 is 9, sleep is rocky three to four nights a week, he avoids that restaurant chain, and he feels guilty he was not at the dinner — but he still plays guitar, watches football, enjoys his kids, and has no suicidal thoughts.
  • Criterion A is narrow: learning of a violent or accidental death of someone close qualifies; a natural death (heart failure in hospice) does not, and a celebrity's accidental death does not count for a fan. Closeness and manner of death both matter.
  • PTSD is global, adjustment is circumscribed: PTSD brings intrusive reliving, nightmares, hypervigilance, and a rewritten view that the world and people cannot be trusted, shutting life down across domains — and most people exposed to a Criterion A event never develop it, because criteria B through E still have to be met. Barry's avoidance stops at one restaurant chain and his distress tracks the stressor.
  • Depression's tell is worthlessness, not sadness: major depression needs depressed mood OR anhedonia, most of the day, most days — a patient can deny sadness and still be fully depressed on anhedonia alone. Depressive guilt is pervasive self-condemnation ('I am a failure'); Barry's is specific ('I could have done the Heimlich').
  • The call for Barry: not PTSD, not major depression — adjustment disorder and grief, and possibly no disorder at all, since adjustment disorder itself requires marked distress or impairment and grief should not be pathologized. Medications are far less effective for adjustment problems than for depression — but keep screening (PCL-5), because PTSD can arrive with delayed expression months later.
• Jul 30, 2026 Choosing Antipsychotics for Bipolar Disorder: 4 Prescribing Pearls | PMHNP Boards

  💎 Ask two questions in order — which pole is in front of me right now, and which pole do I need to prevent next — because bipolar patients spend about three times as long depressed as manic.

  📇 Key Takeaways — the index card

  • Pearl 1, pole coverage differs: Seroquel, Vraylar, and Latuda can treat acute bipolar depression, as can Zyprexa only in combination with fluoxetine (Symbyax) — Zyprexa alone is approved for mania and maintenance, not bipolar depression, and Latuda is not approved for mania; Risperdal, Abilify, Geodon, and Haldol treat mania but will not lift the acute bipolar depression in front of you. Abilify augments antidepressants in unipolar depression — it is not itself an antidepressant.
  • Lamictal is fireproofing, not a fire extinguisher: it needs weeks of slow titration because of the Stevens-Johnson risk and works by preventing depressive relapse. It will not put out today's acute depression.
  • Pearl 2, know the deal-breakers by receptor: Zyprexa is the biggest metabolic offender, with heavy H1 and muscarinic burden (dry mouth, constipation, cognitive dulling). When weight and sedation are refused, look to Latuda, Abilify, Vraylar, and Geodon — remembering Latuda and Geodon need food to be absorbed properly.
  • Binding style predicts the complaint list: Risperdal's tight D2 binding brings prolactin elevation and sexual side effects; Seroquel's loose D2 binding ('kisses the receptor and falls off') means fewer movement disorders — the pick after a scary dystonic reaction, or in Parkinson's. Abilify's signature problem is akathisia, and Geodon carries the QTc caution.
  • Pearl 3, mechanism predicts behavior: Seroquel's metabolite norquetiapine is a potent norepinephrine reuptake inhibitor with 5-HT1A partial agonism (the 'Sero-chill' effect), but sedation can make titration hard, especially toward the higher end of the dose range (bipolar depression target is 300 mg; mania dosing is typically 400–800 mg). Abilify is a dopamine thermostat holding roughly 30% intrinsic activity; Vraylar's tenfold D3-over-D2 preference targets anhedonia and negative symptoms; Latuda's 5-HT7 antagonism drives its bipolar-depression lift.
  • Pearl 4, maintenance is the verdict step — plus one trap: Seroquel treats and prevents both poles, and Zyprexa is approved for bipolar maintenance (recurrence prevention, with the strongest trial evidence at the manic pole) at a heavy metabolic cost, while Latuda treats today's depression but does not prevent mania; if Seroquel is refused, cover both poles with a combination (Lamictal for depression prevention plus Abilify for mania) rather than leaving one pole exposed. And with Zyprexa, remember smokers induce CYP1A2 and need more drug — if they quietly quit, levels climb and side effects hit fast.
• Jul 28, 2026 Antipsychotic Switching: Key Concepts & Clinical Considerations | PMHNP Boards

  💎 Stopping a strong D2 blocker abruptly after years leaves upregulated, supersensitive dopamine receptors unprotected — a low starting dose of the new antipsychotic does not replace that blockade.

  📇 Key Takeaways — the index card

  • Judge the stakes before you switch: Lydia had been stable on risperidone 4 mg for 3 years despite schizoaffective disorder, 3 involuntary hospitalizations for manic, delusional episodes, and 2 past suicide attempts — a checkered history like that means destabilizing her carries a high cost, so the switch has to be planned carefully.
  • Match the D2 blockade you are removing: risperidone has very high D2 affinity, so the replacement must block D2 effectively in the mesolimbic circuits controlling psychosis and mania — the failed switch stopped risperidone one day and started quetiapine 100 mg the next, and she was back in the hospital manic and dysregulated in 4 to 5 days.
  • Quetiapine is dose-dependent, almost three drugs in one: low doses are mainly hypnotic, medium doses reach antidepressant and antimanic mechanisms, and only high doses deliver antipsychotic D2 blockade — 100, 150, or even 200 mg will not cover a patient coming off risperidone, and sedation from its strong histamine antagonism limits how fast you can titrate up.
  • Years of D2 blockade cause upregulation: the brain makes more dopamine receptors and makes them more sensitive to compensate, so abruptly unblocking them opens the door to rebound psychosis or mania, pressured speech and impulsivity — and supersensitive receptors in motor pathways can also produce withdrawal dyskinesia.
  • Do not strip D2 coverage while onboarding the next drug: keep the first antipsychotic on board long enough to block D2 as you carefully bring the new one on, check the prescriber guide for timing, and factor in half-life — how long the discontinued drug will still be in the system after you stop it.
  • Make the switch solve the problem that prompted it: Lydia's irregular periods and galactorrhea came from risperidone blocking D2 in the tuberoinfundibular pathway and raising prolactin, so replacing it with another drug that blocks D2 in that same pathway risks the same side effects and nonadherence — also weigh residual target symptoms and metabolic-pathway interactions with the patient's other medications.
• Jul 26, 2026 Psychopharmacology Made Simple: The Grocery Store Trick | PMHNP Boards

  💎 Every prescription is two grocery-store questions: which checkout lanes can this drug use to be metabolized, and how full is its cart — how much does it block everyone else's lane?

  📇 Key Takeaways — the index card

  • Lexapro runs mainly through CYP2C19, with CYP3A4 (and a smaller CYP2D6 contribution) as additional lanes: the FDA label notes it is metabolized by multiple enzyme systems, so blocking one lane alone may not appreciably cut clearance — but a CYP2C19 poor metabolizer still gets higher exposure and more side effects. Its virtue is the nearly empty cart — it is only buying eggs — so it negligibly inhibits other drugs' metabolism.
  • Zoloft is the flexible shopper: metabolized across multiple lanes (2C19, 2C9, 2D6, 3A4, and 2B6) with only a moderately full cart, so it stays workable alongside antipsychotics — one reason it is the classic studied choice in psychotic depression.
  • Prozac is the hard case on both questions: predominantly 2D6-dependent AND a potent 2D6 blocker with an overflowing cart — it raises levels of Abilify, Risperdal, and Haldol, while doing the opposite to two prodrugs — it blocks CYP2D6 activation of tamoxifen (less endoxifen) and codeine (less morphine), so both can lose efficacy — it inhibits its own metabolism, and the blockade lingers about five weeks after you stop it.
  • Clean and flexible are different virtues: 'does not interact' (Lexapro) describes what a drug does to others; metabolic flexibility (Zoloft) describes what other drugs and the patient's own enzymes do to it. Check both directions before you prescribe.
  • NP Z's practice note: despite Prozac's messy cart, he often has more clinical luck with it than with Zoloft — the grocery store tells you where the interaction risks live, not which drug wins for the patient in front of you.
• Jul 24, 2026 Bipolar Relapse Prevention: The Polarity Index Explained | PMHNP Boards

  💎 Polarity Index above 1 leans antimanic, below 1 leans depression-preventing, and near 1 means balanced coverage — match maintenance to the pole your patient actually relapses into.

  📇 Key Takeaways — the index card

  • The extremes anchor the scale: risperidone sits near 12, the most strongly antimanic, while lamotrigine is 0.4, the strongest for preventing depression — and lamotrigine has almost no antimanic firepower
  • Quetiapine at 1.14 is the outlier: NP Z calls it the only second-generation antipsychotic with robust evidence for preventing both poles as monotherapy and as adjunctive therapy, paid for in weight gain, triglycerides, and sedation
  • Treat the fire in front of you AND the maintenance pole behind it: Marcus, with 3 prior manias and 1 mild depression, fits Abilify for mania — but his depression coverage stays imperfect and may need lamotrigine watched in
  • Acute bipolar depression is not a lamotrigine job: its 4-6-week titration for Stevens-Johnson risk is too slow for a suicidal patient today, so Diana's acute fire gets Latuda (5-HT7 antagonism, FDA-approved for bipolar depression) and lamotrigine becomes the long-game prevention
  • Ray is the curveball — manic now, but 6 depressive episodes against 1 mania: quetiapine to roughly 600-800 mg can put out the mania now while its norquetiapine metabolite (norepinephrine transporter blockade) protects against the depression that is his real enemy
  • The call: for mostly-depressed Tanya with one past mania, Vraylar covers both — FDA-approved for bipolar depression and mania, with D3 affinity about 10 times its D2 affinity aimed at anhedonia and low motivation
• Jul 23, 2026 Abilify (Aripiprazole) for Depression: Augmentation Explained | PMHNP Boards

  💎 Abilify is a helper, not a healer: it has no meaningful antidepressant action on its own — it cleans up the problems an SSRI creates so the SSRI can work.

  📇 Key Takeaways — the index card

  • Without an antidepressant already on board there is nothing for Abilify to fix — NP Z's image is a housemaid arriving after a clumsy plumber; with no muddy footprints, she has no job, and Abilify alone will not lift acute bipolar depression
  • The brake problem: an SSRI's surge triggers the presynaptic 5-HT1A autoreceptor to shut serotonin firing down, which is part of why SSRIs take 2-4 weeks; Abilify's 5-HT1A partial agonism sends a weaker signal, so the autoreceptor chills instead of slamming the brake
  • The wrong-receptor problem: SSRI stimulation of 5-HT2A drives early anxiety, insomnia, agitation, and sexual dysfunction — Abilify antagonizes 5-HT2A (and binds with moderate affinity at 5-HT2C, where the label does not describe simple antagonism), directly countering that early rough patch
  • The blunting problem: excess serotonin suppresses dopamine firing from the ventral tegmental area and drags norepinephrine down with it, leaving patients flat, fatigued, and unable to feel pleasure; Abilify's D2 partial agonism holds a dopamine floor at about 30% intrinsic activity instead of blasting it
  • Dosing tells the story: augmentation starts at 2-5 mg (the FDA adjunctive range is 2-15 mg/day, with efficacy established across that range); push higher and Abilify shifts toward heavy D2 occupancy, motor side effects, and its antimanic/antipsychotic jobs
  • The call: call it augmentation, not an antidepressant — its serotonin reuptake inhibition is, in NP Z's words, pathetically weak, and it earns its place only alongside the antidepressant it is fine-tuning
• Jul 22, 2026 The Polarity Index: Choosing Bipolar Maintenance Medications | PMHNP Boards

  💎 Predominant polarity means roughly two-thirds of a patient's lifetime episodes sit at one pole — count the episodes, because that ratio, not just the bipolar I or II label, should drive maintenance.

  📇 Key Takeaways — the index card

  • Bipolar disorder goes misdiagnosed for roughly 7-10 years in part because depressive symptoms dominate the symptomatic course (about 32% of follow-up weeks in bipolar I and about 51% in bipolar II, versus roughly 9% and 1% respectively for manic/hypomanic symptoms) and hypomania often feels productive, not like a problem worth reporting
  • Mania is not always Hollywood: the less flashy version is edgy, irritable, self-harming, substance-using, and suicidal — put that cluster together before you decide a patient is depression-predominant
  • Separate two questions every visit: acute treatment puts out the fire in front of you (Symbyax, the olanzapine-fluoxetine combination, is NP Z's example of an acute-fire tool), while maintenance fireproofs the house — and lamotrigine's slow 4-6-week titration makes it maintenance only
  • Reading the index: above 1 is antimanic (risperidone around 12, almost entirely antimanic with very little depression prevention), near 1 is balanced (lithium and quetiapine, the Swiss army knives), below 1 is depression-preventing (lamotrigine)
  • The trap: starting Abilify or risperidone for the mania you see in the ER and discharging without flagging that a depression-predominant patient may need transition to lamotrigine in follow-up leaves the pole that actually dominates untreated
  • The call: ask directly — how many manic or hypomanic episodes versus how many depressive episodes? — then pick maintenance above or below an index of 1 to match, weighing risperidone's prolactin elevation against Abilify's easier metabolic profile
• Jul 21, 2026 Naltrexone & the Sinclair Method for Alcohol Use Disorder | PMHNP Boards

  💎 The best naltrexone candidate is the reward drinker: in PREDICT reanalyses, high-reward, low-relief drinkers were significantly less likely to have a heavy-drinking day and took longer to reach a first heavy-drinking day on naltrexone than on placebo.

  📇 Key Takeaways — the index card

  • Sort drinkers before you prescribe: reward drinkers chase the buzz, euphoria, and social enhancement (nucleus accumbens, opioid-mediated), while relief drinkers drink to escape anxiety, depression, stress, or withdrawal (dorsal striatum and amygdala stress circuits) — and phenotypes can shift over the course of the disorder
  • The Sinclair Method is pharmacological extinction: naltrexone 50 mg taken 1-2 hours before drinking, only on drinking days, blocks opioid receptors during the drink so the brain gradually unlearns the alcohol-reward association
  • Be precise about status: Sinclair dosing is not the FDA-approved strategy — the approved regimen is 50 mg daily, typically for at least six months — but targeted dosing can help patients who get nauseated on daily naltrexone or cannot adhere to it
  • The durability is the surprise: a 2022 double-blind RCT in 120 sexual and gender minority men with mild to moderate alcohol use disorder found reductions in binge-drinking days, drinks per month, and craving scores still sustained six months after treatment ended, with a number needed to treat of 2 for binge-drinking days
  • Safety gates before starting: the patient must be opioid-free for 7-10 days, and use caution or avoid with cirrhosis or hepatitis — Marcus, the 34-year-old mock patient drinking 4-6 beers most evenings with normal LFTs and no opioid use, clears both
  • The call: do not just count drinks — ask what the drink does. Marcus drinks for pleasure, not relief (PHQ-9 of 3, GAD-7 of 2), does not want total abstinence or AA, and that reward phenotype is exactly what makes him a Sinclair candidate
• Jul 16, 2026 ADHD Stimulants Explained: 5 Prescribing Pearls | PMHNP Boards

  💎 Every stimulant on the market is just two molecules in different packaging: methylphenidate (the Ritalin family) and amphetamine (the Adderall family).

  📇 Key Takeaways — the index card

  • Pearl 1, potency and response: amphetamine is roughly twice as potent milligram for milligram as methylphenidate, and NP Z cites effect sizes of about 0.79 for amphetamines versus about 0.49 for methylphenidate. About 41% of patients respond equally well to both classes, about 28% do better on amphetamines, and about 16% do better on methylphenidate — and unlike most psych meds, effect usually shows within the hour, not in 4 to 6 weeks. His routine starts: Adderall XR 10 to 20 mg, Concerta 18 mg, or Vyvanse 30 mg.
  • Pearl 2, pick the formulation by hours of coverage needed: immediate-release lasts about 4 to 6 hours and is used most often as an afternoon booster; Adderall XR, Ritalin LA, and Focalin XR run about 8 to 10 hours; Concerta and Vyvanse run about 10 to 13 hours. If a dose wears off early, optimize the dose first — NP Z names underdosing as the most common reason — then switch to a longer-acting formulation in the same class or add an IR booster.
  • Pearl 2, the variables that move those textbook hours: amphetamine is metabolized through CYP2D6, acidic urine speeds its excretion and shortens duration while alkaline urine (and antacids) prolong it, and a high-fat breakfast significantly delays early exposure from Adderall XR but does not affect Concerta the same way — so ask what the patient eats for breakfast before blaming the dose when a 9 a.m. presentation goes badly.
  • Pearl 3, delivery systems shape the day: Ritalin LA's bead system releases about 50% immediately for a morning boost, then a delayed second release about 4 hours later. Concerta's OROS tablet releases about 22% right away and pumps the remaining 78% out slowly over 10 to 12 hours, giving an ascending curve that ramps up into the afternoon. Vyvanse is a prodrug — an enzyme has to cleave off its lysine before the dextroamphetamine is active — which is why its onset is smoother, its duration longer, and its abuse potential lower.
  • Pearl 4, conversions without a table: there is no single validated cross-class conversion table, so use the 2-to-1 rule within reach — 10 mg of methylphenidate is about 5 mg of dextroamphetamine in clinical effect. Within a class, match the daily total: Adderall IR 10 mg twice daily converts to Adderall XR 20 mg, and methylphenidate IR 5 mg three times daily (15 mg total) maps to Concerta 18 mg per the FDA label. Across classes, NP Z does not convert at all — he starts the new drug at a standard dose, such as Vyvanse 30 mg, and titrates in weekly increments.
  • Pearl 5, when stimulants seem to fail: do not declare failure until you have tried both families and titrated to the maximum tolerated dose — most nonresponse is an unoptimized dose, not a patient who cannot benefit. Only after both classes truly fail does he move to the nonstimulants: Strattera (atomoxetine), viloxazine, and guanfacine, including guanfacine combined with atomoxetine.
• Jul 15, 2026 PMDD: Why SSRIs Work in Days — Diagnosis & Luteal-Phase Dosing | PMHNP Boards

  💎 SSRIs work in days for PMDD, not weeks — one proposed reason is a rapid effect on the enzyme (3α-HSD) that makes allopregnanolone, the calming neurohormone whose luteal-phase drop PMDD patients are sensitive to.

  📇 Key Takeaways — the index card

  • Diagnosis is provisional until proven on paper: PMDD requires a daily symptom record (the DRSP) across two or more cycles — it is a DSM-5-TR requirement, not an optional journaling tip
  • It is the drop, not a deficiency: progesterone converts to allopregnanolone, a GABA-enhancing natural sedative, and when no pregnancy occurs it falls rapidly in the luteal phase; susceptible women react to that fall like a withdrawal state, with surge anxiety, irritability, and rage
  • A second hit: midbrain serotonin transporter binding rose about 18% from the periovulatory to the premenstrual phase in PMDD patients (while controls fell about 10%), clearing serotonin faster at that point in the cycle — one more reason an SSRI, which also switches on allopregnanolone synthesis via 3-alpha-HSD, can land within days
  • Three dosing strategies are all legitimate: luteal-phase only (about 10-14 days before the period), symptom-onset dosing, or continuous daily dosing — Cochrane evidence leans toward a greater effect size for continuous, but luteal-only spares patients a month of weight gain, sexual dysfunction, and blunting for roughly half the days
  • FDA-approved options are Zoloft, Prozac, and Paxil — with a strong caution on Paxil in women of childbearing potential, and a practical lean toward Zoloft; lower doses usually work, and stopping after short luteal courses carries less discontinuation concern than stopping high-dose, long-term treatment
  • The call: watch for the simmering volcano — background depression all month with a luteal eruption may need both, e.g. Prozac 20 mg daily bumped to 30 mg in the luteal phase, rather than luteal-only dosing — and rule PMDD in or out before signing off on bipolar II or borderline
• Jul 14, 2026 Caffeine & Mood Disorders: The Detail That Derails Treatment | PMHNP Boards

  💎 Roughly 1,100-1,500 mg of caffeine a day for a month turned a depression case into apparent hypomania — and because the onset was tied to the substance, the diagnosis is substance-induced mood disorder, not bipolar.

  📇 Key Takeaways — the index card

  • Do the milligram math, not the cup count: the mock patient Paul, 41, was taking 3 Red Bulls plus 2-3 caffeine pills daily to self-medicate a month of depression — ask about energy drinks, pre-workout, caffeine pills, green tea, and dark chocolate, because caffeine now hides in flavored waters too
  • Thresholds NP Z anchors on: evidence suggests even 400 mg can induce panic in some people, around 600 mg a day is where marked mood changes become a real concern, and caffeine metabolism varies roughly 40-fold between people
  • Mechanism: caffeine antagonizes adenosine receptors, removing the inhibitory sleep-drive signal and unleashing excitatory dopamine and glutamate release — plus the sleep deprivation itself is a well-known precipitant of hypomania and mania in vulnerable patients
  • Caffeine also sabotages treatment directly: it can lower serum lithium concentrations and destabilize mood, and it is metabolized through CYP1A2, a pathway crowded with psychiatric drug interactions
  • The soft bipolar signs were real but not decisive: father with bipolar disorder, recurrent depressions since his early 20s, a suicide attempt at 19, and prior Lexapro that made him anxious and hyper — always ask why a past SSRI was stopped, and pin down what a patient means by 'I felt great' (recovery versus activation)
  • The call: a negative urine drug screen does not clear substances — Paul's screen was negative and his chart said one coffee a week while a vape pen and Red Bull sat in his tote bag; rule out the medical and substance pieces, caffeine included, before assigning a lifelong bipolar diagnosis and lifelong medication plan
• Jul 13, 2026 CYP450 for Psychiatric Prescribers: 3 Clinical Pearls | PMHNP Boards

  💎 Know the Fab Four, the strong 2D6 blockers, and the timing rule: inhibition hits fast, induction creeps in over weeks — that trio prevents most CYP prescribing accidents.

  📇 Key Takeaways — the index card

  • Pearl 1, the Fab Four: Lexapro, Zoloft, Effexor, and Remeron (plus Pristiq, Effexor's active metabolite) barely inhibit or induce CYP enzymes, so reach for them first on a long med list or in older patients — with one caveat, Zoloft turns into a moderate CYP2D6 inhibitor at higher doses, roughly 150-200 mg
  • Pearl 2, the offenders: Prozac and Paxil (the two Ps) and Wellbutrin are strong CYP2D6 inhibitors that can convert a patient into a functional poor metabolizer; Cymbalta is a moderate 2D6 inhibitor
  • The interaction NP Z actually sees: add Prozac or Paxil to Abilify without cutting the Abilify dose roughly in half and you can manufacture akathisia; Wellbutrin likewise raises Abilify and risperidone levels despite its clean, no-sexual-side-effects reputation
  • The five-fold warning: Wellbutrin co-administered with Strattera can raise Strattera exposure about five-fold — palpitations, sweating, raised heart rate and blood pressure, nausea, insomnia — on top of a pairing NP Z already finds redundant, since both push norepinephrine and dopamine
  • Pearl 3, timing: inhibition is immediate, induction is delayed — a patient who starts smoking loses Zyprexa effectiveness gradually over weeks as CYP1A2 induction builds, and if they then quit, Zyprexa levels climb back up toward toxicity
  • It is the smoke, not the nicotine: polycyclic aromatic hydrocarbons from burning tobacco induce CYP1A2, so nicotine patches and vaping do not do it — ask every patient on Zyprexa about cigarettes specifically
• Jul 11, 2026 Same SSRI Dose, Different Outcomes: CYP Enzymes & Protein Binding | PMHNP Boards

  💎 20 mg of Prozac is not 20 mg in every body: blood levels after a 40 mg dose can range roughly 15-55 ng/mL — a fourfold spread created by CYP enzymes, protein binding, and the blood-brain barrier.

  📇 Key Takeaways — the index card

  • First pass decides the real dose: the pill is swallowed, absorbed in the gut, and sent through the portal vein to the liver, where CYP enzymes (for Prozac, prominently CYP2D6) chew up a genetically variable share before any drug reaches the brain
  • Dennis versus Patty: Dennis metabolizes at a predictable rate and lands in the therapeutic window; Patty, a poor metabolizer, piles drug up until nausea and insomnia become deal-breakers; the ultra-rapid metabolizer at the other end feels nothing at all — same pill, three different effective doses
  • Only the free fraction counts: most drug rides bound to albumin like passengers on life rafts and does nothing until it lets go; low albumin (liver disease, for example) means more free drug and more side effects at the same dose
  • Inflammation flips it the other way: cancer, surgery, trauma, infection, Crohn's, and rheumatoid arthritis raise acute-phase binding proteins, so more drug gets stuck bound, a level can even look high, and the medication appears not to work
  • Displacement is a sumo match: uremic toxins in chronic kidney disease and drugs like ibuprofen can knock Depakote off its albumin sites, suddenly raising free Depakote toward toxicity without any dose change
  • The call: the blood-brain barrier is the third gate — its P-glycoprotein pumps actively eject drugs from the brain and vary genetically — so a failed medication is not a failed class; switching to a drug handled by different CYP pathways and pumps is a rational move, not eeny-meeny-miny-moe
• Jul 7, 2026 Antidepressant Not Working? 4 Questions to Ask First (Zoloft Case) | PMHNP Boards

  💎 Before switching a 'failed' antidepressant, run the four questions in order: Is she taking it? Is the dose adequate? Has it been long enough? Is the diagnosis even right?

  📇 Key Takeaways — the index card

  • Adherence first, because the base rate is brutal: antidepressant nonadherence is estimated around 46% — nearly 1 in 2 outpatients — driven by sexual dysfunction, weight gain, nausea, insomnia, stigma, forgetfulness, and a delayed onset that punishes patience
  • The payoff for fixing it: patients adherent at least 80% of the time have roughly 2.6-3.1 times higher odds of treatment response, so anticipatory guidance — naming the side effects up front and noting most fade in about two weeks — is a treatment intervention, not small talk
  • Maria's case: 42, on Zoloft 50 mg for 10 weeks, PHQ-9 improved from 21 to 16 — that is a partial response, not a failure, and NP Z's move is to press the gas toward 75-100 mg rather than switch; 50 mg is a common starting dose, not most patients' sweet spot in his experience (range 50-200 mg)
  • An adequate trial is 4-12 weeks at a therapeutic dose with consistent adherence — and the clock starts when those conditions are met, not when the prescription was written; 12 weeks at 35% adherence is not a trial at all
  • Skipping the checklist manufactures 'treatment resistance': premature switches add discontinuation symptoms that color the next drug, stack failed-trial labels that demoralize patients, and push people toward TMS or ketamine they may never have needed
  • The call: question 4 is humility — ask what you missed (sleep apnea on a STOP-BANG, hypothyroidism, substance and caffeine use, chronic pain, bipolarity; NP Z notes about 25% of depression presentations in primary care may be unrecognized bipolar) before concluding the medication failed Maria
• Jul 5, 2026 Irritability Differential Diagnosis: Depression, ADHD, Bipolar & More | PMHNP Boards

  💎 Irritability is a symptom, not a diagnosis: the pattern — triggered and threat-based, episodic and theatrical, or brand-new after a dose increase — tells you which neurotransmitter system to target.

  📇 Key Takeaways — the index card

  • Map the mechanism to the med: threat-driven irritability (PTSD, GAD — where irritability is literally a diagnostic criterion) runs through an overactive amygdala, so SSRIs cool the threat circuit and restore prefrontal top-down control; manic irritability runs on excess limbic dopamine, so the answer is D2 blockade
  • Pattern separates bipolar from PTSD: bipolar irritability tends to be episodic — calm seas, then a multi-day rogue storm where anything sets the patient off, spilling into fights at work — while PTSD irritability is usually tied to triggers and feeling physically unsafe
  • Zoloft has the most direct evidence: in the EMBARC study it reduced irritability significantly more than placebo, and the improvement was independent of its effect on depression severity — a specific anti-irritability signal, not just mood lift
  • Know the activation cluster before you raise a dose: new irritability appearing in the first 1-2 weeks of an SSRI or right after an increase, bundled with restlessness, insomnia, impulsivity, extra shopping, and emotional lability, points at the medication — slow down, lower, or switch instead of pushing higher
  • Document baseline irritability thoroughly, because the follow-up decision hinges on it: still-irritable-but-improving from a high baseline can justify a dose increase, while irritability in a patient who told you they are 'not an irritable type' is a red flag for activation or emerging bipolarity
  • The call: check sleep before you blame the drug — sleep loss alone makes the amygdala hyperreactive, and a 5-HT2A antagonist like trazodone or Remeron may fix the irritability by fixing the night; for ADHD-driven irritability, optimize the stimulant and consider guanfacine (alpha-2 agonism strengthening prefrontal control), and treat the patient's most impairing symptom first, not the textbook's
• Jul 1, 2026 Z-Drugs (Zolpidem, Eszopiclone, Zaleplon): Prescribing Pearls | PMHNP Boards

  💎 Z-drugs are selective GABA-A positive allosteric modulators aimed at the alpha-1 sedation subunit — that selectivity is why they spare slow-wave sleep and carry less addiction machinery than benzos, which hit alpha-1, 2, 3, and 5 indiscriminately.

  📇 Key Takeaways — the index card

  • Slow-wave sleep is the prize: it consolidates memory, clears metabolic waste including amyloid-beta and tau via glymphatic flow, supports immunity, and lowers cortisol — Z-drugs do not reduce it to the degree benzodiazepines do, which is the core pharmacologic argument for choosing one over Klonopin for sleep
  • Subunit map: benzos bind alpha-1 (sedation), alpha-2/3 (anxiolysis, muscle relaxation), and alpha-5 (cognition and memory); Z-drugs prefer alpha-1 and largely skip alpha-2/3/5, so they are more targeted — but alpha-1 action on ventral tegmental interneurons is itself linked to benzodiazepine reward and dependence, so Z-drugs remain habit-forming, and tolerance and rebound insomnia still occur
  • NP Z's default is Lunesta (eszopiclone): half-life about 6 hours covers both sleep onset and maintenance, it binds alpha-2/3 more than Ambien or Sonata for a little added anxiolysis, and its FDA trial language noted no development of tolerance to any sleep parameter over six months
  • Match half-life to the complaint: onset-only insomnia can use the shorter agents (Sonata, Ambien) to limit next-day grogginess, while maintenance problems favor Lunesta — and warn that about a third of Lunesta patients report an unpleasant metallic taste
  • Complex sleep behaviors are a hard stop: stop the drug at the first episode, because FDA's 2019 review found serious injuries and deaths from these behaviors in patients with and without any prior episode, and a prior episode on one of these agents is now a labeled contraindication — and never re-challenge a patient with a prior episode on these agents
  • The call: Z-drugs are checkmate territory, not first move — CBT-I stays the gold standard, and doxepin 3 mg rising to 6 mg fits middle-of-the-night insomnia — so confirm the patient has truly exhausted CBT-I, melatonin, ramelteon, doxepin, and trazodone, rule out depression, anxiety, pain, and apnea, then prescribe the lowest effective dose for the shortest duration, per the 2019 guideline posture NP Z cites
• Jun 30, 2026 Lexapro (Escitalopram): Efficacy & Tolerability Evidence | PMHNP Boards

  💎 Lexapro is the banana, not the Brussels sprout: a 2023 BMC Psychiatry meta-analysis of 30 RCTs found it beat Celexa on acute response and remission — and patients tend to stay on it, which is part of its real-world appeal.

  📇 Key Takeaways — the index card

  • Read the study like a clinician first: adults 18+ with primary major depression, response defined as a 50% reduction on the Hamilton or MADRS, remission as the secondary outcome, measured over the acute 6-12 weeks — populations and outcomes that map onto ordinary outpatient depression
  • The headline numbers: versus Celexa, Lexapro was significantly more effective for acute response and for remission in the meta-analysis (reported as RR 0.67 and RR 0.53 respectively, both favoring escitalopram — a real edge, but not the same as being a third more likely to respond or twice as likely to remit), and across SSRIs patients were about 7% less likely to quit because of side effects
  • Why it is low-drama: Lexapro has the highest affinity for the serotonin transporter of the SSRIs and does essentially one clean job — no meaningful histamine or muscarinic activity, so less drowsiness, dry mouth, and constipation than an agent like Paxil
  • Very few CYP450 interactions make it the safer reach on a 20-medication list, where a strong inhibitor like Paxil or Prozac creates interaction risk across the whole regimen
  • Tolerability is an efficacy strategy: a theoretically elegant drug a patient stops taking delivers zero benefit, while a slightly plainer drug taken reliably reaches therapeutic levels — acceptability (they feel better and stay on it) and tolerability (side effects do not drive dropout) compound into real-world response
  • The call: make Lexapro a North Star default when the patient is medication-naive and wary, has low tolerance for side-effect drama, or carries heavy polypharmacy — while still giving anticipatory guidance, because side effects on Lexapro absolutely do happen
• Jun 23, 2026 Depersonalization vs Panic vs PTSD: Diagnostic Case Study | PMHNP Boards

  💎 Elias knows he is real — he just does not feel it. That intact reality testing (Criterion B) is the single feature that makes this depersonalization/derealization disorder and not psychosis.

  📇 Key Takeaways — the index card

  • The case: Elias, 22, a graduate student with seven months of near-constant detachment — his hands look unfamiliar, his voice sounds like a speaker in another room, the world looks flat and two-dimensional, objects change size, colors lose saturation — spending 2-3 hours a day googling whether he has early schizophrenia or permanent brain damage
  • Psychosis check: in psychosis the belief is signed on the dotted line (a nihilistic delusion that one is already dead, held with conviction); Elias is ego-dystonic and distressed, well-groomed and cooperative, with no hallucinations — the distress itself is reassuring evidence his reality testing is intact
  • Panic is the closest differential because depersonalization and derealization are among the 13 DSM-5 panic attack symptoms — but panic is discrete surges of terror lasting minutes with a wide somatic constellation, while Elias has a constant, narrow drip of two symptoms that long outlasted his single precipitating attack
  • PTSD and OCD fall away on the center of gravity: he explicitly denies any Criterion A trauma (a stressful parental divorce at 10, an emotionally unavailable mother, eggshell-walking around a perfectionist father), and his pinching ritual is a reality-check aimed at the depersonalization itself, not classic OCD content like contamination or symmetry
  • The trigger and the timeline matter: a high-potency cannabis edible seven months ago sparked a panic attack within 90 minutes, the panic resolved in hours, and the unreality never cleared — NP Z notes about 15% of depersonalization/derealization cases are precipitated by substances, mostly cannabis or hallucinogens, which catalyze rather than cause the disorder
  • The call: age is a workup trigger — mean onset is around 16, fewer than 20% of cases begin after 20 and only about 5% after 25, so new onset at 40 demands a neurology referral to exclude temporal lobe epilepsy (whose episodes last seconds to minutes, often with smell or taste hallucinations); for Elias, with normal labs and EEG, CBT is the intervention with significant evidence — targeting catastrophic misinterpretation ('I am going crazy'), avoidance, and emotional re-engagement, often as long-term therapy of 50-100 sessions — while SSRI evidence here is very limited
• Jun 19, 2026 Kratom: 5 Clinical Pearls for Psychiatric Providers | PMHNP Boards

  💎 Kratom is a partial mu-opioid agonist hiding in gas stations — invisible on standard drug screens, a CYP2D6 and 3A4 inhibitor, and capable of a withdrawal syndrome that mimics new psychosis.

  📇 Key Takeaways — the index card

  • Ask by name or you will never hear it: patients do not volunteer a $1-2 gas-station capsule or a $10-20 bag of powder when you ask about 'medications,' so ask directly about kratom and other herbal supplements used for energy, pain, or mood; it is not FDA-approved for any use, the FDA has warned against it, and it is banned outright in a growing list of states (including Alabama, Arkansas, Connecticut, Indiana, Louisiana, Tennessee, Vermont, and Wisconsin) — check current state law
  • Dose flips its personality like Seroquel or Remeron: at low doses it is stimulant-like (energy, alertness, talkativeness) with minimal opioid activity; at roughly 5-15 grams the opioid activity dominates with analgesia, sedation, and euphoria; above that, stupor and, rarely, coma
  • The chemistry: over 40 alkaloids, but the two that matter are mitragynine (most abundant) and 7-hydroxymitragynine, about 13 times more potent than morphine — both partial mu agonists with added kappa, delta, 5-HT2A, and alpha-2 activity, making buprenorphine its closest pharmacologic cousin
  • It will not show up: kratom is absent from standard 5-panel, extended 10- and 12-panel screens, and even expanded opioid immunoassays — a clean urine proves nothing; if you suspect it, order the specific mitragynine urine test through Quest or LabCorp
  • The silent interactions: kratom inhibits CYP2D6 (raising Abilify — think akathisia and a patient who stops a perfectly good drug — plus risperidone, Paxil, Prozac, and Effexor, with QT and serotonin-syndrome stakes) and CYP3A4 (raising Seroquel sedation and benzo levels like Xanax, where its own opioid effect plus respiratory depression is how people die)
  • The call: kratom withdrawal arrives 1-3 days after stopping and goes beyond classic opioid withdrawal (joint pain, diarrhea, yawning, tearing, insomnia) into hallucinations, paranoia, persecutory delusions, confusion, and hostility — so new 'psychosis' with dilated pupils and diarrhea is a substance question first, not an automatic antipsychotic; do not compound it by raising an SSRI that kratom is already inhibiting
• Jun 16, 2026 ADHD Inattentive Type: DSM-5-TR Criteria Made Memorable | PMHNP Boards

  💎 Milo is 9 and his recipe has 6 ingredients for a reason: inattentive ADHD needs 6 of 9 symptoms, with onset before age 12.

  📇 Key Takeaways — the index card

  • The numbers are built into the story: Milo is 9 because symptoms must start before age 12, and the recipe's 6 ingredients are the 6 of 9 symptoms required for diagnosis — present in more than one setting, like school and home.
  • Avoidance and careless mistakes: Milo puts off baking for days because it means reading the recipe (avoids tasks needing sustained mental effort), then pours a full cup of salt instead of sugar because they looked the same.
  • Losing things and disorganization: he loses his wooden spoon and stirs dough with a remote control, and the baking powder ends up on the TV stand — a 10-minute delay that shows disorganization and poor time management.
  • Sustained attention, listening, and distractibility in one scene: he gives up rolling individual dough balls for one giant ball, then plays Candy Crush so intently he does not register his mother yelling that the cookies are on fire.
  • Forgetfulness and failure to follow through close the nine: he forgets to set the timer so the cookies burn, and the next morning dough is all over the fridge, table, and windowsills because he never cleaned up.
• Jun 15, 2026 DSM-5-TR Sleep-Wake Disorders: All 10 Categories Explained | PMHNP Boards

  💎 Sort the 10 sleep-wake disorders by the patient's own words: can't fall asleep, always tired, weird stuff happens, trouble breathing, or it started with a substance.

  📇 Key Takeaways — the index card

  • Insomnia disorder is quantitative: trouble falling or staying asleep at least 3 nights a week for at least 3 months despite adequate opportunity, often taking over 30 minutes to fall asleep or get back to sleep — and CBT-I, not medication, is the gold standard.
  • Narcolepsy separates from hypersomnolence on numbers: patients fall asleep in under 8 minutes on the MSLT and enter REM in under 15 minutes instead of the normal ~90 — and only type 1 has cataplexy, the sudden loss of muscle tone.
  • Timing and recall split the parasomnias: non-REM sleepwalking and sleep terrors hit the first third of the night with confusion and no dream recall, while nightmare disorder hits the second half with vivid recall and a patient who wakes alert and oriented.
  • REM sleep behavior disorder is the one where the dream is acted out — punching, kicking, jumping from bed in the second half of the night — because REM atonia is lost; NP Z notes it occurs typically in older males and most will eventually develop Parkinson's disease or Lewy body dementia, so make the bedroom safe.
  • The three breathing disorders are three mechanisms: obstructive apnea is a collapsing airway (obesity the top risk factor, CPAP first-line), central apnea is the brain not sending the breathe signal, and sleep-related hypoventilation is breathing too shallow so CO2 builds up.
  • Restless legs is diagnosed clinically, not by polysomnography: an urge to move worse at rest and in the evening, relieved by moving — and check serum ferritin and transferrin saturation, because low brain iron drives it.
• Jun 14, 2026 Adjustment Disorder: 5 Things Clinicians Get Wrong | PMHNP Boards

  💎 A divorce or job loss is not PTSD: without DSM Criterion A — actual or threatened death, serious injury, or sexual violence — plus the full symptom constellation, it is adjustment disorder.

  📇 Key Takeaways — the index card

  • Criterion A cuts both ways: a stressor that is not Criterion A can never be PTSD, but even a Criterion A event (a near-drowning, a serious car crash) is adjustment disorder if there are no intrusions, avoidance, negative mood/cognition changes, and hyperarousal — PTSD needs 1 intrusion, 1 avoidance, 2 mood/cognition, and 2 hyperarousal symptoms, and cannot be diagnosed before one month.
  • If the patient meets full major depressive disorder criteria, it is MDD, period — even if a firing a month ago clearly triggered it. Adjustment disorder cannot be diagnosed on top of another disorder that explains the picture.
  • There are no FDA-approved medications for adjustment disorder and the pharmacotherapy evidence is thin: CBT and, above all, resolution of the stressor do the work. NP Z warns serotonergic meds can blunt emotions the patient actually needs to process.
  • About 56% of patients with adjustment disorder in some studies have a likely personality disorder — cluster B and dependent or avoidant traits predispose — so an adjustment presentation should trigger a personality assessment, especially when breakups keep being the trigger.
  • Suicide risk is the trap: 12 times the completed-suicide rate of the general population, with attempts that are more impulsive and come sooner after onset. Alcohol use, impulsivity, younger age, and alexithymia raise it further, so screen and restrict lethal means.
  • Mind the clock: adjustment disorder can be diagnosed immediately, acute stress disorder covers 3 days to 1 month, and if subthreshold trauma symptoms persist beyond 6 months after the stressor ends, adjustment disorder no longer applies — think other trauma- and stressor-related disorder, and watch for evolution into MDD or PTSD.
• Jun 12, 2026 Paxil (Paroxetine) Withdrawal vs Depression Relapse | PMHNP Boards

  💎 Terry, 38, is five days off Paxil with brain zaps, nausea, and dizziness — that is discontinuation syndrome, not relapse, because relapse takes weeks to months.

  📇 Key Takeaways — the index card

  • Timing is the strongest differentiator: discontinuation syndrome starts 2 to 4 days after stopping, while depressive relapse takes weeks or months. Terry was tapered 20 mg to 10 mg for one week then stopped, and crashed within days.
  • Somatic symptoms give it away: electric-shock brain zaps, nausea and vomiting, dizziness, and paresthesias are hallmarks of discontinuation — they are not DSM depression criteria. Compare the picture to the patient's own signature depressive episode, which is why NP Z says to paint a detailed portrait of their depression in your notes.
  • The re-challenge test: restart Paxil 10 mg and discontinuation symptoms ease rapidly, within days. A true depressive relapse would take several weeks to respond to the same restart.
  • Half-life decides who gets hurt: Paxil and Effexor, with short half-lives, are the brutal offenders; Prozac rarely causes significant withdrawal because of its built-in taper. A patient burned by Paxil withdrawal should never be set up again on Effexor.
  • Taper slowly and add therapy: NP Z suggests roughly 25% dose reductions every 4 weeks, slowing further at low doses where receptor occupancy changes fastest — a compound pharmacy or a Prozac cross-taper can help — and CBT during or after discontinuation significantly lowered relapse versus continued medication alone.
  • Before any taper, count real episodes: 3 or more properly diagnosed major depressive episodes (at least 2 weeks, not a few bad days of grief) carry about a 90% relapse risk off medication. And withdrawal itself proves nothing — it is a pharmacologic phenomenon, not evidence the patient needs the drug for life.
• Jun 11, 2026 Borderline Personality Disorder: A New Way to Understand BPD | PMHNP Boards

  💎 Haley's BPD symptoms are survival skills: a child whose mother's love appeared and vanished without warning grows an alarm system that never switches off.

  📇 Key Takeaways — the index card

  • The numbers behind invalidation: in a 97-study meta-analysis, people with BPD were about 38 times more likely to report childhood emotional abuse and about 17 times more likely to report neglect than non-clinical controls — far exceeding the associations for physical or sexual abuse in the associations NP Z cites. These are retrospective reporting odds, not proof that abuse alone causes BPD.
  • Abandonment hypervigilance is learned survival: Haley's mother cuddled her one night ('the best thing that ever happened to me') and screamed 'go to your room' the next, so as an adult a late text reply, a changed tone of voice, or cancelled plans trips an alarm built when losing a caregiver felt like a physical survival threat.
  • Splitting started as a child's workaround: she could not hold 'good mom' and 'bad mom' as one person, so she split them — and now a friend who cancels a Cheesecake Factory dinner flips from most amazing person ever to someone who never cared.
  • Identity disturbance comes from failed mirroring: Haley was held, shamed as ridiculous, or ignored depending on her mother's state, so she never got a consistent answer to 'what am I feeling and is it okay?' — leaving the chronic emptiness and chameleon-like identity shifts of BPD.
  • Impulsivity and self-harm are emergency regulation, not manipulation: never co-regulated or taught words for big feelings, she reaches for drinking, spending, or a stranger to shut the feeling down now — and cutting can release endorphins and break dissociation, done privately and with shame.
  • Dissociation completes the map: as a child she could not leave a home with screaming and a father in jail, so she left mentally — the same zoning out she now does as an adult when anger bottled up for decades erupts at a partner.
• Jun 10, 2026 Cannabis-Induced Psychosis vs Schizophrenia: How to Tell | PMHNP Boards

  💎 Henry, 22, has smoked daily since 16 and hallucinated since 18 with no abstinent period ever — so you cannot yet call it schizophrenia, and you treat the psychosis anyway.

  📇 Key Takeaways — the index card

  • The diagnosis is blocked in both directions: schizophrenia Criterion E forbids attributing the disturbance to a substance capable of producing psychosis, and Henry has never had 30 days off cannabis; cannabis-induced psychotic disorder Criterion C requires that it not be better explained by an independent psychotic disorder — so in the ER, use an unspecified diagnosis.
  • Treat first, label later: acute management is a second-generation antipsychotic, with a benzodiazepine like Ativan if he is severely agitated. Thirty days abstinent and still psychotic would point to a primary psychotic disorder; clean resolution off cannabis would point the other way.
  • NP Z's pick is Abilify, for two specific reasons: as a dopamine partial agonist it can dial down mesolimbic psychosis while also reducing cannabis cravings, rather than bluntly shackling the reward pathway the way Zyprexa or Risperdal would.
  • The P-glycoprotein pearl, with a caution: preclinical evidence suggests THC can upregulate P-glycoprotein at the blood-brain barrier, which pumps substrates such as risperidone and paliperidone out of the brain and could lower their levels. Aripiprazole is itself a P-gp substrate, though, so do not count on it being immune to this effect — the human clinical significance of the whole pathway is still unproven.
  • When cannabis is in the picture, think LAI: cannabis use impairs executive function and insight and adherence drops, so a long-acting injectable Abilify shores up treatment. If you later taper after 6 to 12 months of stability, do it very cautiously — prolonged dopamine blockade leaves supersensitive receptors and rebound psychosis risk.
  • Context that raises the stakes: his father has schizophrenia on clozapine, he dropped out at 19, and he uses high-potency concentrates (dabs) multiple times daily — NP Z notes that with a first-degree relative like this, it usually turns out to be schizophrenia with comorbid cannabis use disorder.
• Jun 9, 2026 Illness Anxiety vs Somatic Symptom vs Factitious vs Malingering | PMHNP Boards

  💎 Ask where the center of gravity sits: fear of acquiring an illness, distress over a real symptom, faking for the sick role, or faking for external gain.

  📇 Key Takeaways — the index card

  • Illness anxiety disorder: the preoccupation is acquiring a specific disease — the 32-year-old ICU nurse convinced her immune system is failing despite negative, inconclusive workups. The fear is the illness itself ('I am worried about cancer'), not the symptom.
  • Somatic symptom disorder flips it: a real symptom must actually be present, typically for at least 6 months, and the fixation is the symptom itself ('I am worried about this back pain') with excessive distress attached to it.
  • Factitious disorder is intentional production — like putting blood in urine to fake a bleed — but the payoff is psychological: being nurtured and occupying the sick role, with motivations the patient may not even be fully aware of. There is no obvious external reward.
  • Malingering is the external-gain version: symptoms feigned to get disability, escape a prison sentence, or evade a legal obligation. NP Z repeats his mentor's warning: never assume malingering unless you want to buy a lawyer a Tesla — document doubt and a missed real illness becomes your chart problem.
  • Affect is a tip-off on the mental status exam: illness anxiety and somatic symptom patients are genuinely distressed and their symptoms are ego-dystonic, while in factitious presentations or malingering the affect can be oddly calm, neutral, or almost enthusiastic relative to the feared consequences.
  • NP Z's lean on this case: illness anxiety disorder, because no single hard symptom anchors the interview — she worries about illnesses and her immune system in general. Had the interview centered on a specific symptom like her fatigue or pain, he would diagnose somatic symptom disorder.
• Jun 8, 2026 ADHD vs Anxiety: The Differential That Changes Everything | PMHNP Boards

  💎 What is competing for your attention? Fear points to anxiety, interest points to ADHD — the content of the thoughts, not the racing itself, makes the diagnosis.

  📇 Key Takeaways — the index card

  • Process does not discriminate: racing thoughts, restlessness, and distractibility show up in ADHD, anxiety, bipolar disorder, trauma, and depression — the content of the competing thoughts does.
  • Ask what is competing for attention: future-oriented what-if worries she cannot control land in the fear column (generalized anxiety); a pull toward something more interesting lands in the interest column (ADHD) — fear vs preferential attention, the worm at the core.
  • Carly's body fits GAD: chronic neck and shoulder tension, tension headaches several times a week, GI upset, fatigue despite 7 to 8 hours in bed, restless sleep, and irritability.
  • Her history fits GAD too: a worrier since elementary school, corroborated by her mother, who white-knuckled her way to a 3.7 GPA — with no IEPs, exasperated teachers, or academic underperformance ADHD tends to leave behind.
  • The call for Carly: generalized anxiety disorder, not ADHD — treat the anxiety first with an SSRI plus CBT, then re-test attention and reopen the ADHD workup if impairing inattention remains.

  📋 Flash-Card Summary — the article version

• Jun 7, 2026 Personality Disorders: 4 Ways They Disrupt Treatment Plans | PMHNP Boards

  💎 Up to 45% of patients with major depressive disorder have a comorbid personality disorder — close to a coin flip — and it can sink treatment four distinct ways.

  📇 Key Takeaways — the index card

  • Way 1, alliance rupture: personality disorders are disorders of social communication. Cluster A patients go silent and alienated and treat attachment as threatening; cluster B patients confront, complain, and challenge — and every gain in treatment hinges on a trust they arrive unable to give.
  • Way 2, traits masquerading as symptoms: OCPD rigidity and overwork present as burnout and 'treatment-resistant depression,' and avoidant personality can be misread as severe social anxiety and chased with Prozac up to 80 mg. There is no FDA-approved SSRI for any personality disorder — the lever is psychotherapy like DBT or CBT.
  • Way 3, the personality drives nonadherence itself: paranoid patients do not trust you, schizotypal patients may fold pills into magical thinking about dark energy, borderline black-and-white thinking swings from perfect compliance to abruptly stopping meds as 'the problem,' and OCPD rigidity resists the plan.
  • Way 4, countertransference: unmanaged reactions — NP Z names his own anger at being lied to and manipulated in antisocial presentations — reinforce exactly the suspicious, judgmental worldview the patient walked in with. His reframe: the patient did not choose the disorder; it was built to survive unpredictable, punishing caregivers.
  • The counter-moves: assess personality pathology in every patient and especially before calling anyone treatment-resistant, prioritize psychotherapy instead of reaching reflexively for the prescription pad, and treat the therapeutic relationship like a vital sign — check it every visit, because patients only disclose what changes the diagnosis if they trust you.
• Jun 6, 2026 Tardive Dyskinesia: How to Spot It & What to Do | PMHNP Boards

  💎 Joe, 55, stable 8 years on Haldol 10 mg, now has lip-smacking and tongue-darting TD — the worst move is lowering the Haldol.

  📇 Key Takeaways — the index card

  • Why dose cuts backfire: 8 years of D2 blockade has upregulated dopamine receptors and made them supersensitive, and neurons are packing more dopamine into each vesicle. Lowering or stopping unmasks that flood — worsening TD as withdrawal dyskinesia and risking rebound psychosis that lands a stable patient in hospital.
  • Raising the dose is the opposite trap: more blockade only temporarily suppresses the movements while the brain compensates further, so the TD returns worse. Neither direction treats it.
  • Screen with the AIMS (Abnormal Involuntary Movement Scale): guidelines suggest about every 6 months on a first-generation antipsychotic and every 12 months on a second-generation, but NP Z does it every visit — it is quick, visual, and the patient is already in the chair. Joe scores 14, in the moderate range.
  • For moderate, severe, or disabling TD, add a VMAT2 inhibitor while continuing the antipsychotic: VMAT2 is the loading dock that packages dopamine into vesicles, and blocking it stops that dopamine reaching supersensitive synapses — so Joe keeps the Haldol that controls his schizophrenia and you re-check his AIMS over the following weeks.
  • Switching is the other route, chosen carefully: clozapine has the strongest evidence for reducing TD and quetiapine (Seroquel) has lower D2 affinity — but never abruptly discontinue the antipsychotic, and some patients refuse clozapine's monitoring burden outright.
  • Do not file TD under first-generation drugs only: second-generation agents still block dopamine, dose and duration accumulate, and even a patient augmented with Abilify for depression for 10 to 15 years can develop it. Orofacial movements, piano-playing fingers, and pelvic rocking can progress to trouble speaking, chewing, swallowing, and writing — and can become irreversible.
• Jun 5, 2026 Tardive Dyskinesia Risk Factors: Who's Most at Risk? | PMHNP Boards

  💎 Age is the single greatest risk factor for TD — which is why the 72-year-old on low-dose Abilify beats four younger psychosis patients for tomorrow's AIMS slot.

  📇 Key Takeaways — the index card

  • The verdict: see patient B, the 72-year-old woman on Abilify as an adjunct for major depression for 6 months. TD is not only a schizophrenia problem — Abilify still modulates dopamine as a partial agonist, and her age overwhelms every other variable in the question.
  • The incidence gap is stark: in the classic (largely first-generation-era) data, new TD emerged at roughly 25 to 30% per year in older adults versus 4 to 5% per year in younger adults; rates with second-generation agents are substantially lower, but age still multiplies the risk more than any other single factor. Being female compounds it further — postmenopausal women are at increased risk.
  • Not the dose, not the drug class first: NP Z is explicit that antipsychotic type and dose are relevant, but neither outranks age. Knowing that one fact answers the board question without working through every D2 affinity.
  • The runner-up still matters: the 32-year-old man on Zyprexa 20 mg daily for 5 years carries real risk — olanzapine is a potent D2 blocker, 20 mg is not a low dose, and 5 years is substantial exposure. All antipsychotics, first- and second-generation, carry TD risk.
  • The safer ends of the list: clozapine has the lowest TD risk of any antipsychotic and may even improve existing TD, so the man switched to it after 10 years of Haldol is not the answer; quetiapine also sits lower because it binds D2 loosely and lets go rather than holding an iron grip, even at 600 mg for 2 years.
• Jun 4, 2026 Benzos for Flying Phobia: Pharmacokinetics & Prescribing | PMHNP Boards

  💎 For Aaron's 17-hour New York to Sydney flight, NP Z picks Klonopin — not for its half-life alone, but for its low-to-moderate lipophilicity and 8 to 12 hour clinical duration.

  📇 Key Takeaways — the index card

  • Xanax fails a long flight: clinical duration only about 4 to 6 hours and very high lipophilicity, so it crosses into the brain fast, leaves fast, and brings rebound anxiety mid-Pacific — stacking 3 or 4 doses over 17 hours piles up sedation, amnesia, and ataxia. It fits a 2-hour hop, not Sydney.
  • Ativan is the middle-distance option at about 6 to 8 hours of clinical duration — reasonable for LA to New York, marginal for New York to London — and its Tmax of about 2 hours means timing the dose so peak levels land on the patient's worst moment, usually takeoff.
  • Valium is the trap answer: its half-life looks ideal, but it is highly lipophilic, so the therapeutic effect is in and out quickly while the drug redistributes into fat and lingers, leaving prolonged sedation without sustained anxiolysis.
  • The verdict — Klonopin: clinical duration 8 to 12 hours, half-life around 34 hours, and low-to-moderate lipophilicity, so it trickles into the CNS steadily instead of the Xanax wham-and-gone. Onset is about 60 minutes, so Aaron takes it roughly an hour before boarding, with backup tablets for delays or rerouting.
  • Prescribing guardrails NP Z attaches: give a test dose at home first (hypermetabolizers can burn through a drug in 3 to 4 hours, and benzo-naive patients can be wiped out), absolutely no alcohol in flight, and no driving on arrival in Sydney.
  • A benzo is not the treatment for specific phobia — exposure therapy is the enduring fix, benzos can actually block fear extinction, and no SSRI is FDA-approved for it. NP Z prescribes narrowly for infrequent flyers and asks for something back: a commitment to work on the phobia itself.
• Jun 3, 2026 OCD vs PTSD vs GAD vs Psychosis: Differential Case Study | PMHNP Boards

  💎 Dustin's 'ninjas' turn on one question: does he truly believe they will attack him, or is it an intrusive thought he knows is absurd but cannot shake?

  📇 Key Takeaways — the index card

  • The case spine: Dustin, 34, was mugged at knifepoint outside a 7-Eleven 6 months ago and now avoids stores, has 2 to 3 nightmares a week of being grabbed from behind, startles easily, checks his car locks about 5 times, and counts silently to 7 before entering any building so 'something very bad' does not happen.
  • That exact question separates the diagnoses: in OCD and PTSD the feared thought is ego-dystonic — unwanted, recognized as irrational, and distressing. In delusional disorder it is fixed and unshakable, stated matter-of-factly as part of a broader story arc, with otherwise preserved functioning and no recoil at the belief.
  • The counting and checking are the OCD tell: compulsions performed to neutralize an obsession. NP Z uses the DSM yardstick of roughly an hour or more a day spent on rituals, and asks whether checking, counting, or washing existed before the mugging — OCD usually starts much younger and a trauma can simply give it traumatic content.
  • GAD gets tossed, by specificity: being afraid of ninjas is the opposite of generalized worry. GAD would sound like diffuse, plausible worst-case worries across many domains — NP Z asks 'what else do you worry about?' and a non-GAD patient points back to the attack.
  • Timeline is a diagnostic instrument: this impairment arrived fast, right after a life-threat event, which points to trauma — OCD, GAD, and delusional disorder are gradual, slow-burn conditions. PTSD hypervigilance can also sound almost psychotic: a brain bitten once now reads every stick as a snake.
  • NP Z's conclusion: both constellations can be in the sky at once — PTSD and OCD together. Either way the treatment converges on psychotherapy plus an SSRI — at standard antidepressant doses for PTSD, and typically at higher doses when OCD is driving.
• Jun 2, 2026 Major Depressive Disorder with Psychotic Features: 6 Pearls | PMHNP Boards

  💎 Psychotic depression is not depression-plus: it carries about twice the relapse risk, plus higher hospitalization and all-cause mortality — suicide, accidents, and cardiovascular disease.

  📇 Key Takeaways — the index card

  • Specify congruence every time: mood-congruent psychosis fits the depressive themes — nihilistic delusions of rotting from the inside or already being dead. Mood-incongruent content — aliens controlling the patient, an FBI chip — does not, and the DSM wants that specifier in the chart.
  • Interrogate the psychosis for safety, not just presence: what are the voices telling them to do, could the belief make them refuse food or drink, speed home, or harm someone they believe is a threat? Command hallucinations and beliefs that drive action are what turn an office visit into an emergency.
  • The timing rule that resolves the differential: psychosis only inside depressive episodes is MDD with psychotic features. Psychosis persisting when depression has remitted points to an independent schizoaffective or schizophrenia-spectrum disorder — and psychosis during an elevated episode makes that episode manic, so it is bipolar I — bipolar II excludes psychosis only during hypomania, and bipolar II depressive episodes can themselves carry psychotic features.
  • Treatment is a combination, not an antidepressant alone: an SSRI or SNRI plus a second-generation antipsychotic — olanzapine and quetiapine are the most studied, and olanzapine-fluoxetine exists as the combination product Symbyax — or ECT.
  • ECT is the fastest option with response rates up to about 80% in severe or suicidal psychotic depression, and NP Z calls it underutilized — stigma, cost, and coverage are what usually push clinicians to the medication combination first. In real life the best regimen is still the one the patient will take: a patient with a BMI of 36 may refuse olanzapine, and quetiapine may need 300 mg or more for real D2 blockade.
  • Do not stop early: continue both the antidepressant and the antipsychotic for at least 4 to 6 months after remission, and 9 to 12 months with multiple episodes or residual paranoia — abrupt discontinuation risks rebound psychosis from upregulated, supersensitive dopamine receptors.
• Jun 1, 2026 Autoreceptors Explained: The Key to Psychopharmacology | PMHNP Boards

  💎 Autoreceptors are presynaptic thermostats: when an SSRI floods the synapse, they cut neuron firing — and that brake is why SSRIs take weeks to work.

  📇 Key Takeaways — the index card

  • The mechanism in one image: the autoreceptor is a bouncer at the club. An SSRI raises synaptic serotonin, the bouncer senses 'too much' and reduces serotonin neuron firing and release — only after weeks, when the bouncers tire and desensitize, does serotonin stay in the synapse and the therapeutic effect arrive.
  • Genetics loads the dice: people born with more autoreceptors, or more sensitive ones — super-sensitive smoke alarms — inhibit serotonin more aggressively, show more depressive-like behavior in animal models, and tend to respond poorly to SSRIs or need longer treatment.
  • Mirtazapine (Remeron) skips the wait by removing the brake: it directly blocks presynaptic alpha-2 adrenergic autoreceptors rather than blocking reuptake. The same alpha-2 receptors sit as heteroreceptors on serotonin neurons, so blocking them disinhibits both norepinephrine and serotonin release — which is why Remeron may work faster.
  • Vilazodone and vortioxetine (Trintellix) build the modulation in: alongside reuptake blockade they agonize the presynaptic 5-HT1A autoreceptor — vilazodone as a partial agonist, vortioxetine as an agonist, producing a weaker inhibitory signal than full flooding does — some evidence suggests a somewhat faster onset, though nothing like ketamine, which bypasses this system entirely.
  • Clonidine and guanfacine run the autoreceptor in reverse: they agonize alpha-2 autoreceptors, fooling the neuron into sensing excess norepinephrine, so NE firing and release fall and the patient calms. Guanfacine's separate postsynaptic alpha-2 action in the prefrontal cortex is what helps working memory and impulse control.
• May 31, 2026 Topamax (Topiramate) Explained: A McDonald's Analogy | PMHNP Boards

  💎 Topiramate calms a chaotic brain four ways at once — sodium blockade, calcium blockade, GABA enhancement, and glutamate blockade — which is why one drug can reach PTSD hyperarousal, alcohol cravings, migraine, and binge eating.

  📇 Key Takeaways — the index card

  • Sodium channel blockade is the 'please hold' sign on the drive-thru speaker: neurons stuck in rapid, repetitive firing — as in PTSD, epilepsy, and migraine — get slowed, so one clear order reaches the kitchen at a time instead of nine people shouting at once.
  • Calcium channel blockade slows the delivery trucks: topiramate inhibits high-voltage-activated calcium channels at the nerve terminal, less calcium rushes in, and since calcium influx is the trigger for release, less neurotransmitter is delivered into the synapse.
  • GABA-A enhancement is Ronald McDonald, not the Happy Meal: topiramate is a positive allosteric modulator at a non-benzodiazepine site — it does not activate the receptor itself, it turns up the effect of GABA already present, increasing chloride flow so neurons are harder to fire. A benzodiazepine, by contrast, is also a positive allosteric modulator — it works at the separate benzodiazepine site on the same receptor, so the contrast is the binding site, not direct activation.
  • Glutamate blockade turns down the hysterical cashier: glutamate is the brain's main excitatory neurotransmitter and GABA's seesaw partner. In chronic alcohol use, GABA receptors desensitize and excitatory tone climbs, driving craving — muting that cashier's microphone lowers the excitatory flood.
  • Why four mechanisms matter clinically: the same converging circuits drive alcohol use disorder, PTSD nightmares and hyperarousal, migraine pain, and compulsive binge eating — so topiramate can cut alcohol craving and PTSD severity together, reduce binge urges, and some patients lose a little weight. Much of this use is off-label, but NP Z keeps it as a versatile arrow against polypharmacy.
• May 30, 2026 Ferritin & Mental Health: The Lab That Mimics Half the DSM | PMHNP Boards

  💎 Ferritin below 50 can drive psychiatric symptoms while the CBC and hemoglobin still look perfect — check the warehouse, not just the hemoglobin.

  📇 Key Takeaways — the index card

  • Read ferritin as a spectrum, not a lab cutoff of 10: NP Z's clinical target is roughly 50 to 100 ng/mL — well above standard deficiency cutoffs (WHO uses below 15 ng/mL; many guidelines and labs use below 30) — with symptoms in his experience starting below 50, mimicking full disorders at 15 to 30, and below 15 he has seen severe depression, severe cognitive impairment, and treatment resistance.
  • Iron is needed to build dopamine, serotonin, and norepinephrine, to insulate nerve wiring, and to power mitochondria — low stores therefore present as low motivation, inability to focus, moodiness, lethargy, impaired sleep, and restless legs that get read as ADHD, GAD, or depression.
  • Up to 1 in 3 menstruating women may be iron deficient with a normal CBC; other flags are heavy menstrual bleeding, vegetarian or vegan diet, hair loss, unexplained fatigue, and pica such as chewing ice — and iron deficiency is found in about a quarter of restless leg patients.
  • Ferritin measured 48 hours postpartum, after delivery blood loss that can reach a liter, was associated with later postpartum depression in one prospective cohort NP Z cites (with high specificity but low sensitivity, at a very low ferritin cutoff) — a reason to coordinate that 48-hour window with OB, not a validated stand-alone predictor.
  • Blocking reuptake of serotonin the patient cannot make in the first place is planting a flower in concrete: do not declare someone treatment-resistant until ferritin has been checked, because an SSRI or stimulant layered over empty iron stores is working without its key cofactor.
• May 29, 2026 Hydroxyzine for Anxiety: The Misunderstood Non-Benzo Option | PMHNP Boards

  💎 For Paul, 29 — itchy, edgy, skin-picking, muscle-tense, and 14 months sober — hydroxyzine treats the itch and the edge together, with no habit-forming benzo and no heavy SSRI for a man who does not meet clean GAD criteria.

  📇 Key Takeaways — the index card

  • It is an H1 inverse agonist, but sedation is not the main squeeze: patients typically habituate to the sedation within about a week while the anxiety reduction does not wear off, so in the 10 to 25 mg range it can be dosed through the day, up to four times a day.
  • Its moderate 5-HT2A antagonism is the anxiolytic second mechanism — the same receptor trazodone, mirtazapine, and quetiapine exploit — calming subcortical rumination and directly countering the activating 5-HT2A stimulation an SSRI causes on start-up.
  • That makes it NP Z's preferred SSRI bridge instead of a benzodiazepine: it covers SSRI activation without a prescription patients then resist stopping, and without the benzodiazepine problem in comorbid PTSD and psychotherapy.
  • Hydroxyzine is FDA approved for anxiety, and its label carries the overlooked pearl that it can make a disturbed patient more amenable to psychotherapy — NP Z suggests a PRN dose 30 to 60 minutes before a session to lower arousal enough to participate, without benzodiazepine cognitive blunting.
  • Respect the other edges: anticholinergic dry mouth, constipation, and urinary retention put it on the Beers list over 65, it can prolong QTc when stacked with agents like citalopram, methadone, or ziprasidone, and the FDA label contraindicates it in early pregnancy.
• May 28, 2026 Auvelity (Dextromethorphan-Bupropion): NMDA & Sigma-1 Explained | PMHNP Boards

  💎 For Sarah, 34 — PHQ-9 around 19, third episode in five years, sexual dysfunction and 15 lb gained on sertraline twice, and no time for esketamine's two hours twice a week — Auvelity separated from placebo at week one instead of asking her to wait six weeks again.

  📇 Key Takeaways — the index card

  • Each tablet pairs dextromethorphan 45 mg with bupropion 105 mg; bupropion is the key, not just an ingredient — by inhibiting CYP2D6 it blocks dextromethorphan's rapid conversion to dextrorphan and raises its levels dramatically, without which the cough suppressant would do almost nothing in the brain.
  • The mechanism breaks the monoamine-only pattern: NMDA antagonism like ketamine's, sigma-1 agonism, serotonin reuptake inhibition 10 to 100 times weaker than classic SSRIs despite SERT being its tightest binding, plus norepinephrine and dopamine reuptake inhibition from the bupropion.
  • Sigma-1 is a molecular chaperone sitting between the endoplasmic reticulum and mitochondria, regulating calcium flow and deploying under cell stress against inflammation and oxidative damage — the neuroprotective, pro-plasticity piece NP Z links to possible benefit in an inflammatory subtype of depression.
  • In the phase 2 combination trial NP Z cites, remission was 46.5% on dextromethorphan-bupropion versus 16% on bupropion alone.
  • It is FDA approved for major depression, not proven for treatment-resistant depression, and it is not a swap for a patient thriving on bupropion XL 450 mg, because the full Auvelity dose delivers only 210 mg of bupropion a day; bupropion's seizure, eating-disorder, and abrupt alcohol or benzo withdrawal contraindications still apply, and NP Z says he would not combine it with an SSRI given the serotonin syndrome monitoring burden.
• May 27, 2026 Abilify (Aripiprazole) & Impulse Control: The Gambling Side Effect | PMHNP Boards

  💎 Henrietta, 42, bipolar II and stable on lithium 900 mg with a level of 0.8, lost $12,000 playing online poker 4 to 6 hours a night for three months on aripiprazole 15 mg — with no hypomania at all, that is the drug, not a new gambling disorder.

  📇 Key Takeaways — the index card

  • Separate circumscribed impulsivity from a mood episode before acting: her PHQ-9 is 2, sleep is great, there is no pressured speech, grandiosity, or disorganization, her mental status exam is unremarkable, and her husband corroborates it — the gambling stands alone.
  • The mechanism is D2 and especially D3 partial agonism in the reward pathway, a risk aripiprazole shares with cariprazine; expect it as gambling, shopping, increased sexual urges, or binge eating, not gambling alone, and ask about the timing against starting or raising the dose.
  • The FDA label states these urges have stopped when the dose was reduced or the medication was stopped, and the problem is often dose-related — so raising aripiprazole to 20 mg for breakthrough impulsivity pours fuel on it.
  • Never add when you can subtract: adding valproate to medicate an aripiprazole effect stacks a heavy drug onto lithium for a problem subtraction can solve, and referring for gambling CBT while continuing aripiprazole is burn treatment while the hand stays on the stove.
  • The board answer is C, discontinue aripiprazole and reassess — with NP Z's own qualifier that he prefers reducing first, for example stepping down from 15 mg toward 10 and then 5, after asking what benefit aripiprazole has actually given her, rather than yanking a helpful drug outright.
• May 26, 2026 Major Depressive Disorder Specifiers: Mixed, Anxious & Melancholic | PMHNP Boards

  💎 A specifier is a treatment instruction for the next prescriber: mixed features can stop an antidepressant, psychotic features add an antipsychotic, and melancholic versus atypical point in opposite directions.

  📇 Key Takeaways — the index card

  • Anxious distress rides along in about 75% of major depression: the tell against separate GAD is timing — the anxiety emerges inside the depressive episode, does not need a six-month duration, and is sprinkles on the depression rather than the whole scoop, though first-line SSRI and SNRI treatment overlaps either way.
  • For mixed features, ask one question: are the up symptoms happening at the same time as the depression, or separately? Concurrent means mixed features; separate points toward hypomania or mania — and with mixed features, avoid antidepressant monotherapy because it can worsen cycling and precipitate a switch, with lurasidone carrying the randomized trial evidence NP Z cites and a substantial minority of these patients — roughly 13–20% in follow-up reviews — later receiving a bipolar disorder diagnosis.
  • Psychotic features means psychosis that arrives with the mood episode and is absent outside it; self-critical voices at the worst of depression fit, psychosis while not depressed reopens schizophrenia, delusional disorder, and substance use — treatment is combination antidepressant plus antipsychotic, ECT comes onto the table, and you always ask whether the voices are telling the patient to do anything.
  • Melancholic and atypical are mirror images: melancholic mood does not react even to winning the Powerball or sitting in Fiji, with early-morning waking, worse mood in the morning, weight loss, and guilt, while atypical mood does brighten to good events, with hypersomnia, increased appetite, and heavy, leaden limbs.
  • Catatonic features require 3 or more of 12 psychomotor features in the episode — stupor, waxy flexibility, and mutism among them — and run on their own algorithm of IV or IM lorazepam and ECT.
  • Seasonal pattern requires at least two seasonal major depressive episodes in the last two years, outnumbering non-seasonal ones, and bupropion is the only FDA-approved medication specifically for seasonal depression; peripartum onset means onset in pregnancy or within four weeks of delivery, affects 10 to 15% of postpartum women, and sertraline is often preferred for its low breast-milk transfer, with the oral neuroactive steroid zuranolone now the FDA-approved postpartum-specific option (the IV brexanolone product was withdrawn from the US market in 2025).
• May 25, 2026 Luvox (Fluvoxamine): Sigma-1 Receptors, OCD & Anxiety | PMHNP Boards

  💎 Fluvoxamine has the most potent sigma-1 agonism of any SSRI, and it is not close — that, not its serotonin reuptake inhibition, is why it hits different in OCD, cognition, and inflammatory depression.

  📇 Key Takeaways — the index card

  • Know its actual labels first: fluvoxamine is FDA approved for OCD, and in its extended-release (CR) form also for social anxiety disorder, but not for major depression, which is part of why prescribers pass it by for escitalopram, sertraline, or fluoxetine.
  • Sigma-1 agonism plus SERT inhibition enhances prefrontal dopamine, giving top-down control over the stuck cortico-striato-thalamo-cortical loop in OCD — serotonin alone does not explain OCD, and that prefrontal boost is also the cognitive-enhancement angle NP Z offers when a patient cannot wait weeks on a vortioxetine prior authorization.
  • Sigma-1 receptors sit on immune cells, so agonism puts a brake on the inflammatory cascade before it degrades neurotransmitters, especially dopamine; NP Z puts the inflammatory subtype at up to roughly a third of depression, and flags elevated CRP or IL-6, anhedonia, and brain fog as the picture where fluvoxamine may fit better.
  • Its price is CYP inhibition across 1A2, 2C19, and 3A4 substrates, which can push co-prescribed drugs toward toxicity when records do not travel between prescribers — so the ideal candidate is on little polypharmacy, though the same inhibition is deliberately exploited to reach clozapine effect at lower clozapine doses.
  • One interaction can be used on purpose: CYP1A2 blockade produced roughly threefold higher nocturnal melatonin exposure (area under the curve) after a single dose in the evidence NP Z cites, a lever for sleep and circadian realignment that can also overshoot into daytime sedation; some evidence also suggests less weight gain and fewer sexual side effects than other SSRIs.
• May 24, 2026 Serotonin, Dopamine & Norepinephrine: Choosing the Right Target | PMHNP Boards

  💎 Serotonin is an emotional brake pedal, not a happiness chemical — choose the transmitter by the failure in front of you: too-loud emotion for serotonin, no motivation or joy for dopamine, no energy or focus for norepinephrine.

  📇 Key Takeaways — the index card

  • Target serotonin when emotional intensity itself is the problem — catastrophic rumination, panic, impulsivity, agitation, hypervigilance, and irritability — and set the expectation honestly: the patient should feel steadier and less reactive at four to six weeks, not euphoric, or they will conclude a working drug failed.
  • Serotonin is receptor-specific, not simply good: 5-HT1A stimulation calms, while 5-HT2A stimulation is activating and is why SSRIs can worsen anxiety and insomnia before they help — trazodone and mirtazapine earn their place by blocking 2A — and 5-HT2C blockade, as with mirtazapine, drives weight gain.
  • About 95% of serotonin is made in the gut and peripheral serotonin cannot cross the blood-brain barrier, so the pools are separate; gut 5-HT3 stimulation is why early SSRIs predictably cause nausea, loose stools, and cramping.
  • Dopamine encodes motivation, salience, and reward prediction, not pleasure itself; anhedonia is the distinguishing cue — a patient who is less reactive on an SSRI but still gets no joy from anything and cannot initiate tasks is telling you to recruit dopamine, classically with bupropion alongside the serotonergic drug — while excess dopamine is psychosis, paranoia, and disorganization.
  • Norepinephrine is the spotlight: arousal, vigilance, sustained attention, and the actual energy to act, distinct from dopamine's motivation to act — recruit it with an SNRI or NDRI for fatigue, brain fog, and psychomotor slowing, and respect its excess in PTSD hyperarousal and panic, and in patients who find bupropion too stimulating; excess serotonin, by contrast, is serotonin syndrome with clonus, hyperreflexia, tremor, and rising temperature, especially when an MAOI meets an SSRI.
• May 23, 2026 OCD vs Delusional Disorder: A Tricky Case Study | PMHNP Boards

  💎 Jane, 34, is 100% convinced toxic mold is poisoning her after three inspectors found none — yet this is OCD with absent insight and delusional beliefs, not delusional disorder, and the compulsions are what give it away.

  📇 Key Takeaways — the index card

  • The behaviors carry the diagnosis: 4 to 5 hours a day wiping surfaces with bleach, handwashing until her hands are cracked and bleeding, throwing away furniture, and wearing gloves and a mask at home — OCD does not require both obsessions and compulsions, but clear compulsions like these should raise your suspicion sharply.
  • Her suffering is ego-dystonic: she is exhausted, misses work, and wishes she could stop, driven by dread that something bad will happen to her family if she does not clean — that unwanted, compelled quality is OCD's flavor, not a belief calmly integrated as fact.
  • Ask why she thinks the mold is there: an OCD account stays circumscribed to germs and contamination, while delusional disorder builds a grander explanatory story — someone placed it there, for a reason, tied to a persecutory, grandiose, jealous, or somatic narrative — with no driven ritual to neutralize it.
  • Insight in OCD is a spectrum and it waxes and wanes: good or fair, poor, and absent insight with delusional beliefs, the last in 4% or fewer of OCD patients; most patients will tell you outright that they know the thought is irrational but must act anyway, often with obsessional patterns reaching back to childhood or the early teens.
  • Delusional disorder's criterion C is the contrast: apart from the delusion's impact, functioning is not markedly impaired, so it is usually found incidentally rather than brought in as the chief complaint — Jane is otherwise linear, logical, well groomed, and free of hallucinations or paranoia beyond the mold.
  • There is no hedge drug between these two, so the call decides treatment: OCD goes to high-dose SSRIs over a longer marathon, with exposure therapy and antipsychotic augmentation only as an adjunct, while antipsychotic monotherapy is not first-line OCD care and an SSRI alone will not treat a delusional disorder.
• May 22, 2026 Antipsychotic Cross-Taper: 4 Switching Pearls | PMHNP Boards

  💎 An antipsychotic switch fails on receptors and half-lives, not on the calendar: lose D2 cover too early and you get rebound psychosis, lose H1 and M1 cover and you get the rebound insomnia and cholinergic storm you mistook for relapse.

  📇 Key Takeaways — the index card

  • Pearl one, prove the drug actually failed: at least four to six weeks at a therapeutic dose, with adherence checked first, since adherence runs near 50% — ask how often have you been able to take it, not are you taking it daily, and surface the hidden reasons, including sexual side effects patients rarely volunteer.
  • Pearl two, know both drugs' receptor profiles before you move: olanzapine is a strong D2, H1, and M1 blocker, so switching to quetiapine, a weak D2 blocker that may need 600 to 800 mg to reach antipsychotic effect, can leave the patient uncovered, and switching to lurasidone, with little muscarinic or histamine blockade, predictably brings rebound insomnia plus cholinergic rebound — nausea, vomiting, sweating, diarrhea, and cramps.
  • Pearl three, match the half-lives: olanzapine is about 30 hours and aripiprazole about 75 hours, so an overnight direct switch lets the old drug fall away long before the new one occupies enough D2 receptors — the same trap as stopping short-half-life venlafaxine while waiting for fluoxetine to reach steady state.
  • Pearl four, respect the partial-agonist switch: aripiprazole, brexpiprazole, and cariprazine bind D2 tightly but only partly activate it, so adding one against a potent antagonist can raise dopaminergic tone in a supersensitive brain and produce worsening psychosis, agitation, and insomnia.
  • Choose the strategy to fit the situation: cross-titration is NP Z's usual route for second-generation antipsychotics, while an abrupt switch is reserved for cases such as neuroleptic malignant syndrome or agranulocytosis where the old drug cannot wait — and warn the patient that the transition weeks, including slower-than-expected weight loss off olanzapine and new EPS risk on a high-EPS agent, are the switch talking, not the new drug's final verdict.
• May 21, 2026 OCD Gold Standard Treatment: What Most Clinicians Miss | PMHNP Boards

  💎 Terri, 28, spent three years treated for generalized anxiety while having ego-dystonic intrusive images of stabbing her grandmother — the gold-standard answer is high-dose fluvoxamine, clonazepam tapered off, and ERP, not more of what she already has.

  📇 Key Takeaways — the index card

  • Name the misdiagnosis first: unwanted, horrifying, ego-dystonic violent intrusions plus checking the kitchen knives multiple times a day and seeking reassurance that she is not a monster are obsession and compulsion — GAD worries about real everyday things like money, health, and work, however catastrophically.
  • Her current regimen is the wrong class on both counts: venlafaxine 150 mg is an SNRI without the SSRI evidence base in OCD, and clonazepam 1 mg twice daily has no OCD role and actively interferes with ERP.
  • OCD dosing is a different sport: an SSRI at the maximum tolerated dose for 8 to 12 weeks before you declare failure — fluoxetine 20 mg reassessed at four weeks is a spatula against a charging rhino, where OCD fluoxetine runs 60 to 80 mg, and antipsychotic augmentation only enters after that maximal SSRI trial, which is why adding risperidone 0.5 mg to venlafaxine puts the cart before the horse.
  • Therapy specificity matters as much as the drug: ERP is the gold standard, while generic CBT aimed at restructuring and reassuring the intrusive thought can feed the obsessional cycle, and psychodynamic exploration of unconscious roots has no evidence base here.
  • The verdict is C: stop venlafaxine, start fluvoxamine titrated to the maximum tolerated dose, taper the clonazepam, and refer for ERP — against a backdrop where OCD is misdiagnosed for years as anxiety, depression, ADHD, or even psychosis, and only 5 to 10% of OCD patients ever receive therapist-guided ERP.
  • The neurobiology explains the intensity gap: GAD is an overactive amygdala threat detector, while OCD is a stuck habit loop in the cortico-striato-thalamo-cortical circuit, which is why it demands higher serotonergic pressure for longer, plus ERP.
• May 19, 2026 MDD with Mixed Features: Treatment When SSRIs Don't Fit | PMHNP Boards

  💎 Polly, 28, is still depressed on sertraline 50 mg after three months but now has racing thoughts, pressured speech in arguments, and five hours of sleep she wakes wired from — that is MDD with mixed features, and the reach is lurasidone, not more SSRI.

  📇 Key Takeaways — the index card

  • Mixed means concurrent: three manic symptoms embedded inside the depressive episode, like chocolate chips in the dough — racing thoughts, pressured speech, and decreased need for sleep in Polly's case (her irritability rides along, but the DSM does not count overlapping symptoms such as irritability toward the specifier) — and symptoms occurring separately from depression are a different diagnosis entirely; roughly one in five major depressions carries mixed features.
  • Rule out borderline personality disorder before you commit, because that fork changes everything — DBT rather than a mood stabilizer — and separate trait irritability, the daily irritability baked into generalized anxiety, from a discrete constellation of mixed symptoms arriving together.
  • Treat failed antidepressants as a diagnostic clue, not just bad luck: repeated activation or non-response at therapeutic doses, early and recurrent episodes, and family history like Polly's maternal aunt with bipolar disorder raise conversion risk, which NP Z puts at 5 to 9% over 10 to 15 years overall and up to 20 to 30% within three years in high-risk subgroups.
  • Lurasidone holds the one randomized trial built for this exact specifier: 20 to 60 mg a day for six weeks produced a 64.8% response versus 30% on placebo, an effect size of 0.8 against the 0.3 to 0.4 typical of SSRI trials — and there is still no FDA approval for MDD with mixed features.
  • Its pharmacology fits the problem: D2 blockade taps the brake on racing and agitation without slamming it like haloperidol, 5-HT2A blockade raises prefrontal dopamine and norepinephrine, 5-HT7 blockade is its secret weapon for circadian realignment and antidepressant effect, and with almost no H1 or M1 blockade it stays metabolically cleaner — taken with at least 350 calories.
  • Bupropion is the half measure NP Z warns against: lower switch risk, some help for the depression, but it leaves the agitated, impulsive mixed piece itself untreated while SSRI monotherapy keeps flooding a system that can switch.
• May 18, 2026 Schizophrenia Negative Symptoms & Vraylar (Cariprazine): D3 Explained | PMHNP Boards

  💎 Vic, 28, has no voices left on risperidone 4 mg after three years, yet has not worked in 14 months and sleeps 12 to 14 hours while his mother runs his life — negative symptoms, the greatest driver of disability in schizophrenia, are the untreated half.

  📇 Key Takeaways — the index card

  • Learn the five negatives as functions, not checkboxes: blunted affect, alogia or poverty of speech, avolition, anhedonia, and asociality — and know avolition is the single strongest predictor of work disability, while anhedonia splits into anticipatory, not looking forward to the Packers game, and consummatory, not enjoying it while there.
  • Sort primary from secondary before switching anything: depression is episodic and carries sadness and guilt, and sedation from H1 blockade, EPS parkinsonism, emotional blunting from excess D2 blockade, high prolactin with sexual dysfunction, cannabis, and trauma-driven withdrawal can all impersonate negative symptoms with completely different fixes.
  • Risperidone's bind is anatomical: D2 blockade helps where mesolimbic dopamine is excessive, but in the mesocortical pathway dopamine is already low, so the same blockade deepens avolition and cognitive dulling — and lowering the dose to rescue function risks the psychosis quietly returning.
  • Cariprazine is the D3 play: about ten times greater affinity for D3 than D2 in vitro, with D3 concentrated in the nucleus accumbens, prefrontal cortex, and hippocampus reward and motivation circuitry, backed by one positive randomized negative-symptom trial published in The Lancet in 2017 — with akathisia watched closely, since NP Z warns it is debilitating and has been linked to worsening suicidality.
  • Other levers raise prefrontal dopamine more gently: the partial agonists aripiprazole and brexpiprazole can boost mesocortical tone, and mirtazapine, through 5-HT2A and alpha-2 antagonism, disinhibits prefrontal dopamine, norepinephrine, and serotonin and fits best when true depression and insomnia ride along, at the cost of weight gain.
• May 17, 2026 Schizophrenia Negative Symptoms: Board Bomb Case Study | PMHNP Boards

  💎 Garrett, 32, improved on risperidone — less convinced his neighbors are monitoring him — yet dropped out of vocational training and stopped showering: the board answer for his functional decline is negative symptoms, option C.

  📇 Key Takeaways — the index card

  • Negative symptoms are the single greatest driver of long-term functional disability in schizophrenia, ahead of persecutory delusions, auditory hallucinations, and disorganized thinking — the flashy positive symptoms get the attention while the quiet ones take the function.
  • Read Garrett's decline as the negative-symptom picture itself: no longer showering, out of his vocational training program, not seeing friends, very little interest in activities he previously enjoyed, sparse and minimally spontaneous speech, and a flat affect on exam.
  • Do not declare victory at quieter psychosis: NP Z's standard is that the mission is not accomplished until the positive symptoms are controlled and the negative symptoms are accounted for — untreated, families take the withdrawal personally and relationships corrode without psychoeducation that this is a feature of the illness.
  • There is no FDA-approved treatment in the United States for negative symptoms of schizophrenia, which is exactly why they stay underestimated and undertreated.
  • The forward pearl NP Z plants here is the D3 receptor as the target for negative symptoms, with cariprazine — the D3-preferring agent covered in the deep dive that follows this board bomb — approved in Europe and the US for schizophrenia and backed by a randomized trial in predominant negative symptoms, though no agent holds a standalone approval specifically for negative symptoms in either region.
• May 16, 2026 BPD vs Persistent Depressive Disorder: How to Tell Apart | PMHNP Boards

  💎 Mara, 34, has felt empty as long as she can remember — the verdict is persistent depressive disorder, not borderline personality disorder, and the question that separates them is what she does about the emptiness.

  📇 Key Takeaways — the index card

  • Ask when you feel really empty, what comes next: in persistent depression the answer is passive — scroll the phone, try to sleep, nothing — because the emptiness is flat mood with no energy to act, while in BPD emptiness is an aching, active void, criterion 7, that provokes frantic action to fill it and escape abandonment.
  • Mara's timeline is depressive, not borderline: low-grade sadness since about age 14, forcing herself through college, two stable long relationships of five and three years that faded slowly — one partner called it dating a wall — which is emotional unavailability eroding closeness, not the idealization, devaluation, and chaotic breakups of BPD.
  • Discount the red herrings by testing trait versus state and recurrence: a critical, unpredictable mother and unavailable father feed both diagnoses, one semester of going home with strangers just to feel something is a time-limited state, and scratching her arms in high school, not repeated in over ten years, does not meet BPD's recurrent self-harm criterion or its impulsivity in at least two areas.
  • Affect and anger point the same way: Mara is constricted, blah, and the same as always, and her white-hot rage stays internalized — she goes quiet and leaves the room — versus BPD's labile affect shifting over hours to days and criterion 8's displayed, hard-to-control anger and recurrent fights.
  • Treatment is why the call cannot be shrugged off: persistent depression is treated with the combination of an antidepressant and psychotherapy, while BPD's gold standard is DBT and there is no FDA-approved pharmacotherapy for BPD itself — sending Mara to DBT for dysregulation she does not have misses her neurovegetative depression.
  • Watch for double depression on top of it: a major depressive episode superimposed on persistent depression announces itself with symptoms that are not part of PDD — anhedonia, guilt, psychomotor change, and suicidal ideation, NP Z's PIG-with-SI cue — and both the acute layer and the chronic base need treatment.
• May 15, 2026 Trazodone: More Than a Sleep Med — Receptors & Prescribing | PMHNP Boards

  💎 At 50 mg trazodone is not acting as an SSRI at all — its highest affinity is 5-HT2A antagonism, with alpha-1 and mild H1 blockade doing the sleeping; serotonin reuptake inhibition only arrives around 300 to 400 mg.

  📇 Key Takeaways — the index card

  • The affinity principle runs the whole episode: a drug fills receptors in order of binding affinity, lower Ki meaning higher affinity, so ask of any drug which doors it unlocks at the dose your patient can actually tolerate — trazodone reaches 5-HT2A first.
  • That 2A blockade is a direct antidote to SSRI start-up: SSRIs stimulating 5-HT2A produce anxiety, insomnia, and sexual side effects, and trazodone antagonizing it calms all three while enhancing slow-wave sleep and preserving REM, which SSRIs and Z-drugs can disrupt — and restored sleep alone measurably improves depressive symptoms and builds first-night rapport.
  • Dose rewrites the drug: common prescriptions run 25 to 100 mg with no meaningful SERT inhibition, while at 300 to 400 mg SERT occupancy reaches about 60 to 70% and it behaves as a multimodal antidepressant, adding 5-HT1A partial agonism and 5-HT2C antagonism — a ceiling most patients never reach because next-day wipeout stops the climb.
  • Choose the sexual-dysfunction antidote by the rest of the picture: bupropion when the patient is low-energy, anhedonic, and unmotivated, trazodone when the patient is activated, anxious, and not sleeping, since more trazodone can deepen next-day fatigue.
  • Its alpha-1 blockade softens hyperarousal and has helped nightmares off-label when prazosin is not tolerated, though prazosin is the more potent alpha-1 agent; counsel priapism by its real number, about 1 in 6,000 to 8,000, and respect orthostasis and falls in older patients and QT prolongation in the interaction check.
  • Against the other sleep options it is the Swiss army knife: doxepin at 3 to 6 mg is the clean, purely antihistaminergic pick for middle-of-the-night waking, ramelteon is the circadian option with the weakest evidence, hydroxyzine carries anticholinergic burden and next-day hangover, and mirtazapine shares the 5-HT2A benefit with roughly four times trazodone's weight-gain risk in the evidence NP Z cites.
• May 14, 2026 Gabapentin in Psychiatry: Uses, Myths & Prescribing | PMHNP Boards

  💎 Gabapentin does not bind GABA receptors at all — it binds voltage-gated calcium channels and turns down excitatory neurotransmitter release.

  📇 Key Takeaways — the index card

  • Despite the name, it is not GABAergic: no GABA-receptor binding and no GABA-reuptake effect. It reduces release of glutamate and norepinephrine from hyperexcitable neurons — it lowers the volume, it does not simply inhibit.
  • Almost none of its use is on-label: under 1% of prescriptions are for its FDA approvals — partial-onset seizures and postherpetic neuralgia — while roughly 95% are written for other reasons. (Restless legs syndrome is an approval of gabapentin enacarbil, the Horizant prodrug, not of gabapentin itself.)
  • Pharmacokinetic clean-up hitter: under 3% protein binding, so virtually no displacement of warfarin, SSRIs, or other highly bound drugs, and 100% renally eliminated — valuable with liver disease, polypharmacy, and CYP-interaction problems.
  • It restores slow-wave (deep) sleep, the stage benzodiazepines and Z-drugs suppress — and slow-wave loss is tied to hyperarousal, impaired fear extinction, and emotional dysregulation in anxiety and PTSD.
  • Hard wall: it is not a mood stabilizer. Evidence for bipolar disorder is very weak every time NP Z digs into it, so do not treat it as one.
  • The call: duct tape, not a foundation — a checkmate drug for when first-line options have failed, been refused, or do not fit, not a first move. Watch abuse potential: several states have made it Schedule V even though it is not federally scheduled.
• May 13, 2026 Specific Phobia: The Most Common Anxiety Disorder | PMHNP Boards

  💎 Specific phobia is the most common anxiety disorder — 6 to 12% 12-month prevalence, roughly 1 in 10 people — yet it rarely walks into clinic.

  📇 Key Takeaways — the index card

  • You miss it because avoidance works: patients build their jobs and lives around the feared stimulus — spiders, snakes, heights, blood, flying — so they never present, and every avoidance teaches the brain it was safe only because it avoided.
  • There is no FDA-approved medication for specific phobia, and an SSRI is not the answer for the isolated phobia unless a comorbid condition needs one.
  • Exposure therapy is the gold standard, and it is unusually powerful here: even one-session treatments can virtually extinguish a phobia, making this one of the most treatable disorders in the DSM-5.
  • Earliest onset of the anxiety disorders, and prevalence roughly double that of generalized anxiety disorder — which is the answer most clinicians guess first.
  • Fears cluster on evolutionarily prepared stimuli — snakes, spiders, heights, enclosed spaces — while cars, outlets, and guns, which are statistically far deadlier today, rarely become phobias. Use that to cut the patient's shame.
  • Phobias are also acquired by vicarious learning (watching someone else get bitten or panic) and by informational transmission (being repeatedly taught as a child that something is dangerous).
• May 12, 2026 Post-Discharge Suicide Risk: The Most Dangerous Window | PMHNP Boards

  💎 The first week after psychiatric hospital discharge is the highest-risk window in psychiatry — suicide rates run 100 times the general population in the first three months.

  📇 Key Takeaways — the index card

  • Of patients who die by suicide within two years of discharge, 9% die in the first week alone and 23% in the first month — the danger is front-loaded, not spread out.
  • Discharge is not cure: the housing, job, divorce, and money problems that precipitated admission are waiting unchanged, while new medications are still being adjusted to.
  • Akathisia trap: a patient discharged restless on a new antipsychotic may not know what akathisia is, and akathisia itself is a major suicide risk factor — with no follow-up yet in place to catch it.
  • Follow-up must be seen within seven days, ideally three to five, and some institutions push for 24 hours. Before discharge: lethal-means counseling, confirmed contact information, and a real phone call — not just a text — with a repeat call the same or next day if there is no answer.
  • The distractors are real but smaller: postpartum suicidal behavior rises about sevenfold, antidepressant discontinuation carries a 1.6-fold increase in attempts with the highest risk in the first 28 days, and schizophrenia carries roughly 58% lifetime suicidal ideation and 25% attempts.
  • The call: give the post-discharge visit the time of a full intake — up to two hours. Energy can return before mood lifts, and these are clinically the most complex patients on your panel.
• May 11, 2026 Lamictal (Lamotrigine) vs Seroquel (Quetiapine) for Bipolar Depression | PMHNP Boards

  💎 Seroquel treats the acute bipolar depression happening now; Lamictal prevents the next one — timing picks the winner of each round.

  📇 Key Takeaways — the index card

  • Seroquel is FDA-approved for acute bipolar depression in bipolar I and II; lamotrigine is FDA-approved only for bipolar I maintenance, so its acute and bipolar II use is off-label
  • Quetiapine changes jobs with dose: sleep at low doses, antidepressant-like effects higher up, mood stabilization at 300 mg-plus, and antipsychotic effects at roughly 600-800 mg
  • Lamotrigine needs a 4-6-week titration because of Stevens-Johnson rash risk — any new rash during the climb is a stop-and-call event, and estrogen birth control can cut its levels by about half
  • Seroquel's sedation can restore sleep and circadian rhythm fast, but next-day wipeout and reliable weight gain with glucose and lipid effects are its price
  • Lamotrigine's maintenance strength is preventing depressive relapse — it is not reliable mania prevention — and once patients reach 100-200 mg a day it is weight-neutral with no significant sedation
  • The call: Seroquel landed more punches for the acute episode, Lamictal is its tag-team partner for long-term depression prevention — and the best medication is the one the patient will actually take
• May 10, 2026 Antidepressant-Induced Bruxism: The Hidden Side Effect | PMHNP Boards

  💎 One in seven patients starting an antidepressant — 14% — develops new-onset bruxism, and 80% of them have no idea it is happening.

  📇 Key Takeaways — the index card

  • Mechanism: excess serotonin suppresses dopamine in substantia nigra circuits, loosening control of involuntary movement. Bruxism is essentially a focal movement disorder — an akathisia of the jaw — and it is the number one movement disorder linked to antidepressants.
  • The damage is mechanical and fast: hundreds of pounds of force during sleep cracks enamel, flattens cusps, loosens crowns, fillings, and veneers, and drives TMJ pain and tooth sensitivity — years of wear in months.
  • Ask, because they will not volunteer it: morning headaches, jaw pain or tightness on waking, a partner reporting grinding, new tooth sensitivity the dentist cannot explain, and daytime clenching.
  • Named offenders include Zoloft, Lexapro, Effexor, Paxil, and Cymbalta; among antipsychotics Geodon carries the highest reported risk, with Abilify, olanzapine, and risperidone also implicated.
  • First fix: buspirone 5 to 10 mg at bedtime as a single nightly dose, often relieving bruxism within days. As a 5-HT1A partial agonist it acts like a thermostat on serotonin output, suppressing dopamine less, and it can also augment the antidepressant and help sexual side effects.
  • Alternatives: switch to bupropion when the profile fits (anhedonia, low energy, weight concerns — and no seizure history, alcohol withdrawal, or eating disorder), or mirtazapine, which blocks the 5-HT2C receptor involved — at the price of weight gain. A night guard protects teeth but does not stop the grinding.
• May 9, 2026 Bipolar Medication Mistakes: Board Bomb Case Study | PMHNP Boards

  💎 Latuda is the least appropriate choice for Lenny: it must be taken with at least 350 calories, and fasting cuts the maximum level reaching his system by a factor of three.

  📇 Key Takeaways — the index card

  • The case: Lenny, 34, bipolar I depression for three weeks, BMI 19, sleeping a lot, no other medications, adherent when he has access, prefers once-daily dosing — and he lost his apartment two months ago, rotates through shelters, sleeps outside, and eats when a soup kitchen is available.
  • Quetiapine is a poor fit but not the answer: he is already hypersomnic, heavy sedation leaves an unsheltered patient a sitting target, and quetiapine has street abuse value that can make him a robbery target. His low BMI and once-nightly dosing are the points in its favor.
  • Lamotrigine is reasonable and guideline-backed, but the titration is friction for an insecure life: 25 mg for two weeks, then 50 mg for two weeks, then 100 mg — plus rash monitoring that needs reliable clinic access.
  • Cariprazine is serviceable: FDA-approved for bipolar I depression, a favorable metabolic profile, and an extremely long effective half-life that gives grace if a dose is missed, stolen, or lost in a displacement.
  • Lumateperone is also reasonable and once daily for bipolar I or II depression — its barrier is practical, not pharmacological: cost.
  • The verdict: Latuda (option C). One day he cannot secure a meal, his dose is effectively sunk no matter how adherent he is. Geodon has a similar, though less powerful, food requirement.
• May 8, 2026 Depakote (Valproate) Toxicity: The Red Flag You Can't Miss | PMHNP Boards

  💎 Desiree's total Depakote level of 78 looks therapeutic, but with an albumin of 2.6 her free level can be two to three times what you would expect — order the free level.

  📇 Key Takeaways — the index card

  • The case: Desiree, 38, bipolar I with alcohol-related liver cirrhosis, albumin 2.6 g/dL, on day 5 of Depakote ER for acute mania, now increasingly sedated with a new tremor.
  • Valproate is about 90% protein bound. Albumin is made by the liver, so cirrhosis plus an albumin of 2.6 means far fewer binding sites — and bound drug exerts no effect, while the unbound fraction is the active, toxic one.
  • Sedation and tremor are toxicity, not mania: mania is grandiosity, goal-directed activity, and decreased need for sleep — the opposite of sedation. A mid-range total level (therapeutic range 50 to 125 mcg/mL) does not reassure here.
  • The verdict: order a free (unbound) Depakote level — option C. Total levels mislead in low albumin and liver disease.
  • Do not increase the dose (she is already toxic; more pushes toward severe toxicity or liver failure) and do not add a benzodiazepine for the tremor — that treats the symptom and piles a CNS depressant onto an oversedated patient.
  • Switching to carbamazepine solves nothing: it is also heavily hepatically metabolized and carries its own black-box warnings, including Stevens-Johnson syndrome, in a cirrhotic patient.
• May 7, 2026 Invega Sustenna (Paliperidone): LAI Initiation Board Bomb | PMHNP Boards

  💎 No new oral trial and no oral overlap for Invega Sustenna: paliperidone is risperidone's active metabolite, and he has already tolerated risperidone.

  📇 Key Takeaways — the index card

  • The case: a 24-year-old with schizophrenia, three hospitalizations in 18 months, stabilized each time on oral risperidone 4 mg daily, then stops within two to three weeks of discharge — his mother finds hidden pills. No dystonia, akathisia, or allergic reaction to risperidone.
  • The answer (B): the FDA label allows tolerability to be established with either oral risperidone or oral paliperidone. The point of an oral trial is only to rule out acute deal-breaking reactions before a month-long injection — not to prove it treats his psychosis.
  • Loading is deltoid, day one and day eight: 234 mg on day one, then 156 mg on day eight, then monthly. The deltoid's higher blood flow gives faster absorption and higher initial plasma levels.
  • Gluteal loading is the trap: it produces roughly a 28% lower maximum plasma level and delays therapeutic efficacy — the first two injections must not go in the gluteal muscle.
  • The 21-day oral overlap belongs to a different product: Risperdal Consta's microsphere technology delays drug release about three weeks, so it needs three weeks of oral cover. Sustenna's two loading doses are designed to eliminate that need.
  • Underneath it all is flip-flop pharmacokinetics: with an IM depot, absorption is slower than elimination, so the formulation — not the molecule alone — decides whether oral bridging is required.
• May 6, 2026 Positive Drug Screen on Psychiatric Meds: What Now? | PMHNP Boards

  💎 Bonnie's own prescriptions explain both positives: bupropion causes false-positive amphetamine screens and trazodone causes false-positive benzodiazepine screens.

  📇 Key Takeaways — the index card

  • The case: Bonnie, 28, PTSD and major depression, doing excellently for six months on trazodone 150 mg and bupropion XL 300 mg — sleeping well, mood stable, back at work full time, no substance-use history, no benzo or stimulant prescriptions, no over-the-counter products or supplements — yet a routine screen returns positive for benzodiazepines and amphetamines.
  • Bupropion is one of the most common causes of a false-positive amphetamine immunoassay, reported at 4 to 10% across platforms. Trazodone produces false-positive benzodiazepine results through its metabolite.
  • The 12-pound loss is a red flag or a red herring: ask how the gym actually looks. Three structured sessions a week with planned training days is methodical; a 24-hour frenzy of all-night workouts and pitching a business is not. Bupropion itself commonly raises energy and lowers weight.
  • The verdict (D): reassure her that her medications are the most likely explanation and order confirmatory testing — GC-MS or LC-MS, which separates the sample and identifies compounds by their mass fingerprint — before changing anything.
  • Repeating the immunoassay in two weeks (E) just reproduces the same false positive, because she is still taking the same two drugs, and leaves her in limbo with a stigmatizing result sitting in her chart.
  • Do not stop the bupropion, start a benzodiazepine taper, refer her for a substance-use evaluation, or withhold refills: each punishes a patient who is doing well, and a false addiction label can follow her into future care and coverage.
• May 5, 2026 Spot the Medication Error: Mock Regimen Curveball | PMHNP Boards

  💎 Larry's curveball is timing, not the drug list: he takes his activating Wellbutrin after dinner, so it peaks in the middle of the night.

  📇 Key Takeaways — the index card

  • The case: Larry, 51, depression improving on Lexapro 20 mg for a year, Wellbutrin XL 150 mg added for motivation, plus trazodone 100 mg and Atarax (hydroxyzine) 25 mg at night — sometimes extra Atarax because he feels wired at night. His chief complaint is crushing morning grogginess despite sleeping through the night.
  • Bupropion is dopaminergic and noradrenergic — wakefulness circuitry. Taken after dinner, its activating effect lands overnight: he is wired at night and has already spent his alertness by morning.
  • The sedation is compensatory polypharmacy: trazodone 100 mg and extra hydroxyzine exist to fight a side effect of timing, and that stack is what carries into his foggy morning. Lowering trazodone alone treats the compensation, not the cause.
  • The fix: move Wellbutrin to the morning. Daytime alertness rises, sleep drive builds across the day, trazodone can often drop to 50 mg, and the Atarax may become unnecessary.
  • A second dividend: raising Wellbutrin to 300 mg in the morning can counter his Lexapro-driven sexual dysfunction — SSRIs damp dopamine via 5-HT2C pathways — as well as residual fog and poor concentration.
  • Write the time in the sig: patients reasonably assume that taking a daily medication at any hour counts the same. If the instructions do not say morning, the patient was set up to fail.
• May 4, 2026 Metformin with Antipsychotics (SGAs): The Underuse Problem | PMHNP Boards

  💎 In the youth cohort the episode cites, only 2.3% of young people treated with second-generation antipsychotics were co-prescribed metformin — a tiny fraction, given how reliably these drugs drive weight gain.

  📇 Key Takeaways — the index card

  • The number behind it: a national records review of 30,009 youth treated with second-generation antipsychotics — the cohort cited in the 2025 Lancet Psychiatry metformin trial — found only 677, or 2.3%, had metformin co-prescribed with at least 30 days of overlap.
  • What is being left on the table: metformin helps patients lose weight (around 7.3 lb in the evidence NP Z cites), limits further gain, reduces BMI, and favorably affects A1C, fasting glucose, and triglycerides, with diabetes-prevention benefit.
  • Why it matters most in this population: the number one cause of death in severe mental illness is cardiovascular disease — not suicide and not command hallucinations — and antipsychotics reliably push BMI and lipids upward.
  • Why it is skipped: prescribers forget, never think of it, or feel it is not in their lane — while many of these patients have no primary care provider to pick it up instead.
  • The practical case: generic metformin costs about $4 a month, with no prior authorization, no REMS program, and no abuse potential. NP Z's call: treat it as low-hanging fruit and co-prescribe rather than waiting for metabolic damage.
• May 1, 2026 Bipolar vs MDD with Psychosis: Board Bomb Diagnosis | PMHNP Boards

  💎 Psychosis during an elevated mood episode is mania, full stop — there is no such thing as psychosis in hypomania, so the diagnosis is bipolar I.

  📇 Key Takeaways — the index card

  • The case: Sandy, 28, recurrent major depressive episodes plus distinct four- to five-day episodes of elevated mood, decreased need for sleep, pressured speech, and increased goal-directed activity, none requiring hospitalization. Eighteen days ago, during an elevated episode, she became convinced her neighbor was recording her through the walls; the belief lasted 10 days and resolved as the episode ended. Drug screen negative, labs unremarkable.
  • Use timing as the whole differential: psychosis only during depression suggests MDD with psychotic features; psychosis only during elevated mood is bipolar I; psychosis persisting at least two weeks in the absence of a mood episode points to schizoaffective disorder.
  • Not brief psychotic disorder, even though 10 days fits its one- to 30-day window: brief psychotic disorder cannot be diagnosed when the psychosis is better explained by a mood episode.
  • Neither short duration nor lack of hospitalization rescues a bipolar II call — psychotic features override both. Mania does not require hospitalization, and bipolar I does not require a prior depressive episode; one manic episode is enough.
  • A single episode of psychosis during elevated mood permanently reclassifies the diagnosis to bipolar I, which changes treatment: lithium, valproate, and atypical antipsychotics move to first line, and antidepressant monotherapy should be avoided — guidelines advise against it in bipolar I rather than it being an absolute contraindication in every circumstance.
  • Still rule out substances first: an agent capable of producing mania must be excluded before settling on a primary bipolar diagnosis, even with a negative screen and no use in the record.
• Apr 28, 2026 Acute Bipolar Depression: 5 Essential Medications | PMHNP Boards

  💎 Five medications anchor acute bipolar depression — quetiapine, lurasidone, olanzapine-fluoxetine, cariprazine, and lumateperone — and none of them is a naked antidepressant.

  📇 Key Takeaways — the index card

  • Start from the patient's most impairing symptom, not the diagnosis: cannot sleep, cannot focus at work, or cannot feel joy. That portrait eliminates some of the five and elevates others.
  • Quetiapine for the sleepless presentation: it helps sleep the same night it is prescribed, and its metabolite norquetiapine acts like an SNRI, adding norepinephrine reuptake and some daytime pep as the dose rises — with mania coverage built in. It is also one of the worst metabolic offenders.
  • Olanzapine-fluoxetine has the highest response rate of the group, about 56% — and roughly 1 in 5 patients gain more than 7% of body weight in the acute trials, with rates climbing on longer treatment, exceeding every other option by a mile. Get baseline fasting glucose, lipids, waist circumference, and BMI, and recheck around 12 weeks.
  • Lurasidone for cognition and circadian rhythm: 5-HT7 antagonism, with little muscarinic, anticholinergic, or histaminergic burden, so it spares sedation and focus — but it is weaker at preventing mania, and it needs 350 or more calories with the dose or bioavailability falls sharply.
  • Cariprazine for anhedonia and low motivation: D3 partial agonism in reward circuits, plus 5-HT1A partial agonism that adds prefrontal dopamine and an anxiolytic effect, a favorable metabolic profile, and mania efficacy at higher doses. Cost is its main barrier.
  • Lumateperone is the newest of the five, acting across five distinct receptor and transporter systems — one of the most unusual pharmacological profiles in the class — and it is also expensive, so access has to be checked before it becomes the plan.
• Apr 27, 2026 Ambien (Zolpidem) ER Visits & Psych Med Pharmacokinetics | PMHNP Boards

  💎 Zolpidem (Ambien) accounted for almost 12% of all adult psychiatric-medication adverse-event ED visits — and one in five of those visits in patients 65 and older.

  📇 Key Takeaways — the index card

  • Totals versus rates: Haldol sends patients to the ED at about eight times Ambien's rate per prescription (movement disorders, dystonia, oculogyric crisis) and quetiapine is also higher per prescription — Ambien leads overall because it is prescribed so much more often. Lithium is seen less in the ED but has the highest admission rate of any psychiatric medication.
  • The case: Arthur, 95, falls and hits his head on Ambien 10 mg. If it is used at all in an older adult, 5 mg is the ceiling — it sits on the Beers list, and the FDA has warned about complex sleep behaviors such as driving or sexual activity with no memory of them.
  • Absorption: delayed gastric emptying in aging shifts Tmax later, so instead of peaking while he is safely asleep, Arthur can peak around 4 a.m. on a bathroom trip — with residual sedation still on board for a morning drive.
  • Distribution, the fat trap: lean mass and total body water fall while body fat rises, so lipophilic drugs soak into a larger fat compartment and release more slowly — duration of action stretches beyond what the half-life alone predicts.
  • Metabolism and elimination: Ambien is cleared mainly by CYP3A4 (with 1A2 and 2C9 contributions), hepatic blood flow falls 25 to 40% and liver volume shrinks with age, and GFR declines after age 40. On top of the kinetics, the older brain is pharmacodynamically more sensitive to sedative-hypnotics at the same plasma level.
  • NP Z's alternatives: CBT-I as the gold standard, melatonin or ramelteon to realign circadian rhythm, and doxepin — roughly 100 times more potent at histamine than Benadryl, without Benadryl's muddy anticholinergic baggage. Start low and go slow is a direct consequence of ADME, not a platitude.
• Apr 26, 2026 Sleep Apnea & Depression: The Untreated Link Doubling Risk | PMHNP Boards

  💎 Untreated obstructive sleep apnea roughly doubles depression risk: 27.4% of apnea patients developed a depressive disorder versus 15.8% of matched controls — a hazard ratio of 1.9.

  📇 Key Takeaways — the index card

  • The study behind it: a 2025 population-based study of over 7 million people with an eight-year follow-up. This is not just 'poor sleep, bad mood' — apnea physically changes brain chemistry.
  • Mechanism one: intermittent hypoxia, hundreds of airway collapses a night, cranks up monoamine oxidase A in the hippocampus, destroying serotonin, dopamine, and norepinephrine faster than the brain can make them. More SSRI cannot outrun an enzyme destroying the transmitter.
  • Mechanism two, the double whammy: inflammatory signals divert tryptophan — the raw material for serotonin — away from serotonin production entirely. The patient is simultaneously manufacturing less serotonin and degrading more of it.
  • Neuroinflammation targets the hippocampus and prefrontal cortex, the regions governing mood, motivation, emotional processing, and impulse control — so apnea mimics many disorders at once: irritability that looks like bipolarity, fog that looks like ADHD, and depression that looks treatment-resistant.
  • REM fragmentation: REM is the one period when brain norepinephrine goes quiet so emotional memories can be processed without a fight-or-flight surge. Apnea interrupts it constantly, leaving the amygdala hyperreactive — undermining PTSD therapy and even prazosin.
  • Chronic HPA-axis activation adds cortisol spikes that themselves mimic depression — fatigue, poor concentration, irritability, weight gain, low motivation. The call: in depression that does not budge, screen for apnea early, alongside thyroid, B12, folate, vitamin D, and anemia, and treat it with CPAP rather than escalating a fourth antidepressant.
• Apr 22, 2026 Affinity, Occupancy & Intrinsic Activity: Nightclub Analogy | PMHNP Boards

  💎 Occupancy is not the whole story: aripiprazole can occupy 90% or more of D2 receptors without shutting the party down, because intrinsic activity — what a drug does once it is bound — decides the effect.

  📇 Key Takeaways — the index card

  • Affinity is the strength of binding between a drug and its receptor, quantified by Kd — the lower the Kd, the higher the affinity. In the nightclub, the brain is the club and D2 receptors are the VIP tables: haloperidol is the high-affinity bouncer who reliably gets to those tables and restores order, while a drug with no D2 affinity never stops the party at all.
  • Occupancy is the fraction of those tables taken over, and dose drives it. Block 80% or more with a high-affinity D2 antagonist like haloperidol and NP Z calls it the danger zone — the party goes dead and stiff, which is EPS: rigidity and tremor from too many receptors blocked. Block too few and the thrashing continues and psychosis persists.
  • Quetiapine shows why affinity changes the dose: it is weak at D2, so 50 mg sends in scrawny bouncers who cannot clear the tables — NP Z puts the range that actually restores order in psychosis at 600 to 800 mg. It also slides on and off the receptor rather than gripping it, so endogenous dopamine can still get through, which is part of why its motor side effects are gentler — at the price of heavy sedation.
  • Intrinsic activity is the biological response the drug-receptor complex produces once bound — agonism, antagonism, or partial agonism. Haloperidol has zero intrinsic activity at D2: a pure antagonist that just shuts the table down. Heroin is his full-agonist contrast: instead of a bouncer, you have sent in 100 more partiers and the club gets more intense, not calmer.
  • Aripiprazole breaks the occupancy intuition because it is a partial agonist — the dimmer switch, not the bouncer. It has very high D2 affinity and occupies 90-some percent of the tables like a jazz band taking almost every seat, yet it lowers a signal that is too wild in the mesolimbic pathway and raises a signal that is too low in mesocortical regions, where thinking, motivation, and energy are flat.
  • NP Z's prescribing sequence from the analogy: first identify the target receptor — D2, 5-HT2A, 5-HT1A, 5-HT2C, histamine, or another table entirely — then pick a drug with real affinity for that target, work out the occupancy that effect requires, and know what the drug will actually do when it gets there.
• Apr 21, 2026 Intrinsic Activity in Pharmacology: Prescribing Explained | PMHNP Boards

  💎 A partial agonist is a thermostat set to 65 to 75 degrees: Abilify lowers dopamine where mesolimbic tone is too high and lightly pushes it where mesocortical tone is too low, so it never runs at 100 percent.

  📇 Key Takeaways — the index card

  • Intrinsic activity is separate from binding: a full agonist produces the maximum response at a receptor, an antagonist binds and activates nothing, and an inverse agonist pushes baseline activity below its resting level.
  • Morphine and nicotine are presented as full agonists in this account — full mu activation is what suppresses respiratory drive in overdose, whereas partial agonist buprenorphine gives enough mu activation to stop withdrawal and craving while blocking a full agonist from taking over.
  • Aripiprazole, brexpiprazole, cariprazine and buspirone are named as partial agonists that work as buffers: D2 partial agonism stabilizes dopamine tone, which is why Abilify can be used adjunctively in depression without fully shutting dopamine down, and why EPS can be less severe than with a pure blocker.
  • Haloperidol, risperidone, olanzapine and naltrexone are antagonists in this framework: the bouncer at the door — they stop more signal coming in, they do not raise or lower the baseline themselves.
  • Mirtazapine as an H1 inverse agonist is the contrast case: not just blocking histamine, but reducing histamine's normal wakefulness baseline below resting, which is why the sedation runs deeper than simple antagonism.
• Apr 19, 2026 Antidepressants & Anticoagulants: Bleeding Risk Board Question | PMHNP Boards

  💎 On apixaban, this antidepressant question is really a bleeding question: SSRIs strip platelets of serotonin they cannot make themselves, so the answer is bupropion — the one non-serotonergic option.

  📇 Key Takeaways — the index card

  • The case: a 68-year-old woman with atrial fibrillation on apixaban 5 mg twice daily, PHQ-9 18 three months after her husband died — low energy, sleeping about 12 hours a day, increased appetite, and worthlessness. The choices are three SSRIs — Zoloft, Lexapro, and Prozac — against one NDRI, Wellbutrin.
  • Apixaban is a direct oral anticoagulant, first-line for stroke prevention in atrial fibrillation — it reduced stroke/systemic embolism by 21% versus warfarin in ARISTOTLE (the 55% figure was versus aspirin in AVERROES) — so anything you add has to be checked against bleeding, not just depression efficacy.
  • The mechanism the boards are testing: platelets cannot synthesize serotonin. They rely entirely on uptake from plasma through the serotonin transporter, which SSRIs block. Depleted platelet serotonin impairs platelet aggregation — in NP Z's words, less glue to clot.
  • On an anticoagulant, that shows up as easy bruising, nosebleeds, bleeding gums, and heavier periods, then black stools, fatigue, and anemia if it escalates — and in an older patient who falls and hits her head, an intracranial bleed.
  • Wellbutrin is the correct answer because it is non-serotonergic and does not raise that bleeding risk, and it fits her picture: typically weight-neutral, with some patients losing weight in NP Z's experience, and energizing for hypersomnia, low energy, increased appetite, and a 15-pound gain — the opposite of a sedating, weight-gaining choice like Paxil, which he calls the worst move here.
  • Read the throwaway line in the stem: 'no history of bleeding disorders or seizures' is two clues, not filler. Bleeding points to the anticoagulant trap, and no seizures is the elbow nudge that bupropion — which requires that screen — is safe to use. If seizures had ruled it out too, NP Z's fallback is non-serotonergic paths, grief-focused psychotherapy, and labs for thyroid, vitamin D, B12, and folate before reaching for an SSRI.
• Apr 14, 2026 Remeron (Mirtazapine): Who It's Perfect For & Who It's Not | PMHNP Boards

  💎 Mirtazapine gets less sedating as the dose rises: at low doses H1 blockade dominates, and as alpha-2 blockade recruits, norepinephrine release increases and alertness comes back.

  📇 Key Takeaways — the index card

  • Mirtazapine is a NaSSA, not an SSRI: it does not block serotonin reuptake, it blocks alpha-2 autoreceptors — the brakes on norepinephrine and serotonin neurons — so more of both transmitters are released.
  • The trade-off is quantified in the episode from the FDA label: 7.5% of patients gained at least 7% of body weight, and 15% had a cholesterol increase of 20% or more above the upper limit of normal — so the ideal candidate is depressed, anxious, not sleeping, and not eating, not someone already struggling with weight or lipids.
  • Blocking 5-HT2A and 5-HT3 is why mirtazapine largely avoids the SSRI baggage named here: almost no sexual dysfunction and little GI upset or nausea, which makes it the go-to NP Z describes for patients whose anxiety shows up as nausea or who have IBS or other GI problems.
  • Blocking 5-HT2C helps explain both sides: it raises dopamine and norepinephrine in prefrontal cortex, which can help cognition, and it drives the appetite and weight gain.
  • Warn patients before the first dose that taking an extra pill will not make them sleepier — the episode reports patients who doubled up and got activated, more anxious, even borderline suicidal, instead of more sedated; sedation typically arrives the first night.
• Apr 7, 2026 Trazodone for Sleep & Anxiety: Receptors Explained (Case Study) | PMHNP Boards

  💎 For Randall, 46 — GAD on Lexapro, middle insomnia, nightmares, pre-sleep rumination and SSRI sexual dysfunction, and Silenor 6 mg already failing — trazodone wins on 5-HT2A antagonism, not just on sedation.

  📇 Key Takeaways — the index card

  • Get the insomnia signature before picking a sleep drug: what happens right before sleep, what the patient is thinking about, nightmares, and middle-of-the-night waking — and first re-screen for bipolar activation, substances, and caffeine, whose metabolism NP Z notes can vary 40-fold between people.
  • Silenor (doxepin) is a clean, high-affinity H1 blocker and it still did not help Randall, which points away from histamine: his problem is anxious rumination and hyperarousal at night, a cortical problem.
  • Trazodone antagonizes 5-HT2A — the receptor extra synaptic serotonin from an SSRI stimulates to drive cortical excitability, glutamate, rumination and anxiety — so blocking it turns down that internal amplifier, improves sleep continuity and slow-wave sleep, without directly sedating.
  • Dose decides the job: 25 to 100 mg is mostly hypnotic, 5-HT2A antagonism comes in around 100 mg, and antidepressant recruitment needs roughly 150 mg and up toward 300 mg; alpha-1 antagonism can lower adrenergic arousal and nightmares but also leaves next-morning grogginess, and 5-HT2C antagonism is the piece linked here to easing sexual dysfunction.
  • The call for Randall: start trazodone 50 mg, possibly to 100 mg, keep watching the Lexapro dose and total serotonergic load as trazodone rises — plus the cautions NP Z flags, QT prolongation and arrhythmia risk in overdose and the under-25 suicidal-thoughts warning.
• Apr 6, 2026 ADHD Misdiagnosed as Anxiety: Find the 4 Clinical Errors | PMHNP Boards

  💎 Worrying all day about missing details and falling behind is not fear-based GAD — it is productivity-based, and NP Z says that flavor points down the ADHD track.

  📇 Key Takeaways — the index card

  • Error 1 — wrong diagnosis: The 23-year-old said she is a nervous person, and the clinician anchored on that and called it GAD. GAD worry, as NP Z teaches it, is broad and fear-based and catastrophic — fear of being fired, of cancer, of a loved one dying in a car accident — and when one worry resolves, the next pops up. Hers was narrow: a new, detail-heavy HR director job where she cannot keep up and worries about missing things and falling behind. Missing details, carelessness, and being overwhelmed by information is the ADHD track. Adjustment disorder can stay on the table for a new job; GAD should not have led.
  • Error 2 — venlafaxine for a patient who does not take medications consistently: She was started on Effexor (venlafaxine) immediate-release 37.5 mg, rising to 75 mg by the end of the week, after saying she is wary of medications and has a hard time being consistent. Venlafaxine has a very short half-life, so patients feel miserable when they accidentally miss a dose — poor adherence plus this drug sets her up to feel sick on the days she forgets. NP Z notes the one exception: using that misery deliberately to enforce adherence, like a disulfiram approach, only works with a radically transparent conversation and a patient who is motivated by and on board with it.
  • Error 3 — venlafaxine with uncontrolled hypertension: Her history already included uncontrolled hypertension, and venlafaxine is notorious for contributing to hypertension, so it was not the best choice for this patient. Read the medical history before the prescription, not after: a drug that can push blood pressure up is a poor match for blood pressure that is not yet controlled.
  • Error 4 — venlafaxine with IBS: She also had irritable bowel syndrome, and venlafaxine can worsen GI issues, causing nausea and GI distress. For the GI piece, NP Z contrasts mirtazapine (Remeron) as much more compatible, because it antagonizes the 5-HT3 receptor — the vomit receptor; as he puts it, bad things come in threes.
  • Bonus error — immediate-release instead of XR: If you do prescribe venlafaxine to somebody with GI issues, do not give the immediate-release form she got; give the XR, which is a little smoother. The formulation was part of the mistake, not just the drug name on the order.
  • Failed Lexapro and Prozac were a clue, not just history: She had already tried Lexapro and Prozac and said they did not quite work, and she was asking about another SSRI. NP Z's rule: when a patient arrives with a stack of failed trials, question the core diagnosis — after checking the trial was an adequate dose for an adequate time, because underdosing is common. If nothing has worked, maybe nothing was aimed at the real problem; working on the brakes will never inflate a flat tire.
• Mar 31, 2026 Receptor Occupancy in Pharmacology: A Simple Explanation | PMHNP Boards

  💎 Occupancy plateaus: at 20 mg of Lexapro you may already be near 80 percent serotonin transporter occupancy, so a patient who is less ruminative but still anhedonic and fatigued needs a different transmitter, not more of the same drug.

  📇 Key Takeaways — the index card

  • Occupancy is the percentage of receptors bound at any given time, and each effect has its own threshold — antipsychotic response typically emerges at roughly 65–80 percent D2 occupancy, with EPS risk rising above about 80 percent, while some second-generation agents can work at lower D2 occupancy and spare EPS.
  • The same milligram dose does not mean the same occupancy: an ultra-rapid metabolizer clears Lexapro before it can sit on receptors, a slow metabolizer gets outsized effects and side effects from 10 mg, and dehydration concentrates drug in less plasma volume and pushes occupancy and side effects up.
  • Protein binding competes for occupancy: only free, unbound drug is active — Depakote can displace Zoloft from protein, freeing more Zoloft to cause sexual dysfunction and anxiety — and highly protein-bound Prozac occupies receptors more slowly.
  • Overshoot looks like side effects, not extra benefit: past the useful occupancy range, extra SSRI stimulation lands on gut 5-HT3 receptors (nausea) and 5-HT2A receptors (anxiety and rumination), and excess serotonin can brake dopamine and blunt joy and energy.
  • Half-life is how occupancy leaves: Prozac's long half-life lets it step off slowly with a gentler discontinuation, while short-half-life Effexor exits abruptly — brain zaps, GI upset, irritability, insomnia and anxiety are the pattern NP Z warns about.
• Mar 24, 2026 Schizophrenia Case Errors: Can You Spot All 4? | PMHNP Boards

  💎 When a patient on Abilify says they are anxious, pacing, and want to jump out of their skin, think akathisia first — raising the antipsychotic dose makes the real problem worse.

  📇 Key Takeaways — the index card

  • Error 1 — Abilify started too low and left there: 5 mg is not the recommended starting dose for schizophrenia; the textbook start is 10-15 mg daily. Many patients cannot tolerate jumping straight to 10 mg, but the plan has to be titrating up to 10 mg as fast as tolerated — parking at 5 mg delays response and under-treats a 28-year-old still hearing self-critical voices and seeing shadows and devils.
  • Error 2 — Akathisia misread as anxiety: no patient walks in saying 'I have akathisia.' They say they are super anxious, cannot sit still, are pacing everywhere, and want to jump out of their skin. Pin them down — 'walk me through what this anxiety looks like at home' — and ask whether the voices themselves are actually worse. Mislabel it and you raise the Abilify from 5 mg to 10 mg, worsening the dopamine-blockade restlessness, or pile on a benzodiazepine or SSRI the patient never needed.
  • Akathisia is not a minor nuisance: NP Z ties it to higher suicide rates, treatment failure, and non-adherence. That is why the seesaw matters — be paranoid about side effects, and equally paranoid about under-treating schizophrenia, where suicide risk and the ability to work, shower, and function day to day are on the other side.
  • Error 3 — Propranolol 20 mg twice daily for the hand tremor masked the problem instead of treating it: the root cause was the Abilify, not the tremor. Propranolol has its place — when the antipsychotic is the first drug in ages to quiet the voices and the only complaint is a tremor that interferes with signing papers, cover the tremor. Do not cover a side effect before the drug is at a therapeutic dose and the core psychosis is controlled.
  • Error 4 — A 4-week follow-up for an acutely psychotic patient with a worsening medication side effect: this is a phone check before the visit and an in-clinic visit within a week, not a month. Make a patient sit in akathisia for extra weeks and they may quit the medication on their own — and encode medications in general as harmful for the next 10 years.
• Mar 20, 2026 Board Bombs: 3 High-Yield Psychopharm Questions | PMHNP Boards

  💎 Three board traps, three answers: switch risperidone hyperprolactinemia to aripiprazole, trim — not stop — a slightly high lithium level, and pick duloxetine when depression comes with fibromyalgia pain.

  📇 Key Takeaways — the index card

  • Q1 — Hyperprolactinemia on risperidone: 28-year-old, BMI 31, stable 6 months on risperidone 4 mg, with breast tenderness, milky discharge, 3 months of missed periods, negative pregnancy test, and prolactin 98 (normal below 25) — switch to aripiprazole. As a dopamine partial agonist — NP Z's dimmer switch — it actively lowers prolactin and is far more metabolically friendly. Traps: cutting risperidone to 2 mg risks destabilizing stable schizophrenia, adding cabergoline adds a dopamine agonist that can worsen psychosis, and quetiapine only causes less prolactin elevation, it does not lower it, while adding more metabolic harm.
  • Q2 — Slightly high lithium with a good response: 35-year-old with bipolar I on lithium 900 mg twice daily for 8 weeks, level 1.3 mEq/L (therapeutic range 0.6 to 1.2) drawn 10 hours post-dose, mild hand tremor only, creatinine 1.4 and TSH 6.8 — reduce the dose and recheck in 5 to 7 days, about 12 hours after the last dose. Traps: stopping lithium outright or switching to valproate is too drastic with no ataxia, vomiting, confusion, seizures or arrhythmia, and abrupt lithium discontinuation carries about a 50% relapse risk within 5 months; adding propranolol just masks the tremor while the high level and the kidney and thyroid effects go uncorrected.
  • Q3 — Depression plus fibromyalgia pain: 45-year-old, BMI 32, widespread pain 7 out of 10 with low mood, anhedonia and poor sleep — choose duloxetine (Cymbalta), the SNRI whose norepinephrine reuptake helps modulate pain in the descending inhibitory pathways. Traps: fluoxetine and bupropion treat depression but bring no significant pain benefit here, and bupropion can worsen insomnia, while mirtazapine helps sleep but drives weight gain through H1 and 5-HT2C antagonism, the wrong fit at BMI 32.
  • Match the fix to the severity: when a patient with a serious mental illness is stable and responding, NP Z does not yank a working drug or slash its dose for a mild, correctable problem — he makes the proportionate change that fixes the root cause, because destabilizing schizophrenia or bipolar I is the bigger risk.
  • Read the planted clue in the stem: a BMI of 31 in question 1 and 32 in question 3 is the question nudging you away from metabolically harmful or weight-gaining options — risperidone and quetiapine in the first, mirtazapine in the third.
  • NP Z's test tip from question 1: if an answer drug has almost never appeared in your slides or clinicals — cabergoline here — there is probably a reason, and you are probably being tricked.
• Mar 17, 2026 Continuing Antidepressants After Remission: Preventing Relapse | PMHNP Boards

  💎 Remission is not the stop date — continuing the antidepressant past full remission is the decision that prevents relapse.

  📇 Key Takeaways — the index card

  • Three or more prior major depressive episodes makes a patient a poor candidate to stop: NP Z cites an 84% higher relapse rate with five or more episodes compared with only two, and more than half of patients with a first episode go on to a second.
  • Residual symptoms mean the fire was never put out: NP Z cites about a 5 to 7% rise in relapse risk for each point increase in residual symptoms, and flags early childhood or adolescent onset, child maltreatment, and a short time in remission as added relapse risk.
  • Start the clock at full remission, not at feeling better: full remission is a complete absence of significant depressive symptoms and no longer meeting MDD criteria, while partial remission still leaves symptoms present that predict relapse.
  • Stopping carries a quantified cost: NP Z cites the pooled discontinuation trials in which relapse was 41% on placebo versus 18% on continued antidepressants — a 70% reduction in the odds of relapse, an NNT of about 4 to 5 — continuing treatment for every four to five patients prevents one relapse.
  • The continuation months are when the brain work happens: SSRIs drive neuroplastic change NP Z describes as increased hippocampal neurogenesis and enhanced BDNF, laying down new pathways — stop too soon and, in his snow analogy, the snow melts and the old entrenched trails reassert themselves.
  • Apply the duration rule by history: a first episode gets at least six months of treatment after remission (often nine to twelve months total), recurrent or high-risk depression gets at least two years after remission, and three or more episodes can mean indefinite maintenance.
• Mar 10, 2026 Drug Affinity (Ki) Explained: The Key to Prescribing | PMHNP Boards

  💎 Ki reads backwards: a low Ki of 1 to 4 means Velcro-tight binding, and a Ki around 10,000 means the drug essentially does not touch that receptor at all.

  📇 Key Takeaways — the index card

  • Highest affinity is hit first at the lowest dose: mirtazapine's strongest affinity is for H1, so sedation is its first and dominant effect at 7.5 mg, well before its weaker-affinity actions show up.
  • Mirtazapine's histamine affinity is about 20 times stronger than its alpha-2 affinity in this episode — that ratio is why raising the dose is what recruits alpha-2 blockade, norepinephrine and serotonin release, energy and alertness, and why more mirtazapine can mean less sedation.
  • Affinity predicts which effects need a dose increase: mirtazapine's 5-HT3 blockade (less nausea), 5-HT2A blockade (calmer, fewer motor side effects) and 5-HT2C blockade (weight gain) are lower-affinity actions than its H1 effect, so they arrive later and weaker.
  • Dose can substitute for affinity in the SNRI comparison NP Z gives: Pristiq shows its norepinephrine effect at its 50 mg starting dose, while Effexor needs about 150 mg before the norepinephrine effect is appreciated.
  • Seroquel's weak, hit-and-run D2 binding explains its dose ladder: low doses are mostly histamine and sleep, and the dose has to climb to sustain enough D2 blockade for an antipsychotic or antimanic effect — unlike Haldol, whose strong D2 affinity blocks tightly at low doses and brings EPS with it.
• Mar 3, 2026 Modafinil vs Armodafinil: The Subtle Difference That Matters | PMHNP Boards

  💎 Armodafinil is modafinil's R-enantiomer only — and its higher plasma levels 7 to 11 hours post-dose are what still cover Betty at 3 to 6 a.m.

  📇 Key Takeaways — the index card

  • Modafinil is R plus S enantiomers; armodafinil is the R enantiomer only, the longer-acting half isolated
  • The S enantiomer clears in about 4 hours, giving modafinil a biphasic dip; armodafinil eliminates monophasically
  • Episode-cited pharmacokinetic studies show roughly 44% higher plasma concentrations 7 to 11 hours post-dose with armodafinil
  • Both agents mildly block the dopamine transporter without vesicular dopamine release — wakefulness rather than stimulation, more selective for sleep-wake circuitry than reward centres
  • Raising lithium from a therapeutic 0.8 risks cognitive dulling and tremor, and bedtime quetiapine risks carryover grogginess — both miss Betty's 3 to 6 a.m. sleepiness
  • The call for Betty: armodafinil 150 mg one hour before each night shift, with the lithium foundation kept and mood monitored

  📋 Flash-Card Summary — the article version

• Feb 24, 2026 Antipsychotic Weight Gain: Histamine, Muscarinic & 5HT2c Mechanisms | PMHNP Boards

  💎 Johnny, 30, a welder stable on olanzapine for six months, gained 10 kg (BMI 24 to 28) because olanzapine is a triple threat: H1, 5-HT2C and M3 blockade all pushing weight up at once.

  📇 Key Takeaways — the index card

  • H1 blockade is the hunger-and-sluggishness pathway: antagonizing histamine in the hypothalamus disrupts satiety signaling and slows movement — the Benadryl effect — so patients eat more and move less.
  • 5-HT2C blockade removes a satiety pathway and specifically drives carbohydrate and sweet cravings, not spinach: blocking it also lets dopamine fire more easily in reward pathways, so sugar and carbs feel more rewarding.
  • M3 blockade is the metabolic pathway — M for metabolic: blocking M3 on pancreatic beta cells reduces insulin release, glucose stays in blood longer, insulin resistance signals starvation and promotes fat storage, so triglycerides, glucose and A1C can worsen before the scale moves much.
  • The board-style call: Seroquel is the wrong switch for Johnny, because quetiapine also hits H1 hard, 5-HT2C moderately to strongly, and M3 moderately — NP Z calls it switching from a Big Mac to a Whopper; Abilify, Latuda and Geodon are the lighter options named.
  • Before switching a stable patient, ask how severe the psychosis was, how many hospitalizations, whether he has already failed Abilify, Latuda or Geodon, and monitor A1C and lipids at baseline and regularly — a lighter agent that lets psychosis return is not a win.
• Feb 17, 2026 6 Shocking Mental Health Pearls for Clinical Practice | PMHNP Boards

  💎 Four percent of untreated postpartum psychosis cases end in infanticide, and up to half of the women who develop it have no prior psychiatric history — so NP Z treats it as a dire emergency, not a watch-and-wait.

  📇 Key Takeaways — the index card

  • Postpartum psychosis hides in plain sight: suicidal ideation appears in 19 percent of cases here, and sudden elation with decreased need for sleep can be misread as new-mom energy — and mothers often hide intrusive harm thoughts for fear of losing custody, so normalize the question: some new mothers have scary thoughts about their babies; have you?
  • Vitamin D deficiency is the low-hanging fruit: up to 76 percent of psychiatric inpatients (and up to 83 percent of outpatients in the evidence cited) fall below 30, and vitamin D is a rate-limiting precursor for serotonin synthesis and supports BDNF — check it in stubborn, recurring depression.
  • Bipolar disorder goes undiagnosed for a pooled mean of 9.1 years — median delay 5 years for bipolar I and 11 years for bipolar II — largely because patients are depressed about 75 percent of the symptomatic time and a PHQ-9 contains no manic or hypomanic criteria.
  • Borderline personality disorder carries roughly a 6 percent completed-suicide rate (5 to 10 percent across the evidence), with 52 to 84 percent attempting — and in the study cited it was the most robust predictor of a suicide attempt, independent of depression, substance use, PTSD or childhood trauma.
  • Nearly 25 percent of people first diagnosed with major depression are re-diagnosed as bipolar within five years, which is the risk behind antidepressant monotherapy precipitating cycling, mixed features or mania; and NP Z cites a figure of around 80 percent meeting criteria for a psychiatric disorder at some point in life in the evidence discussed — a reminder that lifetime mental illness is common, not exceptional.
• Feb 13, 2026 Second-Generation Antipsychotics: 3 Board-Style Questions | PMHNP Boards

  💎 D2 intrinsic activity predicts akathisia: brexpiprazole at 45% causes less restlessness than aripiprazole at 60%, even though both are dopamine partial agonists.

  📇 Key Takeaways — the index card

  • Q1 - Metabolic switch off olanzapine (Zyprexa): Answer is switch to aripiprazole (Abilify). The 45-year-old with schizophrenia, BMI 32, prediabetes and hypertension gained 40 pounds and wants out - continuing olanzapine plus metformin is the trap, because he asked to stop it. NP Z ties Abilify's advantage to weak 5-HT2C antagonism, making it one of the weight-neutral SGAs alongside ziprasidone, while quetiapine (Seroquel) is intermediate metabolic risk with significant weight gain and risperidone also causes weight gain, BMI increase and prolactin elevation.
  • Q2 - Cardiac safety and QT: Answer is lurasidone (Latuda). Per the APA guideline NP Z cites, lurasidone and aripiprazole carry the lowest QT prolongation risk. The trap is ziprasidone (Geodon) - metabolically friendly in Q1 but uniquely problematic here, with an FDA QT warning in its labeling, so the label contraindicates it with known QT prolongation, recent acute MI or uncompensated heart failure and with other QT-prolonging drugs, and a family history of sudden cardiac death or an abnormal EKG is a strong reason to avoid it and choose a lower-QT option. Prolonged QT is ventricular repolarization delayed, raising torsades de pointes, ventricular fibrillation and sudden death risk; iloperidone (Fanapt) is the other big offender he names.
  • Q3 - Akathisia as the deal-breaker: Answer is brexpiprazole (Rexulti). The software engineer switching off olanzapine for metabolic syndrome cannot sit still in long meetings and had the same restlessness on haloperidol (Haldol) years ago - that is akathisia, and it overrides the metabolic shortlist. Brexpiprazole wins on pharmacology, not brand: lower D2 intrinsic activity, 45% versus aripiprazole's 60%, so it partially agonizes the motor circuits less and produces less akathisia.
  • Q3 traps - the other partial agonists and lurasidone fail on akathisia rates: Aripiprazole is one of the biggest akathisia offenders NP Z sees in practice, especially with fast dose increases; cariprazine (Vraylar) shows very high akathisia versus placebo, similar to or worse than aripiprazole despite favorable metabolic properties; lurasidone caused akathisia in 13 to 22% in the clinical trials he cites, despite also being metabolically favorable and QT-safe.
  • Cross-cutting food rule NP Z adds as a bonus pearl: Both ziprasidone (Geodon) and lurasidone (Latuda) must be taken with food to be properly absorbed — lurasidone specifically with at least 350 calories, and food can roughly double ziprasidone absorption. They remain metabolically friendly choices, but a patient who takes them on an empty stomach will not absorb them properly.
• Feb 10, 2026 ADHD with Bipolar Disorder: Stimulant Prescribing Guide | PMHNP Boards

  💎 Elliot, 41, with bipolar II stable on lamotrigine 200 mg still cannot finish tasks — and a prior methylphenidate trial that brought irritability and racing thoughts rules Adderall out, because NP Z puts Adderall at roughly double methylphenidate's potency.

  📇 Key Takeaways — the index card

  • Sequence is the safety rule: stabilize mood first, then see which ADHD symptoms remain — treating ADHD while mood is still raging can worsen hypomania or mania, and sometimes no ADHD symptoms are left once mood is treated.
  • Ten to 20 percent of patients with bipolar disorder also have ADHD, and they are hard to separate: ADHD is a trait present before age 12, day in and day out, while bipolar distractibility arrives in 4-, 7- or 12-day episodes; repeated bipolar episodes can also erode executive function until it mimics ADHD.
  • If a stimulant is used at all, the pick here is extended-release methylphenidate, low and slow, with mood stabilization already robust on board and close monitoring — smoother peaks mean less irritability, insomnia and mood disturbance than immediate-release or amphetamine.
  • The verdict for Elliot is clonidine: an alpha-2 agonist that improves prefrontal attention, working memory and impulse control, dampens sympathetic hyperarousal and protects sleep — starting 0.1 mg at night and titrating slowly, with guanfacine in the same class; modafinil and armodafinil are other lower-risk options discussed, acting on wakefulness rather than reward pathways.
  • Do not assume non-stimulant means safe: atomoxetine (Strattera) has case reports of inducing mania and a smaller ADHD effect size, which NP Z calls the worst of both worlds — and watch for the spectrum, not Hollywood mania: irritability, edginess, racing thoughts, faster speech, less need for sleep.
• Feb 3, 2026 Serotonin Syndrome: High-Yield Pearls (Zoloft + Tramadol Case) | PMHNP Boards

  💎 Dale, 49, hit 102.6 degrees with spontaneous lower-extremity clonus within 24 hours of tramadol 50 mg twice daily being added on top of a sertraline increase to 100 mg — that hours-long timeline is serotonin syndrome, not NMS.

  📇 Key Takeaways — the index card

  • It is a clinical diagnosis, not a lab: there is no serum serotonin test. Use the Hunter criteria — a serotonergic agent plus spontaneous clonus, inducible clonus with agitation or diaphoresis, ocular clonus with agitation or diaphoresis, tremor with hyperreflexia, or hypertonia with temperature above 38 degrees Celsius and ocular or inducible clonus.
  • Speed separates the mimics: serotonin syndrome develops within hours (most cases 6 to 24 hours after a start, increase or second agent), while NMS takes days to weeks and gives lead-pipe rigidity instead of clonus and hyperreflexia; anticholinergic toxicity gives dry skin, urinary retention and quiet bowels, where Dale is profusely diaphoretic.
  • Tramadol is a hidden serotonergic offender: it inhibits serotonin reuptake and promotes serotonin release, so pairing it with sertraline is two mechanisms at once — the dangerous version of that synergy is an MAOI plus an SSRI, which needs a two-week washout, five weeks for Prozac.
  • First move for every severity: stop all serotonergic agents, then benzodiazepines for agitation and the hyperadrenergic vital signs — Dale got Ativan 2 mg IV, aggressive IV fluids and external cooling, and his temperature normalized within six hours.
  • Moderate cases add cyproheptadine, a 5-HT2A antagonist, at 12 to 32 mg over 24 hours (Dale received 12 mg by NG tube); severe cases go to the ICU for aggressive cooling, intubation, sedation and neuromuscular paralysis — caught early, most cases resolve within 24 hours, and it can happen at ordinary therapeutic doses, not only in overdose.
• Jan 27, 2026 Partial Antidepressant Response: Increase, Switch or Augment? | PMHNP Boards

  💎 Partial response is a 25–50% reduction in rating scores by week 4–6 — STAR*D's definition — and week 4 is the decision point, not week 2.

  📇 Key Takeaways — the index card

  • Partial response per STAR*D (about 4,000 patients, the largest US antidepressant trial): a 25–50% drop judged at 4–6 weeks on a metric like the PHQ-9 — a patient who says 'a little better' can still have an unchanged or worse score.
  • If the patient is singing the medication's praises — less anxious, back to pickleball for the first time in 8 months, no major side effects — increase the dose: accentuate what is already working instead of augmenting.
  • Augment when the residual complaint points to a different transmitter: Mary on Lexapro is less ruminative but flat, with early-morning low energy and brain fog — that points to dopamine, because serotonin via the 5-HT2C receptor puts the brake on prefrontal dopamine.
  • The reverse case: doing well on bupropion but unable to sleep with no appetite — do not raise the bupropion; augment toward serotonin, for example with mirtazapine, which also antagonizes 5-HT2C.
  • Switch when week 6 arrives without a 50% improvement, side effects are in the way, and the gains are lackluster — and first check adherence (five days out of seven is not adherence), substance use, new stressors, and creeping bipolarity.
  • Do not settle for a 50% response: aim for full remission, because leftover symptoms invite relapse — and many so-called treatment-resistant cases are simply underdosed, like sitting at 5 mg of Lexapro or 10 mg of Prozac.
• Jan 25, 2026 MDD vs Adjustment Disorder: The Diagnostic Detail That Matters | PMHNP Boards

  💎 A clear stressor does not protect against major depressive disorder — if full MDD criteria are met, MDD takes precedence over adjustment disorder, stressor or not

  📇 Key Takeaways — the index card

  • The trap case: Greta, 35, presents 8 weeks after losing a Dunkin' Donuts job she held for 10 years — no prior psychiatric history, functioning well before. The story screams adjustment disorder, and that story is exactly what derails the diagnosis.
  • Count before you narrate: she has depressed mood, anhedonia, 10-pound weight loss with decreased appetite, insomnia taking 2–3 hours to fall asleep, fatigue, worthlessness, poor concentration, and psychomotor retardation — well past the 5 of 9 symptoms for 2 or more weeks MDD requires. NP Z's decision rule: when stuck between adjustment disorder and MDD, start counting symptoms.
  • Test mood reactivity to separate them: adjustment disorder usually leaves pockets of joy — the patient can still enjoy pizza, a movie, or dinner out, and would be excited to win the lottery. Greta is numb and non-reactive — 'nothing makes me feel better, even when my kids try to cheer me up' — and depression's blanket means a lottery win only brings thoughts of the taxes.
  • The DSM-5 chases symptom clusters, not etiology: the same job loss leaves one person relieved and another syndromally depressed, so the precipitating story cannot set the diagnosis. Once sleep, appetite, and reactivity to pleasurable stimuli are gone, the distress has outgrown the single stressor in front of you.
  • Rule out persistent depressive disorder on time alone: PDD needs depressed mood more days than not for at least 2 years, with no symptom-free stretch of more than 2 months. Greta has 8 weeks of misery, so despite overlapping low energy and sleep/appetite changes, PDD fails — and unspecified depressive disorder fails because full MDD criteria are actually met.
  • Call it single episode, even at 35: this is her first known episode with no prior history, which NP Z flags as unusual at her age — most 35-year-olds presenting depressed have had earlier symptoms, so ask family history to make sense of a late first presentation.
• Jan 20, 2026 Cannabis & Mental Health: 4 High-Yield Pearls | PMHNP Boards

  💎 High-potency THC at 10% or more saturates CB1 receptors and down-regulates the endocannabinoid system, the master regulator that keeps glutamate, GABA, and dopamine from getting too loud or too quiet

  📇 Key Takeaways — the index card

  • Pearl 1 - The endocannabinoid system is a balance system, not a feel-good system: through retrograde inhibition a neuron signals back to cool down excitatory glutamate, and that thermostat also touches mood, stress response, pain, immune activity, metabolism, and neuroprotection - high-potency THC throws it off, so serotonin, norepinephrine, acetylcholine, and dopamine signaling get bogged down with it
  • Pearl 2 - Always ask the potency, not just whether they use: at 10% THC or more NP Z cites a 75% increase in psychotic-like experiences, a 65% increase in generalized anxiety presentations, and a fourfold increase in developing cannabis use disorder even after adjusting for frequency of use - and today's average potency has doubled from 20 years ago
  • Pearl 3 - Cannabis use disorder is common, under-recognized, and under-treated: it develops in about 29% of medicinal cannabis users, prevalence is highest at ages 18 to 29 at about 7%, and risk climbs with frequency - about 3.5% with yearly use, 8% monthly, 16% weekly, and 36% with daily use
  • Pearl 4 - Cannabis is diagnostic mud: chronic use is associated with harder endogenous dopamine synthesis and dysregulated dopamine transporters, so it can look like depression, ADHD (inattention, poor executive function, impulse control, processing speed, and working memory), panic, or psychosis - and cannabis use disorder is associated with a 2.5- to 3-fold increase in developing bipolar disorder, with a hazard ratio of 4 for the psychotic form
  • Decision rule before you add a drug: push for at least 25 days of abstinence and re-check - symptoms that persist are more likely a primary disorder, symptoms that clear point to a substance-induced picture, and skipping that step is how a patient ends up on polypharmacy for what was really high-potency THC
• Jan 13, 2026 Remeron (Mirtazapine): 8 Things Every Prescriber Should Know | PMHNP Boards

  💎 Mirtazapine is backwards on sedation: 7.5–15 mg is the most sedating range — raise it to 30–45 mg and norepinephrine release makes it less sedating, not more.

  📇 Key Takeaways — the index card

  • Lenny, on Lexapro 15 mg, down 12 lb in six weeks, sleeping 3–4 hours a night, nauseous and refusing anything activating: mirtazapine fits where bupropion (more weight loss, harder sleep) does not.
  • Low doses hit the histamine H1 receptor hard, so sleep and appetite come quickly; raising the dose releases the alpha-2 brake on norepinephrine and serotonin, so a patient who feels like a zombie at 15 mg may energize at 30–45 mg.
  • 5-HT3 blockade makes mirtazapine an anti-nausea agent in the same receptor family as ondansetron — useful for SSRI GI side effects and for anxiety whose signature symptom is nausea.
  • It makes patients hungry by blocking both H1 and 5-HT2C, two receptors that normally suppress appetite — wanted in Lenny, but a deal-breaker if the patient will not accept weight gain.
  • 5-HT2A blockade does double duty: it can reverse SSRI-induced sexual dysfunction and deepen slow-wave sleep by cutting sleep fragmentation and nighttime hyperarousal.
  • Minimal CYP450 drama makes it a cleaner choice for elderly and polypharmacy patients, and its alpha-2 antagonism can boost the SSRI it is paired with — but avoid it in atypical depression with hypersomnia, overeating, and heavy limbs.
• Jan 6, 2026 Vitamin D & Mental Health: What Clinicians Should Know | PMHNP Boards

  💎 Up to 83% of psychiatric outpatients may have vitamin D insufficiency — and leaving it uncorrected can blunt an antidepressant the way shaving about 4 mg off a Lexapro dose would.

  📇 Key Takeaways — the index card

  • Vitamin D behaves like a hormone, not a vitamin: you synthesize it from sunlight, and it drives neuroplasticity, synaptogenesis, neuronal protection, and the synthesis and signaling of serotonin.
  • Know the cutoffs in ng/mL: deficiency is under 20, insufficiency is 21–29, levels should be over 30, and the optimal range NP Z cites is about 40–75.
  • Sun alone rarely does it: getting there takes roughly 20 minutes a day with 40% of skin exposed, and sunscreen use, indoor or institutional life, aging, and darker skin pigmentation all cut it further.
  • The dose math: every 100 IU ingested daily raises serum levels by roughly 1 ng/mL; a typical course is 5,000 IU of vitamin D3 (preferred over D2) daily for 8–12 weeks, then 1,500–2,000 IU daily for maintenance.
  • Vitamin D also modulates the MAO enzyme, the enzyme that breaks down serotonin, norepinephrine, and dopamine — one more way low levels undercut the antidepressants you prescribe.
  • The antidepressant signal is strongest in major depressive disorder, and strongest in patients who are actually deficient — so check a level before declaring an antidepressant a failure.
• Dec 30, 2025 Lexapro (Escitalopram) vs Prozac (Fluoxetine): Full Comparison | PMHNP Boards

  💎 Prozac's 5-HT2C blockade frees dopamine and norepinephrine — why it wins low-drive, hypersomnic depression. Lexapro wins on clean: the tightest SERT grip in the class, the fewest interactions.

  📇 Key Takeaways — the index card

  • Prozac blocks 5-HT2C — releasing the brake on dopamine and norepinephrine in the prefrontal cortex. That's drive, energy, and a little appetite suppression. Lexapro doesn't touch that receptor.
  • Benny sleeps 10 hours, snacks constantly, and leans on coffee all morning — a low-drive patient hunting for arousal is telling you he needs activation, not calm.
  • Half-lives: Prozac 4–6 days, active metabolite ~2 weeks — it self-tapers. Lexapro 27–32 hours — washed out in days.
  • Lexapro is the 'clean' SSRI: tightest SERT binding plus an allosteric double-lock, minimal CYP interference — the polypharmacy pick.
  • Prozac's tax is CYP2D6: it can raise Abilify and risperidone levels and blunt tramadol and tamoxifen. The call for Benny: Prozac 10 mg → 20 mg.

  📋 Key Takeaways — the full index card

• Dec 23, 2025 ADHD & Mortality Risk: The 7-Year Life Expectancy Gap | PMHNP Boards

  💎 ADHD shortens life expectancy by roughly seven years in men and closer to nine years in women, with a two- to four-fold risk of premature death — and unintentional injury is the number one contributor.

  📇 Key Takeaways — the index card

  • The mechanism is the trifecta in real life: inattention, impulsivity, and hyperactivity behind motor vehicle and heavy-equipment accidents, worst in the vulnerable teenage and young-adult years.
  • The sex gap NP Z flags: females are about three times more likely to die prematurely and males about 1.9 times — and ADHD is missed in girls who sit quietly inattentive at the back of class instead of disrupting it.
  • Suicide occurs at about three times the rate in ADHD, tied to impulsivity and executive dysfunction.
  • The silver lining, from a 2024 Swedish study: ADHD medication was associated with a 19% reduction in all-cause mortality over two years.
  • His answer to 'do I need my medication on weekends?': are you driving, drinking, or talking to your spouse this weekend? Impulsivity and executive function run seven days a week.
  • Take a patient's self-suspicion of ADHD seriously, and screen the depressed or anxious patient who never mentions it — catching and treating this diagnosis can save lives.
• Dec 22, 2025 SSRI Activation & Bipolar Switching: High-Yield Pearls | PMHNP Boards

  💎 Venlafaxine carries the highest switch rate of the common antidepressants — about 15% even with mood stabilization, versus about 5% for bupropion.

  📇 Key Takeaways — the index card

  • Antidepressant monotherapy nearly triples the risk of manic activation in true bipolar disorder, and the subtype matters: about a 31% switch risk in bipolar I versus 18% in bipolar II.
  • Tricyclics carry about a 43% switch rate even with mood stabilization, and venlafaxine used as monotherapy in bipolar I or II is highly discouraged — steer away from both.
  • A subtle switch does not look like hospital mania: watch for new impulsivity, agitation, irritability, dysphoria, self-harm, and increased substance use.
  • The ISBD position NP Z cites: antidepressants only as adjuncts in stable, episodic bipolar depression — no rapid cycling, no mixed features, no history of antidepressant-induced destabilization — and even then the evidence is weak.
  • Hunt the non-DSM risk flags before prescribing: family history of bipolar disorder, depression onset before age 25, prior antidepressant-induced activation, and multiple recurring, treatment-resistant depressive episodes.
  • For bipolar depression itself, the network meta-analysis numbers he quotes: olanzapine-fluoxetine 56.7% response, quetiapine 49%, lurasidone 48.5%, cariprazine 44.5% — with lithium held up as the gold-standard ballast against switching.
• Dec 16, 2025 Reading Research Like a Pro: P-Values & Stats for PMHNPs | PMHNP Boards

  💎 A p-value of 0.01 means that, if there were really no effect, data this extreme would show up only 1% of the time — it is not the probability the result happened by luck, and it says nothing about whether the effect is big enough to matter to your patient.

  📇 Key Takeaways — the index card

  • Read every study in his jelly-bean order: a clear research question, a primary outcome (tummy aches reported to the nurse's office), a secondary outcome (pain rated 0–10), and ask how each was defined — vague self-report, or a real metric like the PHQ-9 for depression?
  • Type 1 error is a false positive: declaring jelly beans, or a drug, effective when they are not. Type 2 error is a false negative, and it can abandon a treatment that actually helps.
  • The hierarchy in one line: a case report (Timmy and his 40 jelly beans) sits below a case series (12 kids, still no control group or denominator), a cross-sectional snapshot, case-control and cohort studies, the RCT — which distributes confounders evenly — and the meta-analysis pooling many studies.
  • Descriptive statistics first: mean pain was 4 for jelly-bean eaters versus 1 for non-eaters, but a few 10-out-of-10 scores can skew a mean — check the median (the middle score was 3), the range, and the standard deviation for how spread out the data are.
  • Effect size answers 'is it big enough to care?': an effect size of 2 in the jelly-bean study is massive, 0.02 is subtle, and effects grow more meaningful as they approach 1 — a statistically real half-point drop in depression may not change a patient's life.
  • Odds ratio and confidence interval travel together: an odds ratio of 6 with a 95% confidence interval of 3–12 means six times the odds, with the true value likely somewhere between 3 and 12 — then check sample power, dropouts, blinding, and whether the patients resemble yours.
• Dec 9, 2025 The Only Transdermal Antidepressant: Selegiline Patch Explained | PMHNP Boards

  💎 Selegiline (Emsam) is the only FDA-approved transdermal antidepressant — and at the 6 mg per 24-hour patch, dietary tyramine restrictions are generally not required.

  📇 Key Takeaways — the index card

  • It is an MAOI, not an SSRI, SNRI, or TCA: it inhibits the monoamine oxidase enzyme that breaks down serotonin, norepinephrine, and dopamine, leaving all three in the synapse longer.
  • The trade-off behind the dietary rules: MAO also clears tyramine, so aged cheeses, sauerkraut, kimchi, and soy products can trigger a hypertensive crisis — severe headache, chest pain, blood pressure through the roof.
  • At 6 mg the patch inhibits both MAO-A and MAO-B in the brain — that combined blockade is the antidepressant action — while sparing gut MAO-A enough that dietary restrictions are generally not required: a fit for sluggish, atypical depression with hypersomnia, low motivation, and leaden paralysis, with lower weight-gain and sexual-dysfunction risk.
  • At the 9 mg and 12 mg patches, tyramine caution returns: the freedom from dietary restrictions applies only at the starting dose.
  • Oral selegiline is a different risk conversation from the patch — with the oral form, dietary restrictions absolutely apply.
  • NP Z's verdict: not a first- or second-line agent, and one he rarely prescribes — a back-pocket option for treatment-resistant depression after multiple SSRI and SNRI trials, with careful patient education.
• Dec 2, 2025 Acute Dystonia Management: Clinical Insights (Risperidone Case) | PMHNP Boards

  💎 Mario, a week into risperidone at 1.5 mg twice daily for first-episode psychosis, presents with a twisting, stuck, painful neck: that is acute dystonia, and IM benztropine 2 mg in clinic resolves it in about 15–30 minutes.

  📇 Key Takeaways — the index card

  • About 2–10% of patients on these agents develop an acute dystonia, and the EPS timeline is the board pattern: dystonia arrives hours to days after starting or raising a dose, akathisia days to weeks, parkinsonism weeks to months, tardive dyskinesia months to years.
  • The mechanism is a seesaw in the striatum: D2 blockade removes dopamine's inhibitory brake, acetylcholine runs unchecked, and muscles over-fire — anticholinergics restore the balance by blocking muscarinic acetylcholine receptors.
  • Risperidone and paliperidone still do this among second-generation agents because of high D2 affinity with roughly 70–80% D2 occupancy even at low-to-moderate doses, overwhelming the protective 5-HT2A antagonism other SGAs rely on.
  • Some dystonias are emergencies, not office problems: tongue, pharynx, or larynx involvement, stridor, choking, or laryngospasm threatens the airway and needs the ER — and an oculogyric crisis, eyes rolled upward for hours, can be mistaken for a seizure.
  • Risk stacks in young males, with high-potency or high-dose D2 blockers and rapid titration — with a prior dystonia on board, prophylactic benztropine, or diphenhydramine 50 mg IM/IV, enters the discussion.
  • Mario's outcome: benztropine acutely, oral benztropine for a few days to bridge, then a cross-taper off risperidone to quetiapine — low D2 affinity, fast-off kinetics, and built-in anticholinergic buffering.
• Nov 25, 2025 The Bipolar Blind Spot: 9-Year Diagnosis Delay | PMHNP Boards

  💎 Bipolar disorder takes a mean of nine years to diagnose correctly after the first depressive episode — largely because patients spend about 70% of their symptomatic time depressed.

  📇 Key Takeaways — the index card

  • Anchoring bias does the damage: the first presentation is a sullen, slow, downcast patient saying they are depressed, and that first impression sticks unless you deliberately challenge it.
  • Hypomania often feels good and gets reported as 'my normal self' — patients do not volunteer the energized, confident, working-into-the-wee-hours stretches, and they rarely come to clinic for them.
  • The overlap trap: impulsivity and fast talking in session can read as ADHD, borderline personality disorder, or caffeine effects, masking bipolar II underneath.
  • Antidepressants can muddy the picture further: activation gets read as 'the antidepressant is working' when the patient is also becoming irritable and agitated.
  • A depressed patient is a poor historian of their own highs — psychomotor slowing makes excavating an episode from years ago genuinely hard, so collateral information and metrics matter.
  • NP Z's challenge: aim to make the diagnosis at the first appointment rather than accept the nine-year average — excavate past periods of energy, reduced sleep, and impulsivity every time depression presents.
• Nov 21, 2025 Board Bombs: 3 High-Yield PMHNP Exam Questions | PMHNP Boards

  💎 Latuda (lurasidone) is the FDA-approved answer for bipolar I depression — Abilify and Zyprexa are mania-side drugs, and approval is by illness state, not by drug class.

  📇 Key Takeaways — the index card

  • Question 1 — Bipolar I depression: the answer is B, Latuda (lurasidone), FDA approved for bipolar I depression. The trap: Abilify is familiar as an adjunct in depression and Abilify and Zyprexa (olanzapine) help control mania, alongside lithium and Depakote — none of that makes them the bipolar I depression approval. Off-label use does not mean ineffective; it means the company never ran the trial to prove it in that specific state of illness.
  • Do not carry the bipolar I answer into bipolar II depression: for bipolar II depression NP Z names lumateperone and Seroquel (quetiapine) as the FDA approvals. Spend an afternoon learning the FDA approvals cold — boards test which drug is approved for which phase of illness, and in practice you have to defend that choice.
  • Question 2 — A 17-year-old with sudden school refusal, intense fear of being called on, and crippling performance anxiety: the answer is B, social anxiety disorder. Ask what the core fear is — here it is being judged, scrutinized, and embarrassed, not having a panic attack. Panic disorder is the trap, but the stem gives no shortness of breath, diaphoresis, trembling, or nausea, and he is avoiding a social stimulus, not a place where a panic attack might strike.
  • The other Question 2 traps fall on pattern, not symptoms: avoidant personality disorder is a pervasive, lifelong pattern, not a sudden, situation-specific school refusal, and generalized anxiety disorder is broad worry about everything — job, family, safety. Generalized means generally everything; this fear is specific to being called on, so GAD is out on the wording alone.
  • Question 3 — Excessive daytime sleepiness with two sleep-onset REM periods (SOREMPs) on an MSLT: the answer is B, narcolepsy type 2. The numbers: narcolepsy patients fall asleep in under 8 minutes on the MSLT and enter REM within 15 minutes of sleep onset, versus 70-plus minutes normally; two or more SOREMPs plus that short latency makes the diagnosis. It is type 2 because there is no cataplexy — add sudden loss of muscle tone and collapsing, and it becomes type 1.
  • Question 3 traps: obstructive sleep apnea means gasping, snoring, unrefreshing sleep, and morning headaches, and its workup is not an MSLT — no OSA criterion asks for SOREMPs. Hypersomnolence disorder is long, unrefreshing sleep with heavy sleep inertia and no required REM intrusion or MSLT metric, and delayed sleep-wake phase disorder is a circadian shift problem with nothing about REM latency. NP Z's cross-cutting rule: know the FDA approval by illness state, name the core fear in every anxiety stem, and learn each sleep diagnosis by the specific marker the DSM requires.
• Nov 18, 2025 Caffeine-Induced Anxiety: A Diagnostic Case Study | PMHNP Boards

  💎 Jean Luc quit coffee but switched to two matchas a day at 70 mg of caffeine each — and as a slow metabolizer he still carried about 24–25 mg of caffeine in his system at 8 a.m. the next day.

  📇 Key Takeaways — the index card

  • The case against GAD and panic disorder: six months of palpitations, tremors, sweating, and erratic sleep with no worry content — he was not a worrier, symptoms lasted all day instead of peaking for two or three minutes, and cardiac causes and hyperthyroidism had already been ruled out.
  • Always ask why a patient stopped a substance: Jean Luc quit Death Wish coffee because it left him jittery and unpleasant — that caffeine sensitivity was the diagnostic clue, not proof caffeine was off the table.
  • Caffeine math worth memorizing: about 95–100 mg in an 8-ounce coffee, 70 mg in a matcha, up to 500 mg in an energy drink, and about 12 mg per ounce of dark chocolate.
  • Half-life is about five hours in regular metabolizers but ten hours or more in slow metabolizers — roughly 10% of people — with up to a 40-fold variance in caffeine metabolism overall, so a 1 p.m. matcha can act like caffeine taken at 1 a.m.
  • The mechanism: caffeine antagonizes adenosine and dissolves sleep pressure until it wears off and crashes back, fragmenting slow-wave and REM sleep, raising next-day cortisol, and undermining memory consolidation and emotional regulation.
  • The verdict and first move: take a full caffeine inventory, including hidden sources like Excedrin and Midol, and ask what symptoms did during any 30-day caffeine-free window — before labelling panic disorder or starting an SSRI or benzodiazepine; remember caffeine also competes at CYP1A2 with olanzapine and can raise its levels.
• Nov 11, 2025 Which DSM-5-TR Diagnosis Requires a Rating Scale? | PMHNP Boards

  💎 PMDD is the only DSM-5-TR diagnosis that requires a rating scale to confirm it: prospective daily ratings over at least two symptomatic cycles — until then the diagnosis is only provisional.

  📇 Key Takeaways — the index card

  • The tool is the DRSP, the Daily Record of Severity of Problems: 31 days of daily ratings from 1 (not at all) to 6 (extreme) across sadness, anxiety, mood swings, irritability, interest, concentration, lethargy, appetite, sleep, breast tenderness, and feeling overwhelmed, plus functional impairment.
  • Retrospective recall will not do: ask a patient to reconstruct last month's symptoms day by day and the detail goes hazy — which is exactly why the DSM requires prospective charting as symptoms happen.
  • Read the pattern, not just the scores: a true case spikes in the 7–14 days before menses and drops or vanishes when the cycle starts; symptoms all month that worsen premenstrually point to premenstrual exacerbation of another mood disorder instead.
  • Severe scores everywhere, all month long, lower suspicion for pure PMDD and push the workup toward depression, bipolar disorder, or personality pathology.
  • Prevalence makes this routine rather than rare: DSM-5-TR puts PMDD's 12-month prevalence at 1.8–5.8% of menstruating women — about 1 in 17 to 1 in 55 in a given year.
  • The distractors are all useful but none is required: ADOS for autism, ASRS and Vanderbilt for ADHD, and MoCA or MMSE for neurocognitive disorders help assessment — only PMDD makes the rating scale a condition of the diagnosis.
• Nov 4, 2025 MDD with Mixed Features: The Case of Gus | PMHNP Boards

  💎 Gus, 23, depressed on bupropion 300 mg XL, gets one to two days of surging energy, faster speech, and little need for sleep while still depressed: that is MDD with mixed features — three or more manic symptoms co-occurring with depression, short of the four-day threshold for hypomania.

  📇 Key Takeaways — the index card

  • Timing separates mixed features from bipolar disorder: the manic symptoms occur together with the depression; manic activity happening separately from depression pushes toward a bipolar-spectrum diagnosis — and flag mixed features, because these patients carry a higher likelihood of later converting to bipolar I or II.
  • Ask Gus's two discriminating questions: on the energized days, what does your sleep look like, and what are you doing while you are not sleeping? A return-to-baseline answer (Netflix, an omelet) differs sharply from a bipolar answer (starting projects, cleaning the entire garage).
  • Psychosis redraws the family tree: psychosis during a hypomanic episode makes that episode manic by definition — bipolar I territory — but psychotic features CAN occur in the depressive episodes of bipolar II; and hallucinations that worsen in tandem with mood point toward MDD with psychotic features.
  • Translate family history: patients say 'Mom was depressed' and 'my uncle had mood problems,' never in specifiers — probe the uncle, because bipolar disorder is highly heritable and bipolar patients spend most of their symptomatic time depressed.
  • Cannabis can muddy the whole picture: ask age of first use, THC potency, and frequency, and whether the voices persisted through a 30-day cannabis-free window.
  • The plan NP Z chose for Gus: add aripiprazole, a dopamine partial agonist he calls a dimmer switch, starting at 2–5 mg and targeting 10–15 mg for mixed features, adding propranolol for the akathisia that appeared on the way up, and optimize bupropion to 450 mg — Gus's depression and psychotic symptoms remitted.
• Oct 28, 2025 Amitriptyline Side Effects: Board Bomb Question | PMHNP Boards

  💎 All three bombs turn on mechanism: M1 blockade from a TCA, a thyroid mimicking depression, and an SSRI dampening the dopamine sex needs.

  📇 Key Takeaways — the index card

  • Q1 - Amitriptyline is a TCA, and dry mouth, constipation, and blurred vision at 2 weeks = muscarinic M1 cholinergic blockade (answer C). Do not take the traps: alpha-1 blockade gives orthostatic hypotension, tachycardia, and dizziness; H1 gives sedation; 5-HT2A is the 'tennis balls' distractor - it explains none of this triad.
  • Q2 - Fatigue, weight gain, constipation, and low mood on sertraline for 4 months with TSH 9.4 (normal 0.4-4.0) and free T4 0.5 is hypothyroidism mimicking depression (answer B): recognize it and coordinate thyroid replacement - levothyroxine where your scope allows. Increasing sertraline, switching to duloxetine, or adding T3 misses the root; T3 augmentation is for treatment-resistant depression with a normal thyroid, not for correcting low T4 in primary hypothyroidism.
  • Q3 - One month on sertraline 50 mg with decreased libido and difficulty achieving climax: switch to bupropion (answer B), the NDRI that raises dopamine and norepinephrine and reverses SSRI sexual inhibition - SSRIs can dampen dopamine. Reassurance fails because sexual effects are dose-dependent and can linger well past 2 weeks; adding an MAOI risks serotonin syndrome on top of sertraline; swapping to imipramine, a TCA, would worsen sexual dysfunction or do nothing.
  • Know who is who in the zoo before you reason: brand, generic, and family - sertraline is Zoloft, an SSRI; fluoxetine is Prozac; amitriptyline and imipramine are TCAs; bupropion is an NDRI. Sertraline and amitriptyline sound alike and act nothing alike, and an unfamiliar drug name in the stem is designed to psych you out.
  • Know what abnormal looks like and hunt the root cause: you do not need every lab memorized, but TSH 9.4 against a normal 0.4-4.0 should stop you cold - and NP Z extends the same warning to magnesium, calcium, and sodium, whose abnormalities can present as psychiatric symptoms if you only follow the depression flowchart.
• Oct 21, 2025 ADHD vs Bipolar in Outpatient Care: Avoiding Anchoring Bias | PMHNP Boards

  💎 Ask Dale 'when': lifelong, always-like-this distractibility is a trait — ADHD; distinct 4-plus-day episodes of confidence, pressured speech and no need for sleep are a state — bipolar.

  📇 Key Takeaways — the index card

  • Don't anchor on the girlfriend's label 'bipolar boyfriend': collect information first, and ask when — do the behaviours come in episodes for four days to a week and then stop, or is this just how he has always been?
  • What he moves TO is the clue: abandoning the kitchen remodel because it got tedious and dinner was due is ADHD loss of interest; abandoning it to buy a thousand Powerball tickets and a grand piano, or to run for mayor of Phoenix since noon today, is bipolar grandiosity.
  • Ask the bipolar question packed with DSM specifics — four or more days unusually confident or irritable, talking fast, surging with energy and feeling no need to sleep at all — vague 'are your moods unpredictable?' would diagnose half of America's spouses.
  • Chronicity vs cyclicity is the power pearl: bipolar is a wave that crashes and recedes back to a different baseline; ADHD is a constant whirlpool of ripples, present before age 12 — and 5 to 10% of adults with ADHD have both, so keep both suspects in the station.
  • Dale's call: ADHD, combined type. Start Adderall XR 10 mg (dopamine for get-up-and-go motivation, norepinephrine for aim and focus), warn it lasts 10 to 12 hours and can cut appetite and sleep, and check blood pressure and cardiovascular history first.
  • Follow-up verdict: 10 mg helped most symptoms but wore off, so NP Z raised Dale to 15 mg XR — his best dose at two weeks, kitchen finished, girlfriend reporting him more focused and less disruptive.
• Oct 14, 2025 Board Bombs: Illness Anxiety, Lamotrigine & MAOI Questions | PMHNP Boards

  💎 Three tells decide these boards: no physical symptoms means illness anxiety, estrogen speeds lamotrigine clearance, and Paxil to an MAOI needs 14 days.

  📇 Key Takeaways — the index card

  • Question 1 answer is C, illness anxiety disorder: the 38-year-old spends hours researching pancreatic and rare cancers, avoids social events over environmental toxins, and stays frustrated after multiple specialists find nothing — but he reports no physical complaints at all. Illness anxiety is preoccupation with having or acquiring a serious illness with minimal or no somatic symptoms; somatic symptom disorder requires actual distressing, disruptive physical symptoms plus excessive thoughts and feelings about them. Trap: the absence of symptoms is the clue — and it is not generalized anxiety disorder, where worry is general, or conversion disorder, where anxiety shows up as physical manifestations.
  • Question 2 answer is B, estrogen-induced metabolism of lamotrigine lowering its effectiveness: a 29-year-old with bipolar II, stable for months on lamotrigine 200 mg daily, relapses into depression weeks after starting a combined oral contraceptive. Estrogen-containing contraceptives induce UGT1A4, the glucuronidation enzyme that clears lamotrigine, so the liver breaks it down faster, blood levels fall, and mood stabilization — particularly for bipolar depression — is lost. Trap: oral contraceptives do not raise lamotrigine into toxicity (and the stem shows returning depression, not toxicity), and 'no known interaction' is the dead-end answer boards rarely intend.
  • Question 3 answer is 14 days: a 44-year-old with treatment-resistant major depressive disorder on paroxetine (Paxil) 40 mg for 12 weeks must wash out for a minimum of 14 days before starting phenelzine, an MAOI, to avoid serotonin syndrome — the potentially fatal hyperthermia, delirium, and clonus NP Z warns against. Trap: fluoxetine (Prozac) is the exception, not the rule here — its much longer half-life requires five weeks or more before an MAOI.
  • Cross-cutting rule: know who's who in the zoo before you answer — phenelzine only makes sense once you recognize it as an old-school MAOI, and NP Z says board stems deliberately use less familiar MAOIs, tricyclics, and first-generation antipsychotics whose names sound alike. If you cannot place the drug class and its half-life, you cannot get the washout, interaction, or safety answer right.
• Oct 7, 2025 Prazosin for PTSD Nightmares: Deep Dive & Case Study | PMHNP Boards

  💎 Marcus has PTSD nightmares 3 to 4 nights a week on sertraline 150 mg — the SSRI cooled his worry but not the nightmares, so add prazosin, the alpha-1 blocker that turns down noradrenergic hyperactivity in REM sleep.

  📇 Key Takeaways — the index card

  • Get the pre-trauma baseline first: Marcus had no depression or worry before he fell into a non-active volcano, so that sound prior functioning is the target treatment is trying to get him back to.
  • One intrusion symptom is enough for that DSM-5-TR box — he already has it with the nightmares; then work the rest: fire and smoke cues, negative beliefs about the world (Criterion D), and whether he is hypervigilant all day or only when he wakes at night.
  • Sertraline's job and its limit: it calms the amygdala and softened Marcus's worry, but SSRIs do not reliably stop trauma nightmares and can even intensify dreaming — and alcohol before bed cuts REM time, undermining the emotional reprocessing sleep is for.
  • Roughly half of people with PTSD also have major depressive disorder, and trauma-related low mood tends to stay flat and persistent rather than cycling back to a joyful baseline like recurrent MDD — ask, because the two can run at the same time.
  • Prazosin dosing: start at 1 mg at bedtime and raise by 1 mg about weekly as tolerated toward 3 mg and beyond — some patients respond at 1 mg, many need 4, 7 or 10 mg, some 15 mg or more; each person has a different 'magic number' where nightmares stop or lose their terror.
  • Safety counsel for that titration: orthostatic hypotension, dizziness and headache are the watch-outs (and rarely priapism) — sit on the edge of the bed with water, rise slowly, hydrate, and track nightmares until the dose is found; keep the sertraline decision separate — push 150 toward 200 mg only if it has clearly helped, otherwise consider switching.
• Sep 23, 2025 Diagnosing Anxiety Disorders: OCD Case Study (Sarah) | PMHNP Boards

  💎 Sarah washes her hands 40 times a day and showers for hours — ask the umbrella question 'how much extra time do you spend avoiding germs?' because obsessions and compulsions taking over 1 hour a day — or causing clinically significant distress or impairment even in less time — meet DSM-5-TR's OCD time-and-impairment criterion.

  📇 Key Takeaways — the index card

  • 'Falling behind in her PhD' does not equal ADHD: depression, adjustment to a stressor, trauma and OCD all steal concentration — keep ADHD at the station, but question every other suspect before planting a flag.
  • The bizarre thought — a rabbit licking a lollipop in a wrestling ring — is OCD, not psychosis, when Sarah has insight, denies seeing or hearing the rabbit, and speaks logically and linearly on mental status exam; a fixed belief like 'I am sure Ebola is in my coffee' would send you down the delusional-disorder path instead.
  • Squeeze the orange before moving to the next one: quantify time spent on the thought, the washing and the avoidance, and ask whether violent intrusive thoughts carry any intent — in OCD patients are usually horrified by those thoughts, not planning them.
  • Pinpoint ground zero for her inattention: if she cannot focus because she is preoccupied with germs and contamination, OCD is the treatment target; lifelong forgetfulness and trouble listening since before age 12 would keep ADHD in your back pocket alongside it.
  • GAD can sit on top of OCD — catastrophic, worst-case worry about everything, described by patients as thinking through a 'fear filter' — and it does not change the first pharmacologic move, because SSRIs are first-line for OCD, GAD and depression alike.
  • The call for Sarah: start an SSRI low and slow (Zoloft 25 mg, up to 50 mg after a couple of weeks to avoid activating severe anxiety), then push toward the higher doses and longer trials OCD needs — response can take past 6 weeks and augmentation is often the rule — plus exposure and response prevention (ERP), the gold-standard therapy.
• Sep 18, 2025 Abilify (Aripiprazole) Decoded: Dopamine System Stabilizer | PMHNP Boards

  💎 Aripiprazole is a dimmer switch, not an on-off switch: a D2 partial agonist that tones down an overactive mesolimbic circuit without the straitjacket of full blockade.

  📇 Key Takeaways — the index card

  • FDA-approved uses to have cold: schizophrenia, bipolar I, adjunctive treatment of major depressive disorder, irritability in autism spectrum disorder, and Tourette's disorder.
  • Dose depends on the job: schizophrenia typically 10 to 30 mg daily, bipolar I 15 to 30 mg daily, but as an MDD adjunct start at 2 to 5 mg and max around 15 mg.
  • Pharmacokinetics that change counselling: Tmax 3 to 5 hours, a 75-hour half-life that lets it partly self-taper, and metabolism through CYP2D6 and CYP3A4 — so inhibitors and inducers on those pathways matter.
  • Receptor tour: partial agonism at 5-HT1A calms the anxious row and frees prefrontal dopamine for mood and concentration; antagonism at 5-HT2A spares patients some of the rigidity and motor problems of hard D2 blockade and supports cognition and mood.
  • Weight is relative, not zero: weak 5-HT2C antagonism means aripiprazole is among the more weight-neutral second-generation antipsychotics — contrasted in the episode with olanzapine clearing out the snack kiosk — but weight gain still happens in some patients.
  • Watch-for list NP Z names: akathisia and restlessness (that in-between 'should I get out of my chair?' purgatory of partial agonism), insomnia, tardive dyskinesia, and impulse-control problems — and because dopamine is not fully blocked, activation into mania is possible.
• Sep 9, 2025 SGA Augmentation for Depression: When SSRIs Aren't Enough | PMHNP Boards

  💎 SSRI monotherapy remits only about 25-30% of major depression — SGA augmentation works not by adding more serotonin, but by blocking or nudging the specific receptor behind the symptom still holding the patient back.

  📇 Key Takeaways — the index card

  • The numbers that justify augmenting: SSRIs alone give a 40-50% response rate and 25-30% remission, leaving roughly 70-75% short of full remission; in the meta-analyses NP Z cites, adding an SGA lifts response toward 50-60% and remission to 35-45%, with aripiprazole showing an odds ratio for response of about 1.9 versus placebo augmentation.
  • 5-HT2A is the rumination receptor in this episode: serotonin binding there stimulates cortical glutamate neurons, producing hyper-excitability, racing thoughts, anxiety, and poor sleep — antagonize it and that glutamate chatter quiets, which is why quetiapine fit Matt, the anxious, ruminating patient on Lexapro who could not sleep or eat.
  • 5-HT1A is serotonin's brake pedal: the autoreceptor tells the neuron to stop releasing serotonin, which can make patients more anxious early on an SSRI, while postsynaptic 5-HT1A activation quiets glutamate neurons and amygdala overdrive — aripiprazole and brexpiprazole work here as partial agonists, a dimmer switch that eases the brake instead of slamming it.
  • 5-HT2C — C for candy: blocking it unleashes dopamine and norepinephrine in the prefrontal cortex, clearing fog and restoring motivation, but that same blockade drives weight gain. Olanzapine blocks it hardest and NP Z has seen 30 pounds gained in a month on it; quetiapine blocks it too, and aripiprazole only weakly, which is the route he would take for Matt if weight gain were a deal-breaker.
  • Dopamine is a dimmer, not a switch: full D2 blockade with risperidone can calm agitation but risks raised prolactin, sexual dysfunction, and apathy if dopamine is blocked too far, while D2 partial agonists such as aripiprazole and brexpiprazole add signal where dopamine runs low — the sluggish, unmotivated picture — and cariprazine's high D3 affinity is his pearl for anhedonia, apathy, and cognitive fog.
  • Monitor past the scale: a patient can gain no weight on quetiapine and still have an A1C and lipid panel that look like a wrecking ball, so check both — and remember olanzapine and quetiapine hit H1 and alpha-1 hardest, buying sleep at the price of daytime sedation and orthostasis the patient's job may not tolerate.
• Aug 26, 2025 Bipolar I Disorder: Diagnosis Through a Mock Patient Case | PMHNP Boards

  💎 Michael, 32, spent $15,000 chasing a boxing match with Mike Tyson — a manic episode makes it bipolar I even with no depression history: psychotic features rule out hypomania, and hospitalization, when necessary, waives the 1-week duration rule.

  📇 Key Takeaways — the index card

  • Bipolar I needs no depression: a distinct period of elevated, expansive or irritable mood with increased goal-directed energy, plus 3 symptoms (4 if the mood is only irritable) — and the usual 1-week minimum is waived when hospitalization is necessary; psychotic features, when present, make an elevated episode manic rather than hypomanic.
  • Ask about decreased NEED for sleep, not decreased sleep: Michael is too excited and goal-directed to sleep and feels great about it — just asking 'how much are you sleeping?' earns false positives.
  • Numbers that reframe the case: bipolar I peaks at onset age 18 to 22 with 50% of cases before 25, carries 79 to 93% heritability, and has a mean diagnostic delay of 7 to 10 years with 70% first misdiagnosed as major depressive disorder — so probe that past Prozac trial for activation, and get collateral, because a manic patient is rarely a good historian.
  • A first sudden manic episode over age 35 should raise suspicion for a medical cause; Michael's workup, negative drug screen and episodic (not chronically deteriorating) course argue against schizophrenia, whose psychosis is more persistent with negative symptoms and cognitive deficits.
  • Bipolar II is the forest fire, not the lesser illness: it requires BOTH hypomania (4 days, no marked impairment, never psychotic — psychosis makes it manic by definition) and major depression, patients spend far more time depressed, and the episode cites a suicide attempt rate around 24% vs 17% for bipolar I.
  • The call: admit Michael and start olanzapine 10 mg for acute mania (target 10 to 20 mg daily) — D2 blockade for the delusions and grandiosity, histamine blockade's sedation usefully calming agitation and restoring sleep — then monitor weight, glucose and lipids and reconsider the agent after discharge for metabolic reasons.
• Aug 26, 2025 Depression & Cannabis Use: Treatment Strategies (Case Study) | PMHNP Boards

  💎 Benny's depression came first (age 15, years before cannabis in college) — treat the depression driving the use, with Wellbutrin: far fewer sexual side effects than an SSRI (low, not zero), weight-neutral, and aimed at his fatigue, oversleeping and anhedonia.

  📇 Key Takeaways — the index card

  • Never accept 'occasional cannabis' at face value: quantify frequency, amount and THC potency, and warn that 1970s cannabis averaged about 3% THC while today's concentrates can exceed 80% — a completely different pharmacologic exposure.
  • Anchor the chicken-and-egg question to life events, not ages: 'what grade were you in when you first felt down?' and 'were you feeling this way when you played basketball?' Benny's first episode was in high school; cannabis started in college after a breakup — and his cannabis-free summer at his aunt's lake house was one where he felt great.
  • Cannabis muddies every follow-up: a few days off it can look like worsening depression (irritability, dysphoria, withdrawal), and ongoing use can worsen depression and blunt dopamine signalling — so you often cannot tell which curve you are watching, and you treat both together.
  • Use his own life as the motivational-interviewing lever: the basketball he can no longer play at his best and the relationships where partners called him bored and checked out — change talk has to come out of Benny's mouth, not a lecture.
  • Why not his other options: Prozac already numbed him and caused bedroom side effects; mirtazapine would spare his sex life but he has already gained weight, craves carbs and can eat a box of Lucky Charms during Jeopardy — so it is ruled out on weight, not on efficacy.
  • The call: bupropion XL 150 mg, then up to 300 mg after 4 to 5 days to a week as tolerated — after ruling out seizures and eating disorders, and noting he is not an anxious patient. At 4 weeks Benny stays on 300 mg, his dry mouth and headaches have resolved, cannabis use is down, and he is headed back to the basketball court.
• Aug 26, 2025 Performance Anxiety: Diagnosis & Propranolol Treatment | PMHNP Boards

  💎 Diagnose the loop, not just the label: anxiety only before speeches and performances, not in daily life, points to performance-only social anxiety — treat it situationally, not with a daily chronic med.

  📇 Key Takeaways — the index card

  • GAD is worry through a fear filter about everything — finances, health, family, worst-case scenarios most days for 6 months. Carly is calm most days as a librarian, sleeps and eats well outside events, and only dreads being in the limelight, so NP Z rules GAD out by timing and scope.
  • Panic disorder is unexpected and out of the blue, with the core fear being the next attack itself. Carly's anthem collapse at 18 looked like panic — short of breath, red face, choking sensation — but the worm at the core was scrutiny: she fears being negatively evaluated while performing, and the bodily symptoms are secondary to that stimulus. Ask: are you afraid of being judged, or of having a panic attack and not escaping?
  • The DSM-5-TR diagnosis is social anxiety disorder, performance only specifier (F40.10): marked fear of possible scrutiny, fear of showing anxiety and being humiliated or rejected, avoidance or enduring with intense fear, out of proportion and lasting 6+ months. Carly meets it because it is limited to speaking or performing in public — she socializes fine with friends and co-workers in ordinary interactions.
  • Propranolol is NP Z's situational tool here: a non-selective beta-blocker that blocks beta-1 and beta-2 receptors so adrenaline cannot drive racing heart, tremor, and sweating. Dose 10-40 mg off-label, taken 30-60 minutes before a discrete event like a eulogy, wedding vows, testimony, or exam — start at 10 mg, especially in small, athletic, or bradycardic patients.
  • Propranolol mutes the somatic feedback loop, not cognitive rumination — daily, all-day worry is SSRI territory, not beta-blocker territory. Screen before using it: avoid with asthma or COPD (beta-2 blockade can close airways), hypotension, or bradycardia, and do not jump straight to high-dose Klonopin and its sedation and brain fog for somatic performance anxiety.
  • Case verdict: Carly — 33, high-functioning, avoiding promotions that require briefings — got propranolol 30-60 minutes before Gary's eulogy and delivered it without the racing heart and trembling hands, with therapy also recommended. If the impairing event is rare, tuck that in your back pocket before committing her to a daily medication.
• Aug 12, 2025 Welcome to Pearls & Prep: Psychiatry Cases for PMHNP Students | PMHNP Boards

  💎 Pearls and Prep is built on one format: a single mock psychiatric case per episode, worked from chart and labs through DSM-5-TR criteria to a medication decision that makes sense.

  📇 Key Takeaways — the index card

  • Who it is for: psych NPs, PAs, residents, med students and curious therapists who want to think deeper, prescribe smarter, and walk into patient care with more clarity and confidence.
  • How each episode runs: start with the patient chart, add puzzles, labs and rating scales, do a DSM-5-TR deep dive, then flip the script with the medication choice — with research nuggets and power pearls woven through.
  • Why mock cases: they let the show use real-world psychopharmacology and memorable, quirky teaching moments without exposing any real patient — cases designed to be tight and practical, not dry or disconnected.
  • Cadence and use: episodes drop every two weeks, built for a drive to clinic, a brush-up before the next patient, or board prep.
  • The call in this welcome episode: follow the show so you never miss an episode, share it with a colleague, and send in the case topic you want covered — the show is built to be shaped by what listeners actually need.
• Jan 14, 2025 MDD with Mixed Features vs Bipolar Spectrum: Demystified | PMHNP Boards

  💎 MDD with mixed features is a sprinkle of mania in a bowl of depression: full major depression plus at least 3 manic or hypomanic symptoms that fall short of a full manic or hypomanic episode.

  📇 Key Takeaways — the index card

  • DSM-5-TR criteria as NP Z teaches them: the patient must first meet full MDD criteria — 5 or more symptoms together over 2 weeks — then have 3 or more manic/hypomanic symptoms on most days of that depressive episode, observable by others: elevated or expansive mood, inflated self-esteem or grandiosity, more talkative or pressured speech, flight of ideas or racing thoughts, increased energy or goal-directed activity, risky behavior, and decreased need for sleep.
  • The tell in Janelle, 29, a dance instructor with a PHQ-9 of 21: 3 weeks of fatigue, hopelessness, guilt, daily crying, low appetite and feeling a burden — yet only 3 hours of sleep and still enough energy to choreograph all night, thoughts racing like music, unable to stop talking in class, flirting and taking risks. That is decreased need for sleep, not depressive insomnia: she is wired and energized and does not feel she needs sleep.
  • Look for soft signs of bipolarity beyond the checklist: earlier-onset depression, a family history of bipolar disorder — Janelle's cousin has bipolar I — multiple or hard-to-treat episodes, and past antidepressants leaving the patient more agitated, dysphoric, impulsive or suicidal. NP Z notes 20 to 30% of patients with MDD may fall on the bipolar spectrum, and most present depressed, not euphoric.
  • Do not let the overlap talk you out of it: racing thoughts, distractibility, irritability, agitation and impulsivity also show up in PTSD, borderline personality disorder, ADHD and generalized anxiety, and irritability alone is too non-specific to carry the diagnosis — which is why these mixed states are so often missed and why 40% of bipolar-spectrum patients are first diagnosed with MDD alone.
  • The flag changes treatment: antidepressant monotherapy with an SSRI or SNRI can exacerbate mixed features — worsening agitation, irritability and insomnia and potentially destabilizing the patient toward mania — so NP Z gravitates toward mood stabilization first, including lithium (especially appealing when suicide risk is elevated) and atypical antipsychotics such as quetiapine and lurasidone.
  • Case verdict for Janelle: her symptoms came in episodes lasting days at a time, occurring with her depression and not separate from it, and short of full hypomania — so NP Z flagged MDD with mixed features, started around a mood stabilizer, watched her closely for her mood to even out, and ruled out the other diagnoses rather than treating her as pure unipolar depression.
• Jan 7, 2025 Vitamin D in Psychiatry: Evidence-Based Pearls | PMHNP Boards

  💎 Vitamin D insufficiency is strikingly common in psychiatric patients — some patient samples report rates above 80% — and vitamin D is involved in serotonin synthesis and signalling, one proposed reason a true deficiency may blunt the SSRI you prescribed.

  📇 Key Takeaways — the index card

  • Vitamin D behaves as a hormone, not a vitamin: you synthesize it from sunlight, and it drives neuroprotection, neuroplasticity and synaptogenesis, modulates gene expression, and even modulates MAO, the enzyme that breaks down serotonin, norepinephrine and dopamine.
  • Know the numbers cold: deficiency is under 20 ng/mL and insufficiency is 21 to 29 ng/mL in the classic framework, which aimed above 30 ng/mL — but the Endocrine Society's 2024 guideline no longer endorses specific sufficiency thresholds or routine testing in healthy adults, so treat any 40 to 75 ng/mL 'optimal' range as contested — against 35 to 55% insufficiency in the general population.
  • Why levels are so rarely optimal: it takes roughly 20 minutes or more of sun a day with 40% of skin exposed — a tall order north of Oklahoma in winter — and each 100 IU ingested daily raises serum vitamin D by only about 1 ng/mL.
  • The antidepressant evidence is strongest for major depressive disorder, and strongest when the patient is actually deficient or insufficient — correcting a true low level is the play, not supplementing everyone as prevention.
  • NP Z's analogy for the stakes: an uncorrected deficiency was likened in one study he cites to shaving about 4 mg off a patient's Lexapro — for some patients the difference between a 10 mg and a 6 mg effect is the difference between response and no response.
  • The regimen he teaches: vitamin D3 (preferred over D2) 5,000 IU daily for 8 to 12 weeks to get above 30 ng/mL, then maintenance of 1,500 to 2,000 IU daily — with 50,000 IU weekly or every-two-weeks dosing as the alternative route; check your own resources for the individual patient.

No episodes match that search. Try a drug name (e.g. “lamotrigine”), a diagnosis, or “Board Bomb.”